{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T00:14:53Z","timestamp":1795047293506,"version":"4.10.2"},"reference-count":611,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cytokine storm (CS) is a severe systemic inflammatory syndrome characterized by the excessive activation of immune cells and a significant increase in circulating levels of cytokines. This pathological process is implicated in the development of life-threatening conditions such as fulminant myocarditis (FM), acute respiratory distress syndrome (ARDS), primary or secondary hemophagocytic lymphohistiocytosis (HLH), cytokine release syndrome (CRS) associated with chimeric antigen receptor-modified T (CAR-T) therapy, and grade III to IV acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. The significant involvement of the JAK-STAT pathway, Toll-like receptors, neutrophil extracellular traps, NLRP3 inflammasome, and other signaling pathways has been recognized in the pathogenesis of CS. Therapies targeting these pathways have been developed or are currently being investigated. While novel drugs have demonstrated promising therapeutic efficacy in mitigating CS, the overall mortality rate of CS resulting from underlying diseases remains high. In the clinical setting, the management of CS typically necessitates a multidisciplinary team strategy encompassing the removal of abnormal inflammatory or immune system activation, the preservation of vital organ function, the treatment of the underlying disease, and the provision of life supportive therapy. This review provides a comprehensive overview of the key signaling pathways and associated cytokines implicated in CS, elucidates the impact of dysregulated immune cell activation, and delineates the resultant organ injury associated with CS. In addition, we offer insights and current literature on the management of CS in cases of FM, ARDS, systemic inflammatory response syndrome, treatment-induced CRS, HLH, and other related conditions.<\/jats:p>","DOI":"10.1038\/s41392-025-02178-y","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T19:01:46Z","timestamp":1744743706000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":235,"title":["Deep insight into cytokine storm: from pathogenesis to treatment"],"prefix":"10.1038","volume":"10","author":[{"given":"Jiali","family":"Nie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiansheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingcheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yicheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9774-3980","authenticated-orcid":false,"given":"Dao Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6435-9368","authenticated-orcid":false,"given":"Jia","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"2178_CR1","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","volume":"383","author":"DC Fajgenbaum","year":"2020","unstructured":"Fajgenbaum, D. C. & June, C. H. Cytokine storm. N. Engl. J. Med. 383, 2255\u20132273 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2178_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41392-021-00679-0","volume":"6","author":"L Yang","year":"2021","unstructured":"Yang, L. et al. The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduct. Target. Ther. 6, 255 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2178_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41577-023-00980-9","volume":"24","author":"A Flemming","year":"2024","unstructured":"Flemming, A. Sleep deprivation whips up cytokine storm. Nat. Rev. Immunol. 24, 2 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"2178_CR4","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41423-024-01174-6","volume":"21","author":"H Kang","year":"2024","unstructured":"Kang, H. et al. Neutrophil-macrophage communication via extracellular vesicle transfer promotes itaconate accumulation and ameliorates cytokine storm syndrome. Cell. Mol. Immunol. 21, 689\u2013706 (2024).","journal-title":"Cell. Mol. Immunol."},{"key":"2178_CR5","first-page":"105","volume":"14","author":"AA Alarabei","year":"2024","unstructured":"Alarabei, A. A. et al. Immunomodulating phytochemicals: an insight into their potential use in cytokine storm situations. Adv. Pharm. Bull. 14, 105\u2013119 (2024).","journal-title":"Adv. Pharm. Bull."},{"key":"2178_CR6","first-page":"487","volume":"9","author":"SJ Lerro","year":"1958","unstructured":"Lerro, S. J., Schmerer, F. & Rapalski, A. J. Unusually severe cases seen in an explosive epidemic of influenza and influenza-like syndrome. US Armed Forces Med. J. 9, 487\u2013497 (1958).","journal-title":"US Armed Forces Med. J."},{"key":"2178_CR7","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.4049\/jimmunol.146.4.1184","volume":"146","author":"ML Alegre","year":"1991","unstructured":"Alegre, M. L. et al. Cytokine release syndrome induced by the 145-2C11 anti-CD3 monoclonal antibody in mice: prevention by high doses of methylprednisolone. J. Immunol. 146, 1184\u20131191 (1991).","journal-title":"J. Immunol."},{"key":"2178_CR8","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1182\/blood.V78.8.1915.1915","volume":"78","author":"PL McCarthy Jr.","year":"1991","unstructured":"McCarthy, P. L. Jr. et al. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 78, 1915\u20131918 (1991).","journal-title":"Blood"},{"key":"2178_CR9","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.1182\/blood.V79.12.3362.bloodjournal79123362","volume":"79","author":"P Herv\u00e9","year":"1992","unstructured":"Herv\u00e9, P. et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 79, 3362\u20133368 (1992).","journal-title":"Blood"},{"key":"2178_CR10","first-page":"1216","volume":"25","author":"JL Ferrara","year":"1993","unstructured":"Ferrara, J. L., Abhyankar, S. & Gilliland, D. G. Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1. Transpl. Proc. 25, 1216\u20131217 (1993).","journal-title":"Transpl. Proc."},{"key":"2178_CR11","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.it.2021.06.001","volume":"42","author":"R Karki","year":"2021","unstructured":"Karki, R. & Kanneganti, T. D. The \u2018cytokine storm\u2019: molecular mechanisms and therapeutic prospects. Trends Immunol. 42, 681\u2013705 (2021).","journal-title":"Trends Immunol."},{"key":"2178_CR12","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1161\/CIRCRESAHA.120.315894","volume":"128","author":"AH Baik","year":"2021","unstructured":"Baik, A. H. et al. Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies. Circ. Res. 128, 1780\u20131801 (2021).","journal-title":"Circ. Res."},{"key":"2178_CR13","doi-asserted-by":"publisher","first-page":"e20200674","DOI":"10.1084\/jem.20200674","volume":"217","author":"T Zhou","year":"2020","unstructured":"Zhou, T., Su, T. T., Mudianto, T. & Wang, J. Immune asynchrony in COVID-19 pathogenesis and potential immunotherapies. J. Exp. Med. 217, e20200674 (2020).","journal-title":"J. Exp. Med."},{"key":"2178_CR14","first-page":"364","volume":"23","author":"G Li","year":"2024","unstructured":"Li, G., Wang, H. & Meftahpour, V. Overall review of curative impact and barriers of CAR-T cells in osteosarcoma. EXCLI J. 23, 364\u2013383 (2024).","journal-title":"EXCLI J."},{"key":"2178_CR15","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41586-024-07469-y","volume":"630","author":"H Jin","year":"2024","unstructured":"Jin, H., Li, M., Jeong, E., Castro-Martinez, F. & Zuker, C. S. A body-brain circuit that regulates body inflammatory responses. Nature 630, 695\u2013703 (2024).","journal-title":"Nature"},{"key":"2178_CR16","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1182\/blood-2016-12-753830","volume":"129","author":"TS Rubin","year":"2017","unstructured":"Rubin, T. S. et al. Perforin and CD107a testing is superior to NK cell function testing for screening patients for genetic HLH. Blood 129, 2993\u20132999 (2017).","journal-title":"Blood"},{"key":"2178_CR17","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1002\/art.38690","volume":"66","author":"L Fardet","year":"2014","unstructured":"Fardet, L. et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 66, 2613\u20132620 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"2178_CR18","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1136\/annrheumdis-2019-215211","volume":"78","author":"F Minoia","year":"2019","unstructured":"Minoia, F. et al. Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Ann. Rheum. Dis. 78, 1357\u20131362 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"2178_CR19","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41392-022-01015-w","volume":"7","author":"Z Lin","year":"2022","unstructured":"Lin, Z., Zuo, J. & He, S. Surrogate cytokine agonists: promising agents against COVID-19. Signal Transduct. Target. Ther. 7, 150 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2178_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41421-023-00593-5","volume":"9","author":"H Li","year":"2023","unstructured":"Li, H. et al. Self-recruited neutrophils trigger over-activated innate immune response and phenotypic change of cardiomyocytes in fulminant viral myocarditis. Cell Discov. 9, 103 (2023).","journal-title":"Cell Discov."},{"key":"2178_CR21","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3390\/vaccines12020194","volume":"12","author":"PMB Sousa","year":"2024","unstructured":"Sousa, P. M. B. et al. Fatal myocarditis following COVID-19 mRNA immunization: a case report and differential diagnosis review. Vaccines 12, 194 (2024).","journal-title":"Vaccines"},{"key":"2178_CR22","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1164\/rccm.202207-1346LE","volume":"206","author":"RFJ Kullberg","year":"2022","unstructured":"Kullberg, R. F. J., de Brabander, J., Boers, L. S., Bos, L. D. J. & Wiersinga, W. J. Reply to: microbial burden-associated cytokine storm may explain non-resolving ARDS in COVID-19 patients. Am. J. Respir. Crit. Care Med. 206, 1183\u20131184 (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2178_CR23","doi-asserted-by":"publisher","first-page":"e154439","DOI":"10.1172\/jci.insight.154439","volume":"6","author":"BHY Gibson","year":"2021","unstructured":"Gibson, B. H. Y. et al. Plasmin drives burn-induced systemic inflammatory response syndrome. JCI Insight 6, e154439 (2021).","journal-title":"JCI Insight"},{"key":"2178_CR24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1517\/14728222.2014.883380","volume":"18","author":"LF Gentile","year":"2014","unstructured":"Gentile, L. F. & Moldawer, L. L. HMGB1 as a therapeutic target for sepsis: it\u2019s all in the timing! Expert Opin. Ther. Targets 18, 243\u2013245 (2014).","journal-title":"Expert Opin. Ther. Targets"},{"key":"2178_CR25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jaci.2023.08.003","volume":"153","author":"V Dettmer-Monaco","year":"2024","unstructured":"Dettmer-Monaco, V. et al. Gene editing of hematopoietic stem cells restores T-cell response in familial hemophagocytic lymphohistiocytosis. J. Allergy Clin. Immunol. 153, 243\u2013255.e214 (2024).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2178_CR26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/leu.2014.151","volume":"29","author":"A Sato","year":"2015","unstructured":"Sato, A. et al. Inhibition of plasmin attenuates murine acute graft-versus-host disease mortality by suppressing the matrix metalloproteinase-9-dependent inflammatory cytokine storm and effector cell trafficking. Leukemia 29, 145\u2013156 (2015).","journal-title":"Leukemia"},{"key":"2178_CR27","first-page":"377","volume":"33","author":"C Zhu","year":"2024","unstructured":"Zhu, C. et al. Rationally designed approaches to augment CAR-T therapy for solid tumor treatment. Bioact. Mater. 33, 377\u2013395 (2024).","journal-title":"Bioact. Mater."},{"key":"2178_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44648-3","volume":"15","author":"S Yang","year":"2024","unstructured":"Yang, S. et al. Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma. Nat. Commun. 15, 360 (2024).","journal-title":"Nat. Commun."},{"key":"2178_CR29","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S1470-2045(20)30309-0","volume":"21","author":"J Tian","year":"2020","unstructured":"Tian, J. et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol. 21, 893\u2013903 (2020).","journal-title":"Lancet Oncol."},{"key":"2178_CR30","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/jmv.25793","volume":"92","author":"J Chu","year":"2020","unstructured":"Chu, J. et al. Clinical characteristics of 54 medical staff with COVID-19: A retrospective study in a single center in Wuhan, China. J. Med. Virol. 92, 807\u2013813 (2020).","journal-title":"J. Med. Virol."},{"key":"2178_CR31","doi-asserted-by":"publisher","first-page":"e137799","DOI":"10.1172\/jci.insight.137799","volume":"5","author":"F Wang","year":"2020","unstructured":"Wang, F. et al. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI insight 5, e137799 (2020).","journal-title":"JCI insight"},{"key":"2178_CR32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41392-022-00907-1","volume":"7","author":"Q Ning","year":"2022","unstructured":"Ning, Q. et al. The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication. Signal Transduct. Target. Ther. 7, 57 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2178_CR33","doi-asserted-by":"publisher","first-page":"m1091","DOI":"10.1136\/bmj.m1091","volume":"368","author":"T Chen","year":"2020","unstructured":"Chen, T. et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 368, m1091 (2020).","journal-title":"BMJ"},{"key":"2178_CR34","doi-asserted-by":"publisher","first-page":"e024417","DOI":"10.1161\/JAHA.121.024417","volume":"11","author":"J Wang","year":"2022","unstructured":"Wang, J. et al. Soluble ST2 is a sensitive and specific biomarker for fulminant myocarditis. J. Am. Heart Assoc. 11, e024417 (2022).","journal-title":"J. Am. Heart Assoc."},{"key":"2178_CR35","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.jaci.2022.06.017","volume":"150","author":"Y Tang","year":"2022","unstructured":"Tang, Y. et al. Excessive IL-10 and IL-18 trigger hemophagocytic lymphohistiocytosis-like hyperinflammation and enhanced myelopoiesis. J. Allergy Clin. Immunol. 150, 1154\u20131167 (2022).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2178_CR36","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1039\/D3SC03438K","volume":"15","author":"Y Gao","year":"2024","unstructured":"Gao, Y. et al. A living neutrophil Biorobot synergistically blocks multifaceted inflammatory pathways in macrophages to effectively neutralize cytokine storm. Chem. Sci. 15, 2243\u20132256 (2024).","journal-title":"Chem. Sci."},{"key":"2178_CR37","doi-asserted-by":"publisher","first-page":"1359946","DOI":"10.3389\/fchem.2024.1359946","volume":"12","author":"Q Gao","year":"2024","unstructured":"Gao, Q. et al. Autologous cryo-shocked neutrophils enable targeted therapy of sepsis via broad-spectrum neutralization of pro-inflammatory cytokines and endotoxins. Front. Chem. 12, 1359946 (2024).","journal-title":"Front. Chem."},{"key":"2178_CR38","doi-asserted-by":"publisher","first-page":"111761","DOI":"10.1016\/j.intimp.2024.111761","volume":"130","author":"Y Pu","year":"2024","unstructured":"Pu, Y. et al. Multi-centers experience using therapeutic plasma exchange for corticosteroid\/tocilizumab-refractory cytokine release syndrome following CAR-T therapy. Int Immunopharmacol. 130, 111761 (2024).","journal-title":"Int Immunopharmacol."},{"key":"2178_CR39","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.3390\/biom11071059","volume":"11","author":"YT Lin","year":"2021","unstructured":"Lin, Y. T. et al. JAK2 phosphorylation signals and their associated cytokines involved in chronic rhinosinusitis with nasal polyps and correlated with disease severity. Biomolecules 11, 1059 (2021).","journal-title":"Biomolecules"},{"key":"2178_CR40","doi-asserted-by":"publisher","first-page":"107430","DOI":"10.1016\/j.bioorg.2024.107430","volume":"148","author":"H Istanbullu","year":"2024","unstructured":"Istanbullu, H., Coban, G., Turunc, E., Disel, C. & Debelec Butuner, B. Discovery of selective TYK2 inhibitors: design, synthesis, in vitro and in silico studies of promising hits with triazolopyrimidinone scaffold. Bioorg. Chem. 148, 107430 (2024).","journal-title":"Bioorg. Chem."},{"key":"2178_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01421-9","volume":"22","author":"R Zhao","year":"2024","unstructured":"Zhao, R. et al. The oncogenic mechanisms of the Janus kinase-signal transducer and activator of transcription pathway in digestive tract tumors. Cell Commun. Signal 22, 68 (2024).","journal-title":"Cell Commun. Signal"},{"key":"2178_CR42","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1136\/ard-2023-224842","volume":"83","author":"S Gupta","year":"2024","unstructured":"Gupta, S. et al. Inhibition of JAK-STAT pathway corrects salivary gland inflammation and interferon driven immune activation in Sjogren\u2019s disease. Ann. Rheum. Dis. 83, 1034\u20131047 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"2178_CR43","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s10787-024-01429-8","volume":"32","author":"EA Ahmed","year":"2024","unstructured":"Ahmed, E. A., Alzahrani, A. M., Abdelsalam, S. A. & Ibrahim, H. M. Flavipin from fungi as a potential inhibitor of rheumatoid arthritis signaling molecules. Inflammopharmacology 32, 1171\u20131186 (2024).","journal-title":"Inflammopharmacology"},{"key":"2178_CR44","doi-asserted-by":"publisher","first-page":"106765","DOI":"10.1016\/j.bioorg.2023.106765","volume":"140","author":"J Xiang","year":"2023","unstructured":"Xiang, J. et al. Design, synthesis, and pharmacological evaluation of quinazoline derivatives as novel and potent pan-JAK inhibitors. Bioorg. Chem. 140, 106765 (2023).","journal-title":"Bioorg. Chem."},{"key":"2178_CR45","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1021\/acschembio.6b00677","volume":"11","author":"JB Telliez","year":"2016","unstructured":"Telliez, J. B. et al. Discovery of a JAK3-selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition. ACS Chem. Biol. 11, 3442\u20133451 (2016).","journal-title":"ACS Chem. Biol."},{"key":"2178_CR46","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","volume":"8","author":"C Xue","year":"2023","unstructured":"Xue, C. et al. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct. Target. Ther. 8, 204 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2178_CR47","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.semcancer.2019.10.002","volume":"60","author":"Y Verhoeven","year":"2020","unstructured":"Verhoeven, Y. et al. The potential and controversy of targeting STAT family members in cancer. Semin. Cancer Biol. 60, 41\u201356 (2020).","journal-title":"Semin. Cancer Biol."},{"key":"2178_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01240-y","volume":"21","author":"M Mahjoor","year":"2023","unstructured":"Mahjoor, M. et al. Double-edged sword of JAK\/STAT signaling pathway in viral infections: novel insights into virotherapy. Cell Commun. Signal. 21, 272 (2023).","journal-title":"Cell Commun. Signal."},{"key":"2178_CR49","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41577-023-00877-7","volume":"23","author":"L Castelo-Soccio","year":"2023","unstructured":"Castelo-Soccio, L. et al. Protein kinases: drug targets for immunological disorders. Nat. Rev. Immunol. 23, 787\u2013806 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"2178_CR50","doi-asserted-by":"publisher","first-page":"e2315898120","DOI":"10.1073\/pnas.2315898120","volume":"121","author":"S Kang","year":"2024","unstructured":"Kang, S. et al. Gp130-HIF1alpha axis-induced vascular damage is prevented by the short-term inhibition of IL-6 receptor signaling. Proc. Natl Acad. Sci. USA 121, e2315898120 (2024).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2178_CR51","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s10787-023-01268-z","volume":"32","author":"SI Shafiey","year":"2024","unstructured":"Shafiey, S. I., Ahmed, K. A., Abo-Saif, A. A., Abo-Youssef, A. M. & Mohamed, W. R. Galantamine mitigates testicular injury and disturbed spermatogenesis in adjuvant arthritic rats via modulating apoptosis, inflammatory signals, and IL-6\/JAK\/STAT3\/SOCS3 signaling. Inflammopharmacology 32, 405\u2013418 (2024).","journal-title":"Inflammopharmacology"},{"key":"2178_CR52","doi-asserted-by":"publisher","first-page":"109568","DOI":"10.1016\/j.jnutbio.2024.109568","volume":"125","author":"R Pradhan","year":"2024","unstructured":"Pradhan, R. et al. Nano formulated Resveratrol inhibits PD-L1 in oral cancer cells by deregulating the association between tumor associated macrophages and cancer associated fibroblasts through IL-6\/JAK2\/STAT3 signaling axis. J. Nutr. Biochem 125, 109568 (2024).","journal-title":"J. Nutr. Biochem"},{"key":"2178_CR53","first-page":"e3021","volume":"20","author":"S Feghhi-Najafabadi","year":"2022","unstructured":"Feghhi-Najafabadi, S. & Shafiee, F. Recombinant production of a mutant form of soluble IL-6 receptor with inhibitory effects against interleukin-6. Iran. J. Biotechnol. 20, e3021 (2022).","journal-title":"Iran. J. Biotechnol."},{"key":"2178_CR54","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/s41577-023-00856-y","volume":"23","author":"S Rose-John","year":"2023","unstructured":"Rose-John, S., Jenkins, B. J., Garbers, C., Moll, J. M. & Scheller, J. Targeting IL-6 trans-signalling: past, present and future prospects. Nat. Rev. Immunol. 23, 666\u2013681 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"2178_CR55","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/cei\/uxac055","volume":"209","author":"GL Cabrera-Rivera","year":"2022","unstructured":"Cabrera-Rivera, G. L. et al. Increased TNF-alpha production in response to IL-6 in patients with systemic inflammation without infection. Clin. Exp. Immunol. 209, 225\u2013235 (2022).","journal-title":"Clin. Exp. Immunol."},{"key":"2178_CR56","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2147\/TCRM.S150524","volume":"15","author":"LL Riegler","year":"2019","unstructured":"Riegler, L. L., Jones, G. P. & Lee, D. W. Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. Ther. Clin. Risk Manag 15, 323\u2013335 (2019).","journal-title":"Ther. Clin. Risk Manag"},{"key":"2178_CR57","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nrd.2018.45","volume":"17","author":"C Garbers","year":"2018","unstructured":"Garbers, C., Heink, S., Korn, T. & Rose-John, S. Interleukin-6: designing specific therapeutics for a complex cytokine. Nat. Rev. Drug Discov. 17, 395\u2013412 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2178_CR58","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.immuni.2019.03.026","volume":"50","author":"S Kang","year":"2019","unstructured":"Kang, S., Tanaka, T., Narazaki, M. & Kishimoto, T. Targeting interleukin-6 signaling in clinic. Immunity 50, 1007\u20131023 (2019).","journal-title":"Immunity"},{"key":"2178_CR59","doi-asserted-by":"publisher","first-page":"6762","DOI":"10.1074\/jbc.RA117.001163","volume":"293","author":"P Baran","year":"2018","unstructured":"Baran, P. et al. The balance of interleukin (IL)-6, IL-6\u00b7soluble IL-6 receptor (sIL-6R), and IL-6\u00b7sIL-6R\u00b7sgp130 complexes allows simultaneous classic and trans-signaling. J. Biol. Chem. 293, 6762\u20136775 (2018).","journal-title":"J. Biol. Chem."},{"key":"2178_CR60","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson, D. E., O\u2019Keefe, R. A. & Grandis, J. R. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 15, 234\u2013248 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2178_CR61","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.4049\/jimmunol.149.5.1666","volume":"149","author":"GM Doherty","year":"1992","unstructured":"Doherty, G. M. et al. Evidence for IFN-gamma as a mediator of the lethality of endotoxin and tumor necrosis factor-alpha. J. Immunol. 149, 1666\u20131670 (1992).","journal-title":"J. Immunol."},{"key":"2178_CR62","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cell.2020.11.025","volume":"184","author":"R Karki","year":"2021","unstructured":"Karki, R. et al. Synergism of TNF-\u03b1 and IFN-\u03b3 triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 Infection and cytokine shock syndromes. Cell 184, 149\u2013168.e117 (2021).","journal-title":"Cell"},{"key":"2178_CR63","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S2352-3026(21)00366-5","volume":"9","author":"A Setiadi","year":"2022","unstructured":"Setiadi, A., Zoref-Lorenz, A., Lee, C. Y., Jordan, M. B. & Chen, L. Y. C. Malignancy-associated haemophagocytic lymphohistiocytosis. Lancet Haematol 9, e217\u2013e227 (2022).","journal-title":"Lancet Haematol"},{"key":"2178_CR64","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood.2023021046","volume":"143","author":"C Keenan","year":"2024","unstructured":"Keenan, C. et al. Differential effects of JAK1 vs. JAK2 inhibition in mouse models of hemophagocytic lymphohistiocytosis. Blood 143, 2386\u20132400 (2024).","journal-title":"Blood"},{"key":"2178_CR65","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1182\/blood.2020006075","volume":"136","author":"LK Meyer","year":"2020","unstructured":"Meyer, L. K. et al. JAK\/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation. Blood 136, 657\u2013668 (2020).","journal-title":"Blood"},{"key":"2178_CR66","first-page":"e521","volume":"30","author":"E Cook","year":"2024","unstructured":"Cook, E. et al. Ruxolitinib pharmacokinetics and pharmacodynamics in children with acute and chronic graft-versus-host disease. Transpl. Cell. Ther. 30, e521\u2013e512 (2024). 528.","journal-title":"Transpl. Cell. Ther."},{"key":"2178_CR67","doi-asserted-by":"publisher","first-page":"6299","DOI":"10.1158\/1078-0432.CCR-20-1739","volume":"26","author":"E Huarte","year":"2020","unstructured":"Huarte, E. et al. Itacitinib (INCB039110), a JAK1 inhibitor, reduces cytokines associated with cytokine release syndrome induced by CAR T-cell therapy. Clin. Cancer Res. 26, 6299\u20136309 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2178_CR68","doi-asserted-by":"publisher","first-page":"e003766","DOI":"10.1136\/jitc-2021-003766","volume":"10","author":"G Leclercq","year":"2022","unstructured":"Leclercq, G. et al. JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy. J. Immunother Cancer 10, e003766 (2022).","journal-title":"J. Immunother Cancer"},{"key":"2178_CR69","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","volume":"185","author":"RL Philips","year":"2022","unstructured":"Philips, R. L. et al. The JAK-STAT pathway at 30: much learned, much more to do. Cell 185, 3857\u20133876 (2022).","journal-title":"Cell"},{"key":"2178_CR70","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1158\/2159-8290.CD-23-0199","volume":"13","author":"M Dougan","year":"2023","unstructured":"Dougan, M. Weighing antitumor immunity against life-threatening myocarditis from immune-checkpoint inhibitors. Cancer Discov. 13, 1040\u20131042 (2023).","journal-title":"Cancer Discov."},{"key":"2178_CR71","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00296-020-04636-y","volume":"41","author":"M Soy","year":"2021","unstructured":"Soy, M., Atag\u00fcnd\u00fcz, P., Atag\u00fcnd\u00fcz, I. & Sucak, G. T. Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic. Rheumatol. Int. 41, 7\u201318 (2021).","journal-title":"Rheumatol. Int."},{"key":"2178_CR72","doi-asserted-by":"publisher","first-page":"614704","DOI":"10.3389\/fimmu.2021.614704","volume":"12","author":"C Keenan","year":"2021","unstructured":"Keenan, C., Nichols, K. E. & Albeituni, S. Use of the JAK inhibitor ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis. Front. Immunol. 12, 614704 (2021).","journal-title":"Front. Immunol."},{"key":"2178_CR73","doi-asserted-by":"publisher","first-page":"658896","DOI":"10.3389\/fimmu.2021.658896","volume":"12","author":"A Lange","year":"2021","unstructured":"Lange, A., Lange, J. & Jasku\u0142a, E. Cytokine overproduction and immune system dysregulation in alloHSCT and COVID-19 patients. Front. Immunol. 12, 658896 (2021).","journal-title":"Front. Immunol."},{"key":"2178_CR74","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1182\/blood.2019000952","volume":"136","author":"GR Hill","year":"2020","unstructured":"Hill, G. R. & Koyama, M. Cytokines and costimulation in acute graft-versus-host disease. Blood 136, 418\u2013428 (2020).","journal-title":"Blood"},{"key":"2178_CR75","doi-asserted-by":"publisher","first-page":"204062072091448","DOI":"10.1177\/2040620720914489","volume":"11","author":"R Abboud","year":"2020","unstructured":"Abboud, R. et al. Insights into the role of the JAK\/STAT signaling pathway in graft-versus-host disease. Ther. Adv. Hematol. 11, 2040620720914489 (2020).","journal-title":"Ther. Adv. Hematol."},{"key":"2178_CR76","doi-asserted-by":"publisher","first-page":"1194984","DOI":"10.3389\/fimmu.2023.1194984","volume":"14","author":"R Harris","year":"2023","unstructured":"Harris, R. & Karimi, M. Dissecting the regulatory network of transcription factors in T cell phenotype\/functioning during GVHD and GVT. Front. Immunol. 14, 1194984 (2023).","journal-title":"Front. Immunol."},{"key":"2178_CR77","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41551-023-01143-w","volume":"8","author":"M Bell","year":"2024","unstructured":"Bell, M. et al. Modular chimeric cytokine receptors with leucine zippers enhance the antitumour activity of CAR T cells via JAK\/STAT signalling. Nat. Biomed. Eng. 8, 380\u2013396 (2024).","journal-title":"Nat. Biomed. Eng."},{"key":"2178_CR78","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1159\/000508247","volume":"181","author":"F Seif","year":"2020","unstructured":"Seif, F. et al. JAK inhibition as a new treatment strategy for patients with COVID-19. Int. Arch. Allergy Immunol. 181, 467\u2013475 (2020).","journal-title":"Int. Arch. Allergy Immunol."},{"key":"2178_CR79","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1172\/JCI16491","volume":"111","author":"H Yasukawa","year":"2003","unstructured":"Yasukawa, H. et al. The suppressor of cytokine signaling-1 (SOCS1) is a novel therapeutic target for enterovirus-induced cardiac injury. J. Clin. Investig. 111, 469\u2013478 (2003).","journal-title":"J. Clin. Investig."},{"key":"2178_CR80","doi-asserted-by":"publisher","first-page":"115587","DOI":"10.1016\/j.bcp.2023.115587","volume":"213","author":"Q Pang","year":"2023","unstructured":"Pang, Q. et al. Regulation of the JAK\/STAT signaling pathway: the promising targets for cardiovascular disease. Biochem. Pharm. 213, 115587 (2023).","journal-title":"Biochem. Pharm."},{"key":"2178_CR81","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1161\/01.RES.0000134921.50377.61","volume":"95","author":"D Hilfiker-Kleiner","year":"2004","unstructured":"Hilfiker-Kleiner, D. et al. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ. Res. 95, 187\u2013195 (2004).","journal-title":"Circ. Res."},{"key":"2178_CR82","doi-asserted-by":"publisher","first-page":"H471","DOI":"10.1152\/ajpheart.00730.2014","volume":"309","author":"D Enomoto","year":"2015","unstructured":"Enomoto, D. et al. Cardiac-specific ablation of the STAT3 gene in the subacute phase of myocardial infarction exacerbated cardiac remodeling. Am. J. Physiol. Heart Circ. Physiol. 309, H471\u2013H480 (2015).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2178_CR83","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/CIRCULATIONAHA.109.933127","volume":"122","author":"D Hilfiker-Kleiner","year":"2010","unstructured":"Hilfiker-Kleiner, D. et al. Continuous glycoprotein-130-mediated signal transducer and activator of transcription-3 activation promotes inflammation, left ventricular rupture, and adverse outcome in subacute myocardial infarction. Circulation 122, 145\u2013155 (2010).","journal-title":"Circulation"},{"key":"2178_CR84","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.yexcr.2018.04.001","volume":"367","author":"L Li","year":"2018","unstructured":"Li, L., Li, L., Xiao, L. & Shangguan, J. Progranulin ameliorates coxsackievirus-B3-induced viral myocarditis by downregulating Th1 and Th17 cells. Exp. Cell Res. 367, 241\u2013250 (2018).","journal-title":"Exp. Cell Res."},{"key":"2178_CR85","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.yexcr.2018.12.005","volume":"375","author":"H Chang","year":"2019","unstructured":"Chang, H. et al. PPARalpha suppresses Th17 cell differentiation through IL-6\/STAT3\/RORgammat pathway in experimental autoimmune myocarditis. Exp. Cell Res. 375, 22\u201330 (2019).","journal-title":"Exp. Cell Res."},{"key":"2178_CR86","first-page":"57","volume":"29","author":"PS Tavares","year":"2010","unstructured":"Tavares, P. S., Rocon-Albuquerque, R. Jr. & Leite-Moreira, A. F. Innate immune receptor activation in viral myocarditis: pathophysiologic implications. Rev. Port. Cardiol. 29, 57\u201378 (2010).","journal-title":"Rev. Port. Cardiol."},{"key":"2178_CR87","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/jmv.27405","volume":"94","author":"M Manik","year":"2022","unstructured":"Manik, M. & Singh, R. K. Role of toll-like receptors in modulation of cytokine storm signaling in SARS-CoV-2-induced COVID-19. J. Med. Virol. 94, 869\u2013877 (2022).","journal-title":"J. Med. Virol."},{"key":"2178_CR88","doi-asserted-by":"publisher","first-page":"101143","DOI":"10.1016\/j.mam.2022.101143","volume":"88","author":"I Ciaston","year":"2022","unstructured":"Ciaston, I., Dobosz, E., Potempa, J. & Koziel, J. The subversion of toll-like receptor signaling by bacterial and viral proteases during the development of infectious diseases. Mol. Asp. Med. 88, 101143 (2022).","journal-title":"Mol. Asp. Med."},{"key":"2178_CR89","doi-asserted-by":"publisher","first-page":"109390","DOI":"10.1016\/j.intimp.2022.109390","volume":"113","author":"M Shafeghat","year":"2022","unstructured":"Shafeghat, M., Kazemian, S., Aminorroaya, A., Aryan, Z. & Rezaei, N. Toll-like receptor 7 regulates cardiovascular diseases. Int Immunopharmacol. 113, 109390 (2022).","journal-title":"Int Immunopharmacol."},{"key":"2178_CR90","doi-asserted-by":"publisher","first-page":"105973","DOI":"10.1016\/j.biocel.2021.105973","volume":"134","author":"A Khawaja","year":"2021","unstructured":"Khawaja, A. & Bromage, D. I. The innate immune response in myocarditis. Int. J. Biochem. Cell Biol. 134, 105973 (2021).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"2178_CR91","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41421-022-00453-8","volume":"8","author":"Y Yao","year":"2022","unstructured":"Yao, Y. et al. Surface translocation of ACE2 and TMPRSS2 upon TLR4\/7\/8 activation is required for SARS-CoV-2 infection in circulating monocytes. Cell Discov. 8, 89 (2022).","journal-title":"Cell Discov."},{"key":"2178_CR92","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41422-021-00495-9","volume":"31","author":"Y Zhao","year":"2021","unstructured":"Zhao, Y. et al. SARS-CoV-2 spike protein interacts with and activates TLR41. Cell Res. 31, 818\u2013820 (2021).","journal-title":"Cell Res."},{"key":"2178_CR93","doi-asserted-by":"publisher","first-page":"121393","DOI":"10.1016\/j.biomaterials.2022.121393","volume":"283","author":"I Naqvi","year":"2022","unstructured":"Naqvi, I. et al. DAMPs\/PAMPs induce monocytic TLR activation and tolerance in COVID-19 patients; nucleic acid binding scavengers can counteract such TLR agonists. Biomaterials 283, 121393 (2022).","journal-title":"Biomaterials"},{"key":"2178_CR94","doi-asserted-by":"publisher","first-page":"23208","DOI":"10.1074\/jbc.M109.047464","volume":"285","author":"C Gorbea","year":"2010","unstructured":"Gorbea, C. et al. A role for Toll-like receptor 3 variants in host susceptibility to enteroviral myocarditis and dilated cardiomyopathy. J. Biol. Chem. 285, 23208\u201323223 (2010).","journal-title":"J. Biol. Chem."},{"key":"2178_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.140","volume":"7","author":"Y Yang","year":"2016","unstructured":"Yang, Y. et al. The emerging role of Toll-like receptor 4 in myocardial inflammation. Cell Death Dis. 7, e2234 (2016).","journal-title":"Cell Death Dis."},{"key":"2178_CR96","doi-asserted-by":"publisher","first-page":"e0193844","DOI":"10.1371\/journal.pone.0193844","volume":"13","author":"PM Becher","year":"2018","unstructured":"Becher, P. M. et al. Role of Toll-like receptors and interferon regulatory factors in different experimental heart failure models of diverse etiology: IRF7 as novel cardiovascular stress-inducible factor. PLoS ONE 13, e0193844 (2018).","journal-title":"PLoS ONE"},{"key":"2178_CR97","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.imbio.2011.07.011","volume":"217","author":"AP Papageorgiou","year":"2012","unstructured":"Papageorgiou, A. P. & Heymans, S. Interactions between the extracellular matrix and inflammation during viral myocarditis. Immunobiology 217, 503\u2013510 (2012).","journal-title":"Immunobiology"},{"key":"2178_CR98","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1146\/annurev.pathmechdis.3.121806.151534","volume":"3","author":"M Esfandiarei","year":"2008","unstructured":"Esfandiarei, M. & McManus, B. M. Molecular biology and pathogenesis of viral myocarditis. Annu. Rev. Pathol. 3, 127\u2013155 (2008).","journal-title":"Annu. Rev. Pathol."},{"key":"2178_CR99","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/0891693042000196200","volume":"37","author":"D Fairweather","year":"2004","unstructured":"Fairweather, D. et al. Mast cells and innate cytokines are associated with susceptibility to autoimmune heart disease following coxsackievirus B3 infection. Autoimmunity 37, 131\u2013145 (2004).","journal-title":"Autoimmunity"},{"key":"2178_CR100","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.molmed.2012.05.005","volume":"18","author":"MF Corsten","year":"2012","unstructured":"Corsten, M. F., Schroen, B. & Heymans, S. Inflammation in viral myocarditis: friend or foe? Trends Mol. Med. 18, 426\u2013437 (2012).","journal-title":"Trends Mol. Med."},{"key":"2178_CR101","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4049\/jimmunol.0800861","volume":"183","author":"P Zhang","year":"2009","unstructured":"Zhang, P., Cox, C. J., Alvarez, K. M. & Cunningham, M. W. Cutting edge: cardiac myosin activates innate immune responses through TLRs. J. Immunol. 183, 27\u201331 (2009).","journal-title":"J. Immunol."},{"key":"2178_CR102","doi-asserted-by":"publisher","first-page":"e85851","DOI":"10.1172\/jci.insight.85851","volume":"1","author":"JM Myers","year":"2016","unstructured":"Myers, J. M. et al. Cardiac myosin-Th17 responses promote heart failure in human myocarditis. JCI insight 1, e85851 (2016).","journal-title":"JCI insight"},{"key":"2178_CR103","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.4049\/jimmunol.1103414","volume":"188","author":"K Tillack","year":"2012","unstructured":"Tillack, K., Breiden, P., Martin, R. & Sospedra, M. T lymphocyte priming by neutrophil extracellular traps links innate and adaptive immune responses. J. Immunol. 188, 3150\u20133159 (2012).","journal-title":"J. Immunol."},{"key":"2178_CR104","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1126\/science.aaa8064","volume":"349","author":"A Warnatsch","year":"2015","unstructured":"Warnatsch, A., Ioannou, M., Wang, Q. & Papayannopoulos, V. Inflammation. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis. Science 349, 316\u2013320 (2015).","journal-title":"Science"},{"key":"2178_CR105","doi-asserted-by":"publisher","first-page":"108516","DOI":"10.1016\/j.intimp.2021.108516","volume":"104","author":"HM Al-Kuraishy","year":"2022","unstructured":"Al-Kuraishy, H. M. et al. Neutrophil Extracellular Traps (NETs) and Covid-19: a new frontiers for therapeutic modality. Int Immunopharmacol. 104, 108516 (2022).","journal-title":"Int Immunopharmacol."},{"key":"2178_CR106","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.3390\/ijms24033001","volume":"24","author":"R Root-Bernstein","year":"2023","unstructured":"Root-Bernstein, R. From co-infections to autoimmune disease via hyperactivated innate immunity: COVID-19 autoimmune coagulopathies, autoimmune myocarditis and multisystem inflammatory syndrome in children. Int. J. Mol. Sci. 24, 3001 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2178_CR107","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1084\/jem.20181102","volume":"216","author":"LT Weckbach","year":"2019","unstructured":"Weckbach, L. T. et al. Midkine drives cardiac inflammation by promoting neutrophil trafficking and NETosis in myocarditis. J. Exp. Med. 216, 350\u2013368 (2019).","journal-title":"J. Exp. Med."},{"key":"2178_CR108","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","volume":"19","author":"KV Swanson","year":"2019","unstructured":"Swanson, K. V., Deng, M. & Ting, J. P. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat. Rev. Immunol. 19, 477\u2013489 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"2178_CR109","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/imcb.12459","volume":"99","author":"AO Bawazeer","year":"2021","unstructured":"Bawazeer, A. O. et al. Interleukin-1beta exacerbates disease and is a potential therapeutic target to reduce pulmonary inflammation during severe influenza A virus infection. Immunol. Cell Biol. 99, 737\u2013748 (2021).","journal-title":"Immunol. Cell Biol."},{"key":"2178_CR110","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3390\/v12040401","volume":"12","author":"G Laghlali","year":"2020","unstructured":"Laghlali, G., Lawlor, K. E. & Tate, M. D. Die another way: interplay between influenza A virus, inflammation and cell death. Viruses 12, 401 (2020).","journal-title":"Viruses"},{"key":"2178_CR111","doi-asserted-by":"publisher","first-page":"112147","DOI":"10.1016\/j.celrep.2023.112147","volume":"42","author":"JT Clark","year":"2023","unstructured":"Clark, J. T. et al. IL-18BP mediates the balance between protective and pathological immune responses to Toxoplasma gondii. Cell Rep. 42, 112147 (2023).","journal-title":"Cell Rep."},{"key":"2178_CR112","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.neuroscience.2020.10.019","volume":"451","author":"Q Gong","year":"2020","unstructured":"Gong, Q., Lin, Y., Lu, Z. & Xiao, Z. Microglia-astrocyte cross talk through IL-18\/IL-18R signaling modulates migraine-like behavior in experimental models of migraine. Neuroscience 451, 207\u2013215 (2020).","journal-title":"Neuroscience"},{"key":"2178_CR113","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/nrd.2018.149","volume":"17","author":"MSJ Mangan","year":"2018","unstructured":"Mangan, M. S. J. et al. Targeting the NLRP3 inflammasome in inflammatory diseases. Nat. Rev. Drug Discov. 17, 688 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2178_CR114","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev-pathol-012414-040431","volume":"10","author":"L Broderick","year":"2015","unstructured":"Broderick, L., De Nardo, D., Franklin, B. S., Hoffman, H. M. & Latz, E. The inflammasomes and autoinflammatory syndromes. Annu Rev. Pathol. 10, 395\u2013424 (2015).","journal-title":"Annu Rev. Pathol."},{"key":"2178_CR115","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/nar\/gkg031","volume":"31","author":"C Sarrauste de Menthi\u00e8re","year":"2003","unstructured":"Sarrauste de Menthi\u00e8re, C. et al. INFEVERS: the registry for FMF and hereditary inflammatory disorders mutations. Nucleic acids Res. 31, 282\u2013285 (2003).","journal-title":"Nucleic acids Res."},{"key":"2178_CR116","doi-asserted-by":"publisher","first-page":"4695","DOI":"10.1172\/JCI71543","volume":"123","author":"SD Brydges","year":"2013","unstructured":"Brydges, S. D. et al. Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies. J. Clin. Investig. 123, 4695\u20134705 (2013).","journal-title":"J. Clin. Investig."},{"key":"2178_CR117","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s00395-022-00948-1","volume":"117","author":"X Liu","year":"2022","unstructured":"Liu, X. et al. Mitochondrial calpain-1 activates NLRP3 inflammasome by cleaving ATP5A1 and inducing mitochondrial ROS in CVB3-induced myocarditis. Basic Res. Cardiol. 117, 40 (2022).","journal-title":"Basic Res. Cardiol."},{"key":"2178_CR118","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/ehf2.13845","volume":"9","author":"K Pappritz","year":"2022","unstructured":"Pappritz, K. et al. Colchicine prevents disease progression in viral myocarditis via modulating the NLRP3 inflammasome in the cardiosplenic axis. ESC Heart Fail 9, 925\u2013941 (2022).","journal-title":"ESC Heart Fail"},{"key":"2178_CR119","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/s41564-019-0371-3","volume":"4","author":"M Ahn","year":"2019","unstructured":"Ahn, M. et al. Dampened NLRP3-mediated inflammation in bats and implications for a special viral reservoir host. Nat. Microbiol 4, 789\u2013799 (2019).","journal-title":"Nat. Microbiol"},{"key":"2178_CR120","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.virol.2015.08.010","volume":"485","author":"JL Nieto-Torres","year":"2015","unstructured":"Nieto-Torres, J. L. et al. Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome. Virology 485, 330\u2013339 (2015).","journal-title":"Virology"},{"key":"2178_CR121","first-page":"138","volume":"14","author":"D Dutta","year":"2022","unstructured":"Dutta, D., Liu, J. & Xiong, H. NLRP3 inflammasome activation and SARS-CoV-2-mediated hyperinflammation, cytokine storm and neurological syndromes. Int. J. Physiol. PathoPhysiol. Pharm. 14, 138\u2013160 (2022).","journal-title":"Int. J. Physiol. PathoPhysiol. Pharm."},{"key":"2178_CR122","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-022-00913-7","volume":"27","author":"Y Kang","year":"2022","unstructured":"Kang, Y. & Wang, Q. Potential therapeutic value of necroptosis inhibitor for the treatment of COVID-19. Eur. J. Med. Res. 27, 283 (2022).","journal-title":"Eur. J. Med. Res."},{"key":"2178_CR123","doi-asserted-by":"publisher","first-page":"37456","DOI":"10.18632\/oncotarget.9648","volume":"7","author":"MJ Oliva-Martin","year":"2016","unstructured":"Oliva-Martin, M. J. et al. Caspase-8 inhibition represses initial human monocyte activation in septic shock model. Oncotarget 7, 37456\u201337470 (2016).","journal-title":"Oncotarget"},{"key":"2178_CR124","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41392-020-00334-0","volume":"5","author":"S Li","year":"2020","unstructured":"Li, S. et al. SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation. Signal Transduct. Target. Ther. 5, 235 (2020).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2178_CR125","doi-asserted-by":"publisher","first-page":"e2410336","DOI":"10.1002\/advs.202410336","volume":"11","author":"H Yin","year":"2024","unstructured":"Yin, H. et al. Pyroptosis-inducing biomaterials pave the way for transformative antitumor immunotherapy. Adv. Sci. 11, e2410336 (2024).","journal-title":"Adv. Sci."},{"key":"2178_CR126","doi-asserted-by":"publisher","first-page":"nwab137","DOI":"10.1093\/nsr\/nwab137","volume":"9","author":"X Wan","year":"2022","unstructured":"Wan, X. et al. H7N9 virus infection triggers lethal cytokine storm by activating gasdermin E-mediated pyroptosis of lung alveolar epithelial cells. Natl Sci. Rev. 9, nwab137 (2022).","journal-title":"Natl Sci. Rev."},{"key":"2178_CR127","doi-asserted-by":"publisher","first-page":"5827","DOI":"10.7150\/ijbs.77561","volume":"18","author":"M Wang","year":"2022","unstructured":"Wang, M., Chang, W., Zhang, L. & Zhang, Y. Pyroptotic cell death in SARS-CoV-2 infection: revealing its roles during the immunopathogenesis of COVID-19. Int. J. Biol. Sci. 18, 5827\u20135848 (2022).","journal-title":"Int. J. Biol. Sci."},{"key":"2178_CR128","doi-asserted-by":"publisher","first-page":"e2250235","DOI":"10.1002\/eji.202250235","volume":"53","author":"W Chen","year":"2023","unstructured":"Chen, W., Gullett, J. M., Tweedell, R. E. & Kanneganti, T. D. Innate immune inflammatory cell death: PANoptosis and PANoptosomes in host defense and disease. Eur. J. Immunol. 53, e2250235 (2023).","journal-title":"Eur. J. Immunol."},{"key":"2178_CR129","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","volume":"181","author":"D Blanco-Melo","year":"2020","unstructured":"Blanco-Melo, D. et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181, 1036\u20131045.e1039 (2020).","journal-title":"Cell"},{"key":"2178_CR130","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1002\/JLB.4AB0420-694R","volume":"108","author":"PH Cheung","year":"2020","unstructured":"Cheung, P. H. et al. PB1-F2 protein of highly pathogenic influenza A (H7N9) virus selectively suppresses RNA-induced NLRP3 inflammasome activation through inhibition of MAVS-NLRP3 interaction. J. Leukoc. Biol. 108, 1655\u20131663 (2020).","journal-title":"J. Leukoc. Biol."},{"key":"2178_CR131","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1038\/s12276-023-01105-x","volume":"55","author":"CH Koh","year":"2023","unstructured":"Koh, C. H., Lee, S., Kwak, M., Kim, B. S. & Chung, Y. CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential. Exp. Mol. Med. 55, 2287\u20132299 (2023).","journal-title":"Exp. Mol. Med."},{"key":"2178_CR132","doi-asserted-by":"publisher","first-page":"840610","DOI":"10.3389\/fimmu.2022.840610","volume":"13","author":"JA Wik","year":"2022","unstructured":"Wik, J. A. & Sk\u00e5lhegg, B. S. T cell metabolism in infection. Front. Immunol. 13, 840610 (2022).","journal-title":"Front. Immunol."},{"key":"2178_CR133","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.molmed.2016.01.001","volume":"22","author":"A Beringer","year":"2016","unstructured":"Beringer, A., Noack, M. & Miossec, P. IL-17 in Chronic Inflammation: From Discovery To Targeting. Trends Mol. Med. 22, 230\u2013241 (2016).","journal-title":"Trends Mol. Med."},{"key":"2178_CR134","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3389\/fimmu.2018.00678","volume":"9","author":"ME Schmidt","year":"2018","unstructured":"Schmidt, M. E. & Varga, S. M. The CD8 T cell response to respiratory virus infections. Front. Immunol. 9, 678 (2018).","journal-title":"Front. Immunol."},{"key":"2178_CR135","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1084\/jem.192.10.1403","volume":"192","author":"VR Sutton","year":"2000","unstructured":"Sutton, V. R. et al. Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation. J. Exp. Med. 192, 1403\u20131414 (2000).","journal-title":"J. Exp. Med."},{"key":"2178_CR136","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-med-042921-112837","volume":"74","author":"RQ Cron","year":"2023","unstructured":"Cron, R. Q. & Goyal, G. & Chatham, W. W. Cytokine storm syndrome. Annu. Rev. Med. 74, 321\u2013337 (2023).","journal-title":"Annu. Rev. Med."},{"key":"2178_CR137","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.cell.2016.01.021","volume":"165","author":"R Basu","year":"2016","unstructured":"Basu, R. et al. Cytotoxic T cells use mechanical force to potentiate target cell killing. Cell 165, 100\u2013110 (2016).","journal-title":"Cell"},{"key":"2178_CR138","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1084\/jem.20140964","volume":"212","author":"MR Jenkins","year":"2015","unstructured":"Jenkins, M. R. et al. Failed CTL\/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time. J. Exp. Med. 212, 307\u2013317 (2015).","journal-title":"J. Exp. Med."},{"key":"2178_CR139","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1182\/blood.V99.1.61","volume":"99","author":"K Kogawa","year":"2002","unstructured":"Kogawa, K. et al. Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood 99, 61\u201366 (2002).","journal-title":"Blood"},{"key":"2178_CR140","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1200\/JCO.2006.07.1100","volume":"24","author":"A Mackensen","year":"2006","unstructured":"Mackensen, A. et al. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J. Clin. Oncol. 24, 5060\u20135069 (2006).","journal-title":"J. Clin. Oncol."},{"key":"2178_CR141","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1126\/science.abb9847","volume":"370","author":"S Krishna","year":"2020","unstructured":"Krishna, S. et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science 370, 1328\u20131334 (2020).","journal-title":"Science"},{"key":"2178_CR142","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1001\/jamaoncol.2023.7182","volume":"10","author":"M Gurney","year":"2024","unstructured":"Gurney, M. et al. Features and factors associated with myeloid neoplasms after chimeric antigen receptor T-Cell therapy. JAMA Oncol. 10, 532\u2013535 (2024).","journal-title":"JAMA Oncol."},{"key":"2178_CR143","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","volume":"9","author":"AM Abel","year":"2018","unstructured":"Abel, A. M., Yang, C., Thakar, M. S. & Malarkannan, S. Natural killer cells: development, maturation, and clinical utilization. Front. Immunol. 9, 1869 (2018).","journal-title":"Front. Immunol."},{"key":"2178_CR144","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","volume":"18","author":"JA Myers","year":"2021","unstructured":"Myers, J. A. & Miller, J. S. Exploring the NK cell platform for cancer immunotherapy. Nat. Rev. Clin. Oncol. 18, 85\u2013100 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2178_CR145","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1182\/blood-2005-03-1154","volume":"106","author":"T Walzer","year":"2005","unstructured":"Walzer, T., Dalod, M., Robbins, S. H., Zitvogel, L. & Vivier, E. Natural-killer cells and dendritic cells: \u201cl\u2019union fait la force\u201d. Blood 106, 2252\u20132258 (2005).","journal-title":"Blood"},{"key":"2178_CR146","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1182\/blood-2003-12-4187","volume":"105","author":"H Kobayashi","year":"2005","unstructured":"Kobayashi, H. et al. Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood 105, 721\u2013727 (2005).","journal-title":"Blood"},{"key":"2178_CR147","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1073\/pnas.0307298101","volume":"101","author":"CA Klebanoff","year":"2004","unstructured":"Klebanoff, C. A. et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc. Natl Acad. Sci. USA 101, 1969\u20131974 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2178_CR148","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrrheum.2015.179","volume":"12","author":"AA Grom","year":"2016","unstructured":"Grom, A. A., Horne, A. & De Benedetti, F. Macrophage activation syndrome in the era of biologic therapy. Nat. Rev. Rheumatol. 12, 259\u2013268 (2016).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2178_CR149","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.cellimm.2011.08.013","volume":"271","author":"C Massilamany","year":"2011","unstructured":"Massilamany, C., Gangaplara, A., Steffen, D. & Reddy, J. Identification of novel mimicry epitopes for cardiac myosin heavy chain-alpha that induce autoimmune myocarditis in A\/J mice. Cell Immunol. 271, 438\u2013449 (2011).","journal-title":"Cell Immunol."},{"key":"2178_CR150","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nri3800","volume":"15","author":"S Epelman","year":"2015","unstructured":"Epelman, S., Liu, P. P. & Mann, D. L. Role of innate and adaptive immune mechanisms in cardiac injury and repair. Nat. Rev. Immunol. 15, 117\u2013129 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"2178_CR151","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.imbio.2011.06.009","volume":"217","author":"JG Barin","year":"2012","unstructured":"Barin, J. G., Rose, N. R. & Cihakova, D. Macrophage diversity in cardiac inflammation: a review. Immunobiology 217, 468\u2013475 (2012).","journal-title":"Immunobiology"},{"key":"2178_CR152","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-023-01478-6","volume":"16","author":"M Li","year":"2023","unstructured":"Li, M. et al. Metabolism, metabolites, and macrophages in cancer. J. Hematol. Oncol. 16, 80 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"2178_CR153","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/nri3607","volume":"14","author":"IK Poon","year":"2014","unstructured":"Poon, I. K., Lucas, C. D., Rossi, A. G. & Ravichandran, K. S. Apoptotic cell clearance: basic biology and therapeutic potential. Nat. Rev. Immunol. 14, 166\u2013180 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"2178_CR154","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1126\/science.aai8132","volume":"356","author":"L Bosurgi","year":"2017","unstructured":"Bosurgi, L. et al. Macrophage function in tissue repair and remodeling requires IL-4 or IL-13 with apoptotic cells. Science 356, 1072\u20131076 (2017).","journal-title":"Science"},{"key":"2178_CR155","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.immuni.2024.01.001","volume":"57","author":"Z Zhou","year":"2024","unstructured":"Zhou, Z. et al. Type 2 cytokine signaling in macrophages protects from cellular senescence and organismal aging. Immunity 57, 513\u2013527.e516 (2024).","journal-title":"Immunity"},{"key":"2178_CR156","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1158\/2159-8290.CD-16-0329","volume":"6","author":"MM Chen","year":"2016","unstructured":"Chen, M. M. et al. Polarization of tissue-resident TFH-like cells in human hepatoma bridges innate monocyte inflammation and M2b macrophage polarization. Cancer Discov. 6, 1182\u20131195 (2016).","journal-title":"Cancer Discov."},{"key":"2178_CR157","doi-asserted-by":"publisher","first-page":"6425","DOI":"10.1002\/jcp.26429","volume":"233","author":"A Shapouri-Moghaddam","year":"2018","unstructured":"Shapouri-Moghaddam, A. et al. Macrophage plasticity, polarization, and function in health and disease. J. Cell Physiol. 233, 6425\u20136440 (2018).","journal-title":"J. Cell Physiol."},{"key":"2178_CR158","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/ki.2013.135","volume":"84","author":"J Lu","year":"2013","unstructured":"Lu, J. et al. Discrete functions of M2a and M2c macrophage subsets determine their relative efficacy in treating chronic kidney disease. Kidney Int. 84, 745\u2013755 (2013).","journal-title":"Kidney Int."},{"key":"2178_CR159","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/cr.2010.52","volume":"20","author":"Q Wang","year":"2010","unstructured":"Wang, Q. et al. Fra-1 protooncogene regulates IL-6 expression in macrophages and promotes the generation of M2d macrophages. Cell Res. 20, 701\u2013712 (2010).","journal-title":"Cell Res."},{"key":"2178_CR160","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1080\/15412555.2017.1346069","volume":"14","author":"DS Sales","year":"2017","unstructured":"Sales, D. S. et al. Regulatory T-cell distribution within lung compartments in COPD. COPD 14, 533\u2013542 (2017).","journal-title":"COPD"},{"key":"2178_CR161","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1684\/ecn.2019.0433","volume":"30","author":"C Maucourant","year":"2019","unstructured":"Maucourant, C. et al. Zika virus in the eye of the cytokine storm. Eur. Cytokine Netw. 30, 74\u201381 (2019).","journal-title":"Eur. Cytokine Netw."},{"key":"2178_CR162","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1007\/s11684-019-0714-8","volume":"13","author":"H Chen","year":"2019","unstructured":"Chen, H. et al. Management of cytokine release syndrome related to CAR-T cell therapy. Front. Med. 13, 610\u2013617 (2019).","journal-title":"Front. Med."},{"key":"2178_CR163","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00705-016-3093-3","volume":"162","author":"IL Indalao","year":"2017","unstructured":"Indalao, I. L., Sawabuchi, T., Takahashi, E. & Kido, H. IL-1beta is a key cytokine that induces trypsin upregulation in the influenza virus-cytokine-trypsin cycle. Arch. Virol. 162, 201\u2013211 (2017).","journal-title":"Arch. Virol."},{"key":"2178_CR164","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1152\/physrev.00012.2018","volume":"99","author":"PX Liew","year":"2019","unstructured":"Liew, P. X. & Kubes, P. The neutrophil\u2019s role during health and disease. Physiol. Rev. 99, 1223\u20131248 (2019).","journal-title":"Physiol. Rev."},{"key":"2178_CR165","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.3390\/v13112318","volume":"13","author":"L Chan","year":"2021","unstructured":"Chan, L. et al. The roles of neutrophils in cytokine storms. Viruses 13, 2318 (2021).","journal-title":"Viruses"},{"key":"2178_CR166","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3389\/fphys.2018.00113","volume":"9","author":"C Rosales","year":"2018","unstructured":"Rosales, C. Neutrophil: a cell with many roles in inflammation or several cell types? Front. Physiol. 9, 113 (2018).","journal-title":"Front. Physiol."},{"key":"2178_CR167","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/JLB.4MIR0220-574RR","volume":"108","author":"C Rosales","year":"2020","unstructured":"Rosales, C. Neutrophils at the crossroads of innate and adaptive immunity. J. Leukoc. Biol. 108, 377\u2013396 (2020).","journal-title":"J. Leukoc. Biol."},{"key":"2178_CR168","doi-asserted-by":"publisher","first-page":"e1458","DOI":"10.1002\/wsbm.1458","volume":"12","author":"V Rungelrath","year":"2020","unstructured":"Rungelrath, V., Kobayashi, S. D. & DeLeo, F. R. Neutrophils in innate immunity and systems biology-level approaches. Wiley Interdiscip. Rev. Syst. Biol. Med. 12, e1458 (2020).","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."},{"key":"2178_CR169","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.it.2019.05.003","volume":"40","author":"MA Cassatella","year":"2019","unstructured":"Cassatella, M. A., \u00d6stberg, N. K., Tamassia, N. & Soehnlein, O. Biological roles of neutrophil-derived granule proteins and cytokines. Trends Immunol. 40, 648\u2013664 (2019).","journal-title":"Trends Immunol."},{"key":"2178_CR170","doi-asserted-by":"publisher","first-page":"e12952","DOI":"10.1111\/eci.12952","volume":"48","author":"N Tamassia","year":"2018","unstructured":"Tamassia, N. et al. Cytokine production by human neutrophils: revisiting the \u201cdark side of the moon\u201d. Eur. J. Clin. Investig. 48, e12952 (2018).","journal-title":"Eur. J. Clin. Investig."},{"key":"2178_CR171","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1093\/cvr\/cvac052","volume":"118","author":"P Carai","year":"2023","unstructured":"Carai, P. et al. Neutrophil inhibition improves acute inflammation in a murine model of viral myocarditis. Cardiovasc. Res. 118, 3331\u20133345 (2023).","journal-title":"Cardiovasc. Res."},{"key":"2178_CR172","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2013.48","volume":"45","author":"YS Jung","year":"2013","unstructured":"Jung, Y. S. et al. Wnt5a stimulates chemotactic migration and chemokine production in human neutrophils. Exp. Mol. Med. 45, e27 (2013).","journal-title":"Exp. Mol. Med."},{"key":"2178_CR173","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1172\/JCI35740","volume":"118","author":"O Soehnlein","year":"2008","unstructured":"Soehnlein, O. et al. Neutrophil primary granule proteins HBP and HNP1-3 boost bacterial phagocytosis by human and murine macrophages. J. Clin. Investig. 118, 3491\u20133502 (2008).","journal-title":"J. Clin. Investig."},{"key":"2178_CR174","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1164\/rccm.201203-0508OC","volume":"187","author":"A Ichikawa","year":"2013","unstructured":"Ichikawa, A. et al. CXCL10-CXCR3 enhances the development of neutrophil-mediated fulminant lung injury of viral and nonviral origin. Am. J. Respir. Crit. Care Med. 187, 65\u201377 (2013).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2178_CR175","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.4049\/jimmunol.178.7.4595","volume":"178","author":"M Scannell","year":"2007","unstructured":"Scannell, M. et al. Annexin-1 and peptide derivatives are released by apoptotic cells and stimulate phagocytosis of apoptotic neutrophils by macrophages. J. Immunol. 178, 4595\u20134605 (2007).","journal-title":"J. Immunol."},{"key":"2178_CR176","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nri2779","volume":"10","author":"O Soehnlein","year":"2010","unstructured":"Soehnlein, O. & Lindbom, L. Phagocyte partnership during the onset and resolution of inflammation. Nat. Rev. Immunol. 10, 427\u2013439 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"2178_CR177","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.3389\/fimmu.2019.02759","volume":"10","author":"M Gschwandtner","year":"2019","unstructured":"Gschwandtner, M., Derler, R. & Midwood, K. S. More than just attractive: how CCL2 influences myeloid cell behavior beyond chemotaxis. Front. Immunol. 10, 2759 (2019).","journal-title":"Front. Immunol."},{"key":"2178_CR178","doi-asserted-by":"publisher","first-page":"18073","DOI":"10.1073\/pnas.1008737107","volume":"107","author":"D Kreisel","year":"2010","unstructured":"Kreisel, D. et al. In vivo two-photon imaging reveals monocyte-dependent neutrophil extravasation during pulmonary inflammation. Proc. Natl Acad. Sci. USA 107, 18073\u201318078 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2178_CR179","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1080\/15548627.2022.2099206","volume":"19","author":"R Zhang","year":"2023","unstructured":"Zhang, R. et al. Neutrophil autophagy and NETosis in COVID-19: perspectives. Autophagy 19, 758\u2013767 (2023).","journal-title":"Autophagy"},{"key":"2178_CR180","doi-asserted-by":"publisher","first-page":"e20200652","DOI":"10.1084\/jem.20200652","volume":"217","author":"BJ Barnes","year":"2020","unstructured":"Barnes, B. J. et al. Targeting potential drivers of COVID-19: neutrophil extracellular traps. J. Exp. Med. 217, e20200652 (2020).","journal-title":"J. Exp. Med."},{"key":"2178_CR181","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3389\/fmolb.2020.00157","volume":"7","author":"B Zhang","year":"2020","unstructured":"Zhang, B. et al. Immune phenotyping based on the neutrophil-to-lymphocyte ratio and IgG level predicts disease severity and outcome for patients With COVID-19. Front. Mol. Biosci. 7, 157 (2020).","journal-title":"Front. Mol. Biosci."},{"key":"2178_CR182","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/JLB.3COVCRA0720-359R","volume":"109","author":"H Shi","year":"2021","unstructured":"Shi, H. et al. Neutrophil calprotectin identifies severe pulmonary disease in COVID-19. J. Leukoc. Biol. 109, 67\u201372 (2021).","journal-title":"J. Leukoc. Biol."},{"key":"2178_CR183","doi-asserted-by":"publisher","first-page":"5566826","DOI":"10.1155\/2021\/5566826","volume":"2021","author":"A Obermayer","year":"2021","unstructured":"Obermayer, A. et al. Neutrophil extracellular traps in fatal COVID-19-associated lung injury. Dis. Markers 2021, 5566826 (2021).","journal-title":"Dis. Markers"},{"key":"2178_CR184","doi-asserted-by":"publisher","first-page":"5301548","DOI":"10.1155\/2018\/5301548","volume":"2018","author":"L Zhao","year":"2018","unstructured":"Zhao, L. & Fu, Z. Roles of host immunity in viral myocarditis and dilated cardiomyopathy. J. Immunol. Res. 2018, 5301548 (2018).","journal-title":"J. Immunol. Res."},{"key":"2178_CR185","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1007\/s10753-021-01472-5","volume":"44","author":"Z Cen","year":"2021","unstructured":"Cen, Z. et al. The role of B cells in regulation of Th cell differentiation in coxsackievirus B3-induced acute myocarditis. Inflammation 44, 1949\u20131960 (2021).","journal-title":"Inflammation"},{"key":"2178_CR186","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/imm.13556","volume":"167","author":"Y Luo","year":"2022","unstructured":"Luo, Y. et al. Stem cell factor\/mast cell\/CCL2\/monocyte\/macrophage axis promotes Coxsackievirus B3 myocarditis and cardiac fibrosis by increasing Ly6C(high) monocyte influx and fibrogenic mediators production. Immunology 167, 590\u2013605 (2022).","journal-title":"Immunology"},{"key":"2178_CR187","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.cardiores.2003.08.016","volume":"60","author":"S Gilles","year":"2003","unstructured":"Gilles, S., Zahler, S., Welsch, U., Sommerhoff, C. P. & Becker, B. F. Release of TNF-alpha during myocardial reperfusion depends on oxidative stress and is prevented by mast cell stabilizers. Cardiovasc. Res. 60, 608\u2013616 (2003).","journal-title":"Cardiovasc. Res."},{"key":"2178_CR188","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2019.01.005","volume":"208","author":"A He","year":"2019","unstructured":"He, A. et al. Mast cell-deficiency protects mice from streptozotocin-induced diabetic cardiomyopathy. Transl. Res. 208, 1\u201314 (2019).","journal-title":"Transl. Res."},{"key":"2178_CR189","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jaci.2017.09.022","volume":"141","author":"JA O\u2019Sullivan","year":"2018","unstructured":"O\u2019Sullivan, J. A. & Bochner, B. S. Eosinophils and eosinophil-associated diseases: an update. J. Allergy Clin. Immunol. 141, 505\u2013517 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2178_CR190","doi-asserted-by":"publisher","first-page":"17406","DOI":"10.1074\/jbc.R113.546218","volume":"289","author":"KR Acharya","year":"2014","unstructured":"Acharya, K. R. & Ackerman, S. J. Eosinophil granule proteins: form and function. J. Biol. Chem. 289, 17406\u201317415 (2014).","journal-title":"J. Biol. Chem."},{"key":"2178_CR191","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/JLB.1MR1117-442RR","volume":"104","author":"H Abdala-Valencia","year":"2018","unstructured":"Abdala-Valencia, H. et al. Shaping eosinophil identity in the tissue contexts of development, homeostasis, and disease. J. Leukoc. Biol. 104, 95\u2013108 (2018).","journal-title":"J. Leukoc. Biol."},{"key":"2178_CR192","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3389\/fmed.2017.00093","volume":"4","author":"CN McBrien","year":"2017","unstructured":"McBrien, C. N. & Menzies-Gow, A. The biology of eosinophils and their role in asthma. Front. Med. 4, 93 (2017).","journal-title":"Front. Med."},{"key":"2178_CR193","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/cea.12880","volume":"47","author":"D Robinson","year":"2017","unstructured":"Robinson, D. et al. Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin. Exp. Allergy 47, 161\u2013175 (2017).","journal-title":"Clin. Exp. Allergy"},{"key":"2178_CR194","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1016\/j.mayocp.2021.04.025","volume":"96","author":"ME Wechsler","year":"2021","unstructured":"Wechsler, M. E. et al. Eosinophils in health and disease: a state-of-the-art review. Mayo Clin. Proc. 96, 2694\u20132707 (2021).","journal-title":"Mayo Clin. Proc."},{"key":"2178_CR195","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/s12276-021-00649-0","volume":"53","author":"S Kang","year":"2021","unstructured":"Kang, S. & Kishimoto, T. Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms. Exp. Mol. Med. 53, 1116\u20131123 (2021).","journal-title":"Exp. Mol. Med."},{"key":"2178_CR196","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41577-021-00536-9","volume":"21","author":"A Bonaventura","year":"2021","unstructured":"Bonaventura, A. et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat. Rev. Immunol. 21, 319\u2013329 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"2178_CR197","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.thromres.2020.04.014","volume":"190","author":"R Escher","year":"2020","unstructured":"Escher, R., Breakey, N. & L\u00e4mmle, B. Severe COVID-19 infection associated with endothelial activation. Thromb. Res. 190, 62 (2020).","journal-title":"Thromb. Res."},{"key":"2178_CR198","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41577-022-00762-9","volume":"22","author":"EM Conway","year":"2022","unstructured":"Conway, E. M. et al. Understanding COVID-19-associated coagulopathy. Nat. Rev. Immunol. 22, 639\u2013649 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"2178_CR199","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1038\/s41591-020-1021-2","volume":"26","author":"V Ramlall","year":"2020","unstructured":"Ramlall, V. et al. Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection. Nat. Med. 26, 1609\u20131615 (2020).","journal-title":"Nat. Med."},{"key":"2178_CR200","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1182\/blood.2020007008","volume":"136","author":"EA Middleton","year":"2020","unstructured":"Middleton, E. A. et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood 136, 1169\u20131179 (2020).","journal-title":"Blood"},{"key":"2178_CR201","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/08820139.2016.1208220","volume":"46","author":"V Kazanski","year":"2017","unstructured":"Kazanski, V., Mitrokhin, V. M., Mladenov, M. I. & Kamkin, A. G. Cytokine effects on mechano-induced electrical activity in atrial myocardium. Immunol. Investig. 46, 22\u201337 (2017).","journal-title":"Immunol. Investig."},{"key":"2178_CR202","doi-asserted-by":"publisher","first-page":"e751","DOI":"10.1097\/CCM.0000000000001654","volume":"44","author":"G Cavalli","year":"2016","unstructured":"Cavalli, G. et al. Treating life-threatening myocarditis by blocking interleukin-1. Crit. Care Med. 44, e751\u2013e754 (2016).","journal-title":"Crit. Care Med."},{"key":"2178_CR203","doi-asserted-by":"publisher","first-page":"635080","DOI":"10.3389\/fped.2020.635080","volume":"8","author":"A Meneghel","year":"2020","unstructured":"Meneghel, A. et al. Case report: life-threatening macrophage activation syndrome with fulminant myocarditis successfully rescued by high dose intravenous anakinra. Front. Pediatr. 8, 635080 (2020).","journal-title":"Front. Pediatr."},{"key":"2178_CR204","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3389\/fimmu.2017.00131","volume":"8","author":"G Cavalli","year":"2017","unstructured":"Cavalli, G. et al. Interleukin-1 receptor blockade rescues myocarditis-associated end-stage heart failure. Front. Immunol. 8, 131 (2017).","journal-title":"Front. Immunol."},{"key":"2178_CR205","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1161\/CIRCRESAHA.112.275867","volume":"111","author":"GW Dorn 2nd","year":"2012","unstructured":"Dorn, G. W. 2nd Inflame on!: mitochondrial escape provokes cytokine storms that doom the heart. Circ. Res. 111, 271\u2013273 (2012).","journal-title":"Circ. Res."},{"key":"2178_CR206","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.3390\/cells9071565","volume":"9","author":"H Keshavarz-Bahaghighat","year":"2020","unstructured":"Keshavarz-Bahaghighat, H., Darwesh, A. M., Sosnowski, D. K. & Seubert, J. M. Mitochondrial dysfunction and inflammaging in heart failure: novel roles of CYP-derived epoxylipids. Cells 9, 1565 (2020).","journal-title":"Cells"},{"key":"2178_CR207","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/cbin.11249","volume":"44","author":"J Nie","year":"2020","unstructured":"Nie, J. et al. Activation of CaMKII via ER-stress mediates coxsackievirus B3-induced cardiomyocyte apoptosis. Cell Biol. Int. 44, 488\u2013498 (2020).","journal-title":"Cell Biol. Int."},{"key":"2178_CR208","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.hrthm.2018.11.024","volume":"16","author":"G Peretto","year":"2019","unstructured":"Peretto, G. et al. Arrhythmias in myocarditis: state of the art. Heart Rhythm 16, 793\u2013801 (2019).","journal-title":"Heart Rhythm"},{"key":"2178_CR209","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41392-020-00360-y","volume":"5","author":"W Hang","year":"2020","unstructured":"Hang, W., Chen, C., Seubert, J. M. & Wang, D. W. Fulminant myocarditis: a comprehensive review from etiology to treatments and outcomes. Signal Transduct. Target. Ther. 5, 287 (2020).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2178_CR210","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1002\/ehf2.13431","volume":"8","author":"CJ Tian","year":"2021","unstructured":"Tian, C. J., Zhang, J. H., Liu, J., Ma, Z. & Zhen, Z. Ryanodine receptor and immune-related molecules in diabetic cardiomyopathy. ESC Heart Fail 8, 2637\u20132646 (2021).","journal-title":"ESC Heart Fail"},{"key":"2178_CR211","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00011-009-0093-8","volume":"59","author":"A Zhang","year":"2010","unstructured":"Zhang, A., Zhang, H. & Wu, S. Immunomodulation by atorvastatin upregulates expression of gap junction proteins in coxsackievirus B3 (CVB3)-induced myocarditis. Inflamm. Res. 59, 255\u2013262 (2010).","journal-title":"Inflamm. Res."},{"key":"2178_CR212","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1161\/CIRCULATIONAHA.120.046900","volume":"142","author":"M Casella","year":"2020","unstructured":"Casella, M. et al. Diagnostic yield of electroanatomic voltage mapping in guiding endomyocardial biopsies. Circulation 142, 1249\u20131260 (2020).","journal-title":"Circulation"},{"key":"2178_CR213","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1253\/circj.CJ-18-0136","volume":"82","author":"A Sawamura","year":"2018","unstructured":"Sawamura, A. et al. Prognostic Value of electrocardiography in patients with fulminant myocarditis supported by percutaneous venoarterial extracorporeal membrane oxygenation- analysis from the CHANGE PUMP study. Circ. J. 82, 2089\u20132095 (2018).","journal-title":"Circ. J."},{"key":"2178_CR214","doi-asserted-by":"publisher","first-page":"808799","DOI":"10.3389\/fimmu.2021.808799","volume":"12","author":"C Manosalva","year":"2021","unstructured":"Manosalva, C. et al. Role of lactate in inflammatory processes: friend or foe. Front. Immunol. 12, 808799 (2021).","journal-title":"Front. Immunol."},{"key":"2178_CR215","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10787-023-01353-3","volume":"32","author":"J Kaur","year":"2024","unstructured":"Kaur, J. et al. Protective effect of olopatadine hydrochloride against LPS-induced acute lung injury: via targeting NF-kappaB signaling pathway. Inflammopharmacology 32, 603\u2013627 (2024).","journal-title":"Inflammopharmacology"},{"key":"2178_CR216","doi-asserted-by":"publisher","first-page":"959","DOI":"10.2217\/imt-2016-0020","volume":"8","author":"T Tanaka","year":"2016","unstructured":"Tanaka, T., Narazaki, M. & Kishimoto, T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy 8, 959\u2013970 (2016).","journal-title":"Immunotherapy"},{"key":"2178_CR217","doi-asserted-by":"publisher","first-page":"7947596","DOI":"10.1155\/2019\/7947596","volume":"2019","author":"JM Shieh","year":"2019","unstructured":"Shieh, J. M., Tseng, H. Y., Jung, F., Yang, S. H. & Lin, J. C. Elevation of IL-6 and IL-33 levels in serum associated with lung fibrosis and skeletal muscle wasting in a bleomycin-induced lung injury mouse model. Mediat. Inflamm. 2019, 7947596 (2019).","journal-title":"Mediat. Inflamm."},{"key":"2178_CR218","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/intimm\/dxv070","volume":"28","author":"R Sakaguchi","year":"2016","unstructured":"Sakaguchi, R. et al. Innate-like function of memory Th17 cells for enhancing endotoxin-induced acute lung inflammation through IL-22. Int. Immunol. 28, 233\u2013243 (2016).","journal-title":"Int. Immunol."},{"key":"2178_CR219","doi-asserted-by":"publisher","first-page":"e459","DOI":"10.1016\/S2352-3026(24)00077-2","volume":"11","author":"K Rejeski","year":"2024","unstructured":"Rejeski, K., Jain, M. D., Shah, N. N., Perales, M. A. & Subklewe, M. Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management. Lancet Haematol 11, e459\u2013e470 (2024).","journal-title":"Lancet Haematol"},{"key":"2178_CR220","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1182\/bloodadvances.2020004142","volume":"6","author":"KR Juluri","year":"2022","unstructured":"Juluri, K. R. et al. Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. Blood Adv. 6, 2055\u20132068 (2022).","journal-title":"Blood Adv."},{"key":"2178_CR221","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/cbin.11545","volume":"45","author":"S Najafi","year":"2021","unstructured":"Najafi, S., Ghanavat, M., Shahrabi, S., Gatavizadeh, Z. & Saki, N. The effect of inflammatory factors and their inhibitors on the hematopoietic stem cells fate. Cell Biol. Int. 45, 900\u2013912 (2021).","journal-title":"Cell Biol. Int."},{"key":"2178_CR222","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.humimm.2020.01.004","volume":"81","author":"B Jahandideh","year":"2020","unstructured":"Jahandideh, B. et al. The pro-Inflammatory cytokines effects on mobilization, self-renewal and differentiation of hematopoietic stem cells. Hum. Immunol. 81, 206\u2013217 (2020).","journal-title":"Hum. Immunol."},{"key":"2178_CR223","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1182\/blood.2019003910","volume":"136","author":"H He","year":"2020","unstructured":"He, H. et al. Aging-induced IL27Ra signaling impairs hematopoietic stem cells. Blood 136, 183\u2013198 (2020).","journal-title":"Blood"},{"key":"2178_CR224","doi-asserted-by":"publisher","first-page":"752","DOI":"10.4049\/jimmunol.174.2.752","volume":"174","author":"L Yang","year":"2005","unstructured":"Yang, L. et al. IFN-gamma negatively modulates self-renewal of repopulating human hemopoietic stem cells. J. Immunol. 174, 752\u2013757 (2005).","journal-title":"J. Immunol."},{"key":"2178_CR225","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.stem.2022.06.012","volume":"29","author":"R Bogeska","year":"2022","unstructured":"Bogeska, R. et al. Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging. Cell Stem Cell 29, 1273\u20131284.e1278 (2022).","journal-title":"Cell Stem Cell"},{"key":"2178_CR226","doi-asserted-by":"publisher","first-page":"eadg3919","DOI":"10.1126\/sciadv.adg3919","volume":"9","author":"K Rejeski","year":"2023","unstructured":"Rejeski, K. et al. Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion. Sci. Adv. 9, eadg3919 (2023).","journal-title":"Sci. Adv."},{"key":"2178_CR227","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/bjh.18747","volume":"202","author":"W Kitamura","year":"2023","unstructured":"Kitamura, W. et al. Bone marrow microenvironment disruption and sustained inflammation with prolonged haematologic toxicity after CAR T-cell therapy. Br. J. Haematol. 202, 294\u2013307 (2023).","journal-title":"Br. J. Haematol."},{"key":"2178_CR228","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41556-022-01053-0","volume":"25","author":"CA Mitchell","year":"2023","unstructured":"Mitchell, C. A. et al. Stromal niche inflammation mediated by IL-1 signalling is a targetable driver of haematopoietic ageing. Nat. Cell Biol. 25, 30\u201341 (2023).","journal-title":"Nat. Cell Biol."},{"key":"2178_CR229","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-023-00438-1","volume":"9","author":"F Malard","year":"2023","unstructured":"Malard, F., Holler, E., Sandmaier, B. M., Huang, H. & Mohty, M. Acute graft-versus-host disease. Nat. Rev. Dis. Prim. 9, 27 (2023).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2178_CR230","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1182\/blood-2009-11-253559","volume":"115","author":"Y Shono","year":"2010","unstructured":"Shono, Y. et al. Bone marrow graft-versus-host disease: early destruction of hematopoietic niche after MHC-mismatched hematopoietic stem cell transplantation. Blood 115, 5401\u20135411 (2010).","journal-title":"Blood"},{"key":"2178_CR231","doi-asserted-by":"publisher","first-page":"e104607","DOI":"10.1371\/journal.pone.0104607","volume":"9","author":"Y Yao","year":"2014","unstructured":"Yao, Y. et al. Dysfunction of bone marrow vascular niche in acute graft-versus-host disease after MHC-haploidentical bone marrow transplantation. PLoS ONE 9, e104607 (2014).","journal-title":"PLoS ONE"},{"key":"2178_CR232","doi-asserted-by":"publisher","first-page":"1016318","DOI":"10.3389\/fonc.2022.1016318","volume":"12","author":"J Paolino","year":"2022","unstructured":"Paolino, J., Berliner, N. & Degar, B. Hemophagocytic lymphohistiocytosis as an etiology of bone marrow failure. Front. Oncol. 12, 1016318 (2022).","journal-title":"Front. Oncol."},{"key":"2178_CR233","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen, A. et al. Cytokine release syndrome. J. Immunother. Cancer 6, 56 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"2178_CR234","doi-asserted-by":"publisher","first-page":"5719","DOI":"10.1128\/MCB.17.10.5719","volume":"17","author":"J Alonso","year":"1997","unstructured":"Alonso, J., S\u00e1nchez de Miguel, L., Mont\u00f3n, M., Casado, S. & L\u00f3pez-Farr\u00e9, A. Endothelial cytosolic proteins bind to the 3\u2019 untranslated region of endothelial nitric oxide synthase mRNA: regulation by tumor necrosis factor alpha. Mol. Cell Biol. 17, 5719\u20135726 (1997).","journal-title":"Mol. Cell Biol."},{"key":"2178_CR235","doi-asserted-by":"publisher","first-page":"E68","DOI":"10.1161\/hh1101.092677","volume":"88","author":"I Fleming","year":"2001","unstructured":"Fleming, I., Fisslthaler, B., Dimmeler, S., Kemp, B. E. & Busse, R. Phosphorylation of Thr(495) regulates Ca(2+)\/calmodulin-dependent endothelial nitric oxide synthase activity. Circ. Res. 88, E68\u2013E75 (2001).","journal-title":"Circ. Res."},{"key":"2178_CR236","doi-asserted-by":"publisher","first-page":"L452","DOI":"10.1152\/ajplung.00378.2002","volume":"286","author":"P Neumann","year":"2004","unstructured":"Neumann, P., Gertzberg, N. & Johnson, A. TNF-alpha induces a decrease in eNOS promoter activity. Am. J. Physiol. Lung Cell Mol. Physiol. 286, L452\u2013L459 (2004).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"2178_CR237","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.bbaexp.2006.07.003","volume":"1759","author":"S Jain","year":"2006","unstructured":"Jain, S. et al. Upregulation of human angiotensinogen (AGT) gene transcription by interferon-gamma: involvement of the STAT1-binding motif in the AGT promoter. Biochim. Biophys. Acta 1759, 340\u2013347 (2006).","journal-title":"Biochim. Biophys. Acta"},{"key":"2178_CR238","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.116.303697","volume":"116","author":"WG McMaster","year":"2015","unstructured":"McMaster, W. G., Kirabo, A., Madhur, M. S. & Harrison, D. G. Inflammation, immunity, and hypertensive end-organ damage. Circ. Res. 116, 1022\u20131033 (2015).","journal-title":"Circ. Res."},{"key":"2178_CR239","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.3390\/v13081553","volume":"13","author":"S Koskela","year":"2021","unstructured":"Koskela, S. et al. Coagulopathy in acute Puumala hantavirus infection. Viruses 13, 1553 (2021).","journal-title":"Viruses"},{"key":"2178_CR240","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41581-020-0284-7","volume":"16","author":"C Ronco","year":"2020","unstructured":"Ronco, C. & Reis, T. Kidney involvement in COVID-19 and rationale for extracorporeal therapies. Nat. Rev. Nephrol. 16, 308\u2013310 (2020).","journal-title":"Nat. Rev. Nephrol."},{"key":"2178_CR241","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2147\/JIR.S267280","volume":"13","author":"T Shibabaw","year":"2020","unstructured":"Shibabaw, T., Molla, M. D., Teferi, B. & Ayelign, B. Role of IFN and complements system: innate immunity in SARS-CoV-2. J. Inflamm. Res. 13, 507\u2013518 (2020).","journal-title":"J. Inflamm. Res."},{"key":"2178_CR242","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/s41581-023-00766-1","volume":"19","author":"V Petr","year":"2023","unstructured":"Petr, V. & Thurman, J. M. The role of complement in kidney disease. Nat. Rev. Nephrol. 19, 771\u2013787 (2023).","journal-title":"Nat. Rev. Nephrol."},{"key":"2178_CR243","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1042\/bj2650621","volume":"265","author":"PC Heinrich","year":"1990","unstructured":"Heinrich, P. C., Castell, J. V. & Andus, T. Interleukin-6 and the acute phase response. Biochem. J. 265, 621\u2013636 (1990).","journal-title":"Biochem. J."},{"key":"2178_CR244","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1080\/14397595.2018.1515145","volume":"29","author":"YA Okuda","year":"2019","unstructured":"Okuda, Y. A. A amyloidosis\u2014benefits and prospects of IL-6 inhibitors. Mod. Rheumatol. 29, 268\u2013274 (2019).","journal-title":"Mod. Rheumatol."},{"key":"2178_CR245","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/j.jhep.2016.02.004","volume":"64","author":"D Schmidt-Arras","year":"2016","unstructured":"Schmidt-Arras, D. & Rose-John, S. IL-6 pathway in the liver: from physiopathology to therapy. J. Hepatol. 64, 1403\u20131415 (2016).","journal-title":"J. Hepatol."},{"key":"2178_CR246","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1002\/ajh.25829","volume":"95","author":"E Terpos","year":"2020","unstructured":"Terpos, E. et al. Hematological findings and complications of COVID-19. Am. J. Hematol. 95, 834\u2013847 (2020).","journal-title":"Am. J. Hematol."},{"key":"2178_CR247","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41577-020-0331-4","volume":"20","author":"M Merad","year":"2020","unstructured":"Merad, M. & Martin, J. C. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat. Rev. Immunol. 20, 355\u2013362 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"2178_CR248","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nrgastro.2015.94","volume":"12","author":"G Szabo","year":"2015","unstructured":"Szabo, G. & Petrasek, J. Inflammasome activation and function in liver disease. Nat. Rev. Gastroenterol. Hepatol. 12, 387\u2013400 (2015).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2178_CR249","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/hep.21344","volume":"44","author":"R Sun","year":"2006","unstructured":"Sun, R. et al. STAT1 contributes to dsRNA inhibition of liver regeneration after partial hepatectomy in mice. Hepatology 44, 955\u2013966 (2006).","journal-title":"Hepatology"},{"key":"2178_CR250","doi-asserted-by":"publisher","first-page":"G583","DOI":"10.1152\/ajpgi.00422.2005","volume":"290","author":"RF Schwabe","year":"2006","unstructured":"Schwabe, R. F. & Brenner, D. A. Mechanisms of liver injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G583\u2013G589 (2006).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"2178_CR251","doi-asserted-by":"publisher","first-page":"577027","DOI":"10.3389\/fimmu.2020.577027","volume":"11","author":"J Gust","year":"2020","unstructured":"Gust, J., Ponce, R., Liles, W. C., Garden, G. A. & Turtle, C. J. Cytokines in CAR T cell-associated neurotoxicity. Front. Immunol. 11, 577027 (2020).","journal-title":"Front. Immunol."},{"key":"2178_CR252","doi-asserted-by":"publisher","first-page":"S331","DOI":"10.1097\/CCM.0b013e3181b6ed58","volume":"37","author":"E Iacobone","year":"2009","unstructured":"Iacobone, E. et al. Sepsis-associated encephalopathy and its differential diagnosis. Crit. Care Med. 37, S331\u2013S336 (2009).","journal-title":"Crit. Care Med."},{"key":"2178_CR253","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/0036554021000026986","volume":"35","author":"T Ichiyama","year":"2003","unstructured":"Ichiyama, T. et al. Cerebrospinal fluid and serum levels of cytokines and soluble tumor necrosis factor receptor in influenza virus-associated encephalopathy. Scand. J. Infect. Dis. 35, 59\u201361 (2003).","journal-title":"Scand. J. Infect. Dis."},{"key":"2178_CR254","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","volume":"29","author":"J Mahdi","year":"2023","unstructured":"Mahdi, J. et al. Tumor inflammation-associated neurotoxicity. Nat. Med. 29, 803\u2013810 (2023).","journal-title":"Nat. Med."},{"key":"2178_CR255","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.cyto.2004.03.012","volume":"27","author":"T Ichiyama","year":"2004","unstructured":"Ichiyama, T. et al. Analysis of cytokine levels and NF-kappaB activation in peripheral blood mononuclear cells in influenza virus-associated encephalopathy. Cytokine 27, 31\u201337 (2004).","journal-title":"Cytokine"},{"key":"2178_CR256","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1086\/423328","volume":"190","author":"PM Winter","year":"2004","unstructured":"Winter, P. M. et al. Proinflammatory cytokines and chemokines in humans with Japanese encephalitis. J. Infect. Dis. 190, 1618\u20131626 (2004).","journal-title":"J. Infect. Dis."},{"key":"2178_CR257","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno, J. N. & Kochenderfer, J. N. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 34, 45\u201355 (2019).","journal-title":"Blood Rev."},{"key":"2178_CR258","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00281-017-0625-1","volume":"39","author":"A Srikiatkhachorn","year":"2017","unstructured":"Srikiatkhachorn, A., Mathew, A. & Rothman, A. L. Immune-mediated cytokine storm and its role in severe dengue. Semin Immunopathol. 39, 563\u2013574 (2017).","journal-title":"Semin Immunopathol."},{"key":"2178_CR259","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust, J. et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 7, 1404\u20131419 (2017).","journal-title":"Cancer Discov."},{"key":"2178_CR260","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1042\/BST20140319","volume":"43","author":"KD Rochfort","year":"2015","unstructured":"Rochfort, K. D. & Cummins, P. M. The blood-brain barrier endothelium: a target for pro-inflammatory cytokines. Biochem. Soc. Trans. 43, 702\u2013706 (2015).","journal-title":"Biochem. Soc. Trans."},{"key":"2178_CR261","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.bbamcr.2016.03.018","volume":"1863","author":"M Rothaug","year":"2016","unstructured":"Rothaug, M., Becker-Pauly, C. & Rose-John, S. The role of interleukin-6 signaling in nervous tissue. Biochim. Biophys. Acta 1863, 1218\u20131227 (2016).","journal-title":"Biochim. Biophys. Acta"},{"key":"2178_CR262","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1152\/physrev.00011.2010","volume":"91","author":"H Kettenmann","year":"2011","unstructured":"Kettenmann, H., Hanisch, U. K., Noda, M. & Verkhratsky, A. Physiology of microglia. Physiol. Rev. 91, 461\u2013553 (2011).","journal-title":"Physiol. Rev."},{"key":"2178_CR263","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1073\/pnas.0808698106","volume":"106","author":"AT Argaw","year":"2009","unstructured":"Argaw, A. T., Gurfein, B. T., Zhang, Y., Zameer, A. & John, G. R. VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. Proc. Natl Acad. Sci. USA 106, 1977\u20131982 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2178_CR264","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1182\/blood.2023020571","volume":"142","author":"P Karschnia","year":"2023","unstructured":"Karschnia, P. et al. Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells. Blood 142, 1243\u20131248 (2023).","journal-title":"Blood"},{"key":"2178_CR265","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.immuni.2009.03.020","volume":"30","author":"DE Smith","year":"2009","unstructured":"Smith, D. E. et al. A central nervous system-restricted isoform of the interleukin-1 receptor accessory protein modulates neuronal responses to interleukin-1. Immunity 30, 817\u2013831 (2009).","journal-title":"Immunity"},{"key":"2178_CR266","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1200\/JCO.23.02019","volume":"42","author":"FY Lin","year":"2024","unstructured":"Lin, F. Y. et al. Phase I trial of GD2.CART cells augmented with constitutive interleukin-7 receptor for treatment of high-grade pediatric CNS tumors. J. Clin. Oncol. 42, 2769\u20132779 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2178_CR267","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1016\/j.amjcard.2019.09.017","volume":"124","author":"AN Sharma","year":"2019","unstructured":"Sharma, A. N., Stultz, J. R., Bellamkonda, N. & Amsterdam, E. A. Fulminant myocarditis: epidemiology, pathogenesis, diagnosis, and management. Am. J. Cardiol. 124, 1954\u20131960 (2019).","journal-title":"Am. J. Cardiol."},{"key":"2178_CR268","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.tcm.2020.05.008","volume":"31","author":"E Ammirati","year":"2021","unstructured":"Ammirati, E. et al. Update on acute myocarditis. Trends Cardiovasc. Med. 31, 370\u2013379 (2021).","journal-title":"Trends Cardiovasc. Med."},{"key":"2178_CR269","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jacc.2022.04.056","volume":"80","author":"P Barhoum","year":"2022","unstructured":"Barhoum, P. et al. Phenotypic heterogeneity of fulminant COVID-19-related myocarditis in adults. J. Am. Coll. Cardiol. 80, 299\u2013312 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2178_CR270","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s11427-023-2421-0","volume":"67","author":"J Jiang","year":"2024","unstructured":"Jiang, J. et al. Chinese Society of Cardiology guidelines on the diagnosis and treatment of adult fulminant myocarditis. Sci. China Life Sci. 67, 913\u2013939 (2024).","journal-title":"Sci. China Life Sci."},{"key":"2178_CR271","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1253\/jcj.39.463","volume":"39","author":"M Okuni","year":"1975","unstructured":"Okuni, M., Yamada, T., Mochizuki, S. & Sakurai, I. Studies on myocarditis in childhood, with special reference to the possible role of immunological process and the thymus in the chronicity of the disease. Jpn Circ. J. 39, 463\u2013470 (1975).","journal-title":"Jpn Circ. J."},{"key":"2178_CR272","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1161\/CIR.0000000000000745","volume":"141","author":"RD Kociol","year":"2020","unstructured":"Kociol, R. D. et al. Recognition and initial management of fulminant myocarditis: a scientific statement from the American Heart Association. Circulation 141, e69\u2013e92 (2020).","journal-title":"Circulation"},{"key":"2178_CR273","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1056\/NEJM200003093421003","volume":"342","author":"RE McCarthy 3rd","year":"2000","unstructured":"McCarthy, R. E. 3rd et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N. Engl. J. Med. 342, 690\u2013695 (2000).","journal-title":"N. Engl. J. Med."},{"key":"2178_CR274","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1093\/eurheartj\/ehad707","volume":"44","author":"F Huang","year":"2023","unstructured":"Huang, F. et al. Fulminant myocarditis proven by early biopsy and outcomes. Eur. Heart J. 44, 5110\u20135124 (2023).","journal-title":"Eur. Heart J."},{"key":"2178_CR275","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/ncpcardio1331","volume":"5","author":"S Gupta","year":"2008","unstructured":"Gupta, S., Markham, D. W., Drazner, M. H. & Mammen, P. P. Fulminant myocarditis. Nat. Clin. Pr. Cardiovasc. Med. 5, 693\u2013706 (2008).","journal-title":"Nat. Clin. Pr. Cardiovasc. Med."},{"key":"2178_CR276","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.15420\/ecr.2020.16","volume":"15","author":"M Abdelnabi","year":"2020","unstructured":"Abdelnabi, M., Eshak, N., Saleh, Y. & Almaghraby, A. Coronavirus disease 2019 myocarditis: insights into pathophysiology and management. Eur. Cardiol. 15, e51 (2020).","journal-title":"Eur. Cardiol."},{"key":"2178_CR277","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1161\/CIRCRESAHA.120.317055","volume":"126","author":"A Akhmerov","year":"2020","unstructured":"Akhmerov, A. & Marb\u00e1n, E. COVID-19 and the heart. Circ. Res. 126, 1443\u20131455 (2020).","journal-title":"Circ. Res."},{"key":"2178_CR278","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","volume":"17","author":"J Herrmann","year":"2020","unstructured":"Herrmann, J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat. Rev. Cardiol. 17, 474\u2013502 (2020).","journal-title":"Nat. Rev. Cardiol."},{"key":"2178_CR279","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jacc.2004.06.026","volume":"44","author":"KU Knowlton","year":"2004","unstructured":"Knowlton, K. U. & Yajima, T. Interleukin-10: biomarker or pathologic cytokine in fulminant myocarditis? J. Am. Coll. Cardiol. 44, 1298\u20131300 (2004).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2178_CR280","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.jacc.2004.01.055","volume":"44","author":"M Nishii","year":"2004","unstructured":"Nishii, M. et al. Serum levels of interleukin-10 on admission as a prognostic predictor of human fulminant myocarditis. J. Am. Coll. Cardiol. 44, 1292\u20131297 (2004).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2178_CR281","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1161\/01.CIR.0000141803.41217.B6","volume":"110","author":"W Liu","year":"2004","unstructured":"Liu, W. et al. Thioredoxin-1 ameliorates myosin-induced autoimmune myocarditis by suppressing chemokine expressions and leukocyte chemotaxis in mice. Circulation 110, 1276\u20131283 (2004).","journal-title":"Circulation"},{"key":"2178_CR282","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.122.062551","volume":"149","author":"P Ma","year":"2024","unstructured":"Ma, P. et al. Expansion of pathogenic cardiac macrophages in immune checkpoint inhibitor myocarditis. Circulation 149, 48\u201366 (2024).","journal-title":"Circulation"},{"key":"2178_CR283","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1161\/CIRCULATIONAHA.121.058869","volume":"146","author":"K Kanaoka","year":"2022","unstructured":"Kanaoka, K. et al. Features and outcomes of histologically proven myocarditis with fulminant presentation. Circulation 146, 1425\u20131433 (2022).","journal-title":"Circulation"},{"key":"2178_CR284","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.hrthm.2020.05.001","volume":"17","author":"B Siripanthong","year":"2020","unstructured":"Siripanthong, B. et al. Recognizing COVID-19-related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm 17, 1463\u20131471 (2020).","journal-title":"Heart Rhythm"},{"key":"2178_CR285","doi-asserted-by":"publisher","first-page":"e145186","DOI":"10.1172\/JCI145186","volume":"131","author":"J Moslehi","year":"2021","unstructured":"Moslehi, J., Lichtman, A. H., Sharpe, A. H., Galluzzi, L. & Kitsis, R. N. Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. J. Clin. Investig. 131, e145186 (2021).","journal-title":"J. Clin. Investig."},{"key":"2178_CR286","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1161\/hh1801.096263","volume":"89","author":"K Shioji","year":"2001","unstructured":"Shioji, K., Kishimoto, C. & Sasayama, S. Fc receptor-mediated inhibitory effect of immunoglobulin therapy on autoimmune giant cell myocarditis: concomitant suppression of the expression of dendritic cells. Circ. Res. 89, 540\u2013546 (2001).","journal-title":"Circ. Res."},{"key":"2178_CR287","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1093\/eurheartj\/ehaa357","volume":"41","author":"X Wei","year":"2020","unstructured":"Wei, X., Fang, Y. & Hu, H. Glucocorticoid and immunoglobulin to treat viral fulminant myocarditis. Eur. Heart J. 41, 2122 (2020).","journal-title":"Eur. Heart J."},{"key":"2178_CR288","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/eurheartj\/ehaa190","volume":"42","author":"H Hu","year":"2021","unstructured":"Hu, H., Ma, F., Wei, X. & Fang, Y. Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin. Eur. Heart J. 42, 206 (2021).","journal-title":"Eur. Heart J."},{"key":"2178_CR289","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jacc.2019.04.063","volume":"74","author":"E Ammirati","year":"2019","unstructured":"Ammirati, E. et al. Fulminant versus acute nonfulminant myocarditis in patients with left ventricular systolic dysfunction. J. Am. Coll. Cardiol. 74, 299\u2013311 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2178_CR290","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1002\/ejhf.2523","volume":"24","author":"M Yamamoto","year":"2022","unstructured":"Yamamoto, M., Tajiri, K., Ayuzawa, S. & Ieda, M. Pathological findings of clinically suspected myocarditis temporally associated with COVID-19 vaccination. Eur. J. Heart Fail 24, 1132\u20131138 (2022).","journal-title":"Eur. J. Heart Fail"},{"key":"2178_CR291","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/nrcardio.2015.108","volume":"12","author":"A Pollack","year":"2015","unstructured":"Pollack, A., Kontorovich, A. R., Fuster, V. & Dec, G. W. Viral myocarditis\u2013diagnosis, treatment options, and current controversies. Nat. Rev. Cardiol. 12, 670\u2013680 (2015).","journal-title":"Nat. Rev. Cardiol."},{"key":"2178_CR292","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1093\/eurheartj\/eht210","volume":"34","author":"AL Caforio","year":"2013","unstructured":"Caforio, A. L. et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur. Heart J. 34, 2636\u20132648 (2013).","journal-title":"Eur. Heart J."},{"key":"2178_CR293","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s11897-014-0196-6","volume":"11","author":"B Maisch","year":"2014","unstructured":"Maisch, B., Ruppert, V. & Pankuweit, S. Management of fulminant myocarditis: a diagnosis in search of its etiology but with therapeutic options. Curr. Heart Fail Rep. 11, 166\u2013177 (2014).","journal-title":"Curr. Heart Fail Rep."},{"key":"2178_CR294","doi-asserted-by":"publisher","first-page":"843891","DOI":"10.3389\/fimmu.2022.843891","volume":"13","author":"SY Zheng","year":"2022","unstructured":"Zheng, S. Y. & Dong, J. Z. Role of toll-like receptors and th responses in viral myocarditis. Front. Immunol. 13, 843891 (2022).","journal-title":"Front. Immunol."},{"key":"2178_CR295","doi-asserted-by":"publisher","first-page":"5374","DOI":"10.3390\/ijms24065374","volume":"24","author":"P Pannucci","year":"2023","unstructured":"Pannucci, P. et al. COVID-19-induced myocarditis: pathophysiological roles of ACE2 and toll-like receptors. Int. J. Mol. Sci. 24, 5374 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2178_CR296","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nature10992","volume":"485","author":"T Oka","year":"2012","unstructured":"Oka, T. et al. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature 485, 251\u2013255 (2012).","journal-title":"Nature"},{"key":"2178_CR297","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/cvr\/cvt118","volume":"99","author":"A Jenke","year":"2013","unstructured":"Jenke, A. et al. Adiponectin protects against Toll-like receptor 4-mediated cardiac inflammation and injury. Cardiovasc. Res. 99, 422\u2013431 (2013).","journal-title":"Cardiovasc. Res."},{"key":"2178_CR298","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1159\/000369342","volume":"7","author":"EI Lafferty","year":"2015","unstructured":"Lafferty, E. I., Wiltshire, S. A., Angers, I., Vidal, S. M. & Qureshi, S. T. Unc93b1 -dependent endosomal toll-like receptor signaling regulates inflammation and mortality during coxsackievirus B3 infection. J. Innate Immun. 7, 315\u2013330 (2015).","journal-title":"J. Innate Immun."},{"key":"2178_CR299","doi-asserted-by":"publisher","first-page":"109343","DOI":"10.1016\/j.intimp.2022.109343","volume":"113","author":"B Li","year":"2022","unstructured":"Li, B. et al. Interleukin-37 alleviates myocardial injury induced by coxsackievirus B3 via inhibiting neutrophil extracellular traps formation. Int. Immunopharmacol. 113, 109343 (2022).","journal-title":"Int. Immunopharmacol."},{"key":"2178_CR300","first-page":"3384","volume":"103","author":"YF Chen","year":"2023","unstructured":"Chen, Y. F. et al. Investigate the role of neutrophil extracellular traps in immune checkpoint inhibitor-associated myocarditis with programmed death protein-1 inhibitors involvement. Zhonghua Yi Xue Za Zhi 103, 3384\u20133393 (2023).","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"2178_CR301","first-page":"1954","volume":"12","author":"Y Yu","year":"2020","unstructured":"Yu, Y. et al. Inhibition of calpain alleviates coxsackievirus B3-induced myocarditis through suppressing the canonical NLRP3 inflammasome\/caspase-1-mediated and noncanonical caspase-11-mediated pyroptosis pathways. Am. J. Transl. Res. 12, 1954\u20131964 (2020).","journal-title":"Am. J. Transl. Res."},{"key":"2178_CR302","doi-asserted-by":"publisher","first-page":"1149911","DOI":"10.3389\/fcimb.2023.1149911","volume":"13","author":"J Xu","year":"2023","unstructured":"Xu, J. et al. Roles of inflammasomes in viral myocarditis. Front. Cell. Infect. Microbiol. 13, 1149911 (2023).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"2178_CR303","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3389\/fcimb.2018.00157","volume":"8","author":"D Xu","year":"2018","unstructured":"Xu, D. et al. Gr-1+ cells other than Ly6G+ neutrophils limit virus replication and promote myocardial inflammation and fibrosis following coxsackievirus B3 infection of mice. Front. Cell. Infect. Microbiol. 8, 157 (2018).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"2178_CR304","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.yjmcc.2018.08.029","volume":"125","author":"L Rivadeneyra","year":"2018","unstructured":"Rivadeneyra, L. et al. Role of neutrophils in CVB3 infection and viral myocarditis. J. Mol. Cell Cardiol. 125, 149\u2013161 (2018).","journal-title":"J. Mol. Cell Cardiol."},{"key":"2178_CR305","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/978-3-319-57613-8_10","volume":"1003","author":"W Bracamonte-Baran","year":"2017","unstructured":"Bracamonte-Baran, W. & \u010cih\u00e1kov\u00e1, D. Cardiac autoimmunity: myocarditis. Adv. Exp. Med. Biol. 1003, 187\u2013221 (2017).","journal-title":"Adv. Exp. Med. Biol."},{"key":"2178_CR306","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/nyas.12134","volume":"1285","author":"JG Barin","year":"2013","unstructured":"Barin, J. G. & Cihakova, D. Control of inflammatory heart disease by CD4+ T cells. Ann. N. Y. Acad. Sci. 1285, 80\u201396 (2013).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"2178_CR307","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1006\/jmcc.2000.1102","volume":"32","author":"C Kishimoto","year":"2000","unstructured":"Kishimoto, C., Kawamata, H., Sakai, S., Shinohara, H. & Ochiai, H. Role of MIP-2 in coxsackievirus B3 myocarditis. J. Mol. Cell Cardiol. 32, 631\u2013638 (2000).","journal-title":"J. Mol. Cell Cardiol."},{"key":"2178_CR308","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1161\/CIRCULATIONAHA.105.572396","volume":"112","author":"S G\u00f6ser","year":"2005","unstructured":"G\u00f6ser, S. et al. Critical role for monocyte chemoattractant protein-1 and macrophage inflammatory protein-1alpha in induction of experimental autoimmune myocarditis and effective anti-monocyte chemoattractant protein-1 gene therapy. Circulation 112, 3400\u20133407 (2005).","journal-title":"Circulation"},{"key":"2178_CR309","doi-asserted-by":"publisher","first-page":"2180951","DOI":"10.1080\/21505594.2023.2180951","volume":"14","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y., Zhou, X., Chen, S., Sun, X. & Zhou, C. Immune mechanisms of group B coxsackievirus induced viral myocarditis. Virulence 14, 2180951 (2023).","journal-title":"Virulence"},{"key":"2178_CR310","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/pin.12868","volume":"70","author":"K Imanaka-Yoshida","year":"2020","unstructured":"Imanaka-Yoshida, K. Inflammation in myocardial disease: From myocarditis to dilated cardiomyopathy. Pathol. Int. 70, 1\u201311 (2020).","journal-title":"Pathol. Int."},{"key":"2178_CR311","first-page":"e217818","volume":"50","author":"JY Lee","year":"2023","unstructured":"Lee, J. Y., Lee, S. H. & Kim, W. H. Fulminant eosinophilic myocarditis without peripheral eosinophilia. Tex. Heart Inst. J. 50, e217818 (2023).","journal-title":"Tex. Heart Inst. J."},{"key":"2178_CR312","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1016\/j.jacc.2017.09.023","volume":"70","author":"M Brambatti","year":"2017","unstructured":"Brambatti, M. et al. Eosinophilic myocarditis: characteristics, treatment, and outcomes. J. Am. Coll. Cardiol. 70, 2363\u20132375 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2178_CR313","doi-asserted-by":"publisher","first-page":"4038","DOI":"10.4049\/jimmunol.1301282","volume":"191","author":"JG Barin","year":"2013","unstructured":"Barin, J. G. et al. Fatal eosinophilic myocarditis develops in the absence of IFN-\u03b3 and IL-17A. J. Immunol. 191, 4038\u20134047 (2013).","journal-title":"J. Immunol."},{"key":"2178_CR314","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1161\/CIRCULATIONAHA.121.056730","volume":"146","author":"H Zhu","year":"2022","unstructured":"Zhu, H. et al. Identification of pathogenic immune cell subsets associated with checkpoint inhibitor-induced myocarditis. Circulation 146, 316\u2013335 (2022).","journal-title":"Circulation"},{"key":"2178_CR315","doi-asserted-by":"publisher","first-page":"4876","DOI":"10.4049\/jimmunol.1200389","volume":"188","author":"ML Tarrio","year":"2012","unstructured":"Tarrio, M. L., Grabie, N., Bu, D. X., Sharpe, A. H. & Lichtman, A. H. PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J. Immunol. 188, 4876\u20134884 (2012).","journal-title":"J. Immunol."},{"key":"2178_CR316","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/intimm\/dxq026","volume":"22","author":"J Wang","year":"2010","unstructured":"Wang, J. et al. PD-1 deficiency results in the development of fatal myocarditis in MRL mice. Int. Immunol. 22, 443\u2013452 (2010).","journal-title":"Int. Immunol."},{"key":"2178_CR317","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1161\/CIRCULATIONAHA.119.043171","volume":"141","author":"M Bockstahler","year":"2020","unstructured":"Bockstahler, M. et al. Heart-specific immune responses in an animal model of autoimmune-related myocarditis mitigated by an immunoproteasome inhibitor and genetic ablation. Circulation 141, 1885\u20131902 (2020).","journal-title":"Circulation"},{"key":"2178_CR318","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1093\/cvr\/cvz025","volume":"115","author":"N Grabie","year":"2019","unstructured":"Grabie, N., Lichtman, A. H. & Padera, R. T cell checkpoint regulators in the heart. Cardiovasc. Res. 115, 869\u2013877 (2019).","journal-title":"Cardiovasc. Res."},{"key":"2178_CR319","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson, D. B. et al. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med. 375, 1749\u20131755 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2178_CR320","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1272\/jnms.78.4","volume":"78","author":"Y Kusama","year":"2011","unstructured":"Kusama, Y. et al. Variant angina and coronary artery spasm: the clinical spectrum, pathophysiology, and management. J. Nippon Med. Sch. 78, 4\u201312 (2011).","journal-title":"J. Nippon Med. Sch."},{"key":"2178_CR321","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ijcard.2015.02.021","volume":"184","author":"BG Choi","year":"2015","unstructured":"Choi, B. G. et al. Five-year clinical outcomes in patients with significant coronary artery spasm: a propensity score-matched analysis. Int J. Cardiol. 184, 533\u2013539 (2015).","journal-title":"Int J. Cardiol."},{"key":"2178_CR322","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1177\/0025817217695904","volume":"85","author":"I Kitulwatte","year":"2017","unstructured":"Kitulwatte, I., Gangahawatte, S., Perera, U. & Edirisinghe, P. Death following ceftazidime-induced Kounis syndrome. Med. Leg. J. 85, 215\u2013218 (2017).","journal-title":"Med. Leg. J."},{"key":"2178_CR323","doi-asserted-by":"publisher","first-page":"4939","DOI":"10.2147\/JIR.S378152","volume":"15","author":"X Xu","year":"2022","unstructured":"Xu, X. et al. Variant angina is associated with myocarditis. J. Inflamm. Res. 15, 4939\u20134949 (2022).","journal-title":"J. Inflamm. Res."},{"key":"2178_CR324","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s11427-018-9501-9","volume":"62","author":"S Li","year":"2019","unstructured":"Li, S. et al. A life support-based comprehensive treatment regimen dramatically lowers the in-hospital mortality of patients with fulminant myocarditis: a multiple center study. Sci. China Life Sci. 62, 369\u2013380 (2019).","journal-title":"Sci. China Life Sci."},{"key":"2178_CR325","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-02925-3","volume":"24","author":"M Kowalewski","year":"2020","unstructured":"Kowalewski, M. et al. COVID-19 and ECMO: the interplay between coagulation and inflammation-a narrative review. Crit. Care 24, 205 (2020).","journal-title":"Crit. Care"},{"key":"2178_CR326","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-016-1570-4","volume":"20","author":"JE Millar","year":"2016","unstructured":"Millar, J. E., Fanning, J. P., McDonald, C. I., McAuley, D. F. & Fraser, J. F. The inflammatory response to extracorporeal membrane oxygenation (ECMO): a review of the pathophysiology. Crit. Care 20, 387 (2016).","journal-title":"Crit. Care"},{"key":"2178_CR327","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s12265-018-9820-2","volume":"12","author":"C Tschope","year":"2019","unstructured":"Tschope, C. et al. Mechanical unloading by fulminant myocarditis: LV-IMPELLA, ECMELLA, BI-PELLA, and PROPELLA concepts. J. Cardiovasc. Transl. Res. 12, 116\u2013123 (2019).","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"2178_CR328","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41586-024-07282-7","volume":"629","author":"JP Auger","year":"2024","unstructured":"Auger, J. P. et al. Metabolic rewiring promotes anti-inflammatory effects of glucocorticoids. Nature 629, 184\u2013192 (2024).","journal-title":"Nature"},{"key":"2178_CR329","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nri.2017.1","volume":"17","author":"DW Cain","year":"2017","unstructured":"Cain, D. W. & Cidlowski, J. A. Immune regulation by glucocorticoids. Nat. Rev. Immunol. 17, 233\u2013247 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"2178_CR330","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1016\/j.molcel.2022.05.009","volume":"82","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z. et al. Itaconate is a lysosomal inducer that promotes antibacterial innate immunity. Mol. Cell 82, 2844\u20132857.e2810 (2022).","journal-title":"Mol. Cell"},{"key":"2178_CR331","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18764-3","volume":"11","author":"D Olagnier","year":"2020","unstructured":"Olagnier, D. et al. SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate. Nat. Commun. 11, 4938 (2020).","journal-title":"Nat. Commun."},{"key":"2178_CR332","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jjcc.2012.11.006","volume":"61","author":"H Nakamura","year":"2013","unstructured":"Nakamura, H., Kunitsugu, I., Fukuda, K., Matsuzaki, M. & Sano, M. Diverse stage-dependent effects of glucocorticoids in a murine model of viral myocarditis. J. Cardiol. 61, 237\u2013242 (2013).","journal-title":"J. Cardiol."},{"key":"2178_CR333","doi-asserted-by":"publisher","first-page":"107260","DOI":"10.1016\/j.carpath.2020.107260","volume":"49","author":"O Blagova","year":"2020","unstructured":"Blagova, O., Nedostup, A., Kogan, E., Zaitsev, A. & Fomin, V. Immunosuppressive therapy of biopsy proved immune-mediated lymphocytic myocarditis in the virus-negative and virus-positive patients. Cardiovasc. Pathol. 49, 107260 (2020).","journal-title":"Cardiovasc. Pathol."},{"key":"2178_CR334","doi-asserted-by":"publisher","first-page":"3873","DOI":"10.3390\/molecules27123873","volume":"27","author":"Z Shi","year":"2022","unstructured":"Shi, Z., He, Z. & Wang, D. W. CYP450 epoxygenase metabolites, epoxyeicosatrienoic acids, as novel anti-inflammatory mediators. Molecules 27, 3873 (2022).","journal-title":"Molecules"},{"key":"2178_CR335","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1161\/CIRCRESAHA.123.322619","volume":"133","author":"Z Zhou","year":"2023","unstructured":"Zhou, Z. et al. Epoxyeicosatrienoic acids prevent cardiac dysfunction in viral myocarditis via interferon type I signaling. Circ. Res. 133, 772\u2013788 (2023).","journal-title":"Circ. Res."},{"key":"2178_CR336","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1161\/01.CIR.89.1.252","volume":"89","author":"NA Drucker","year":"1994","unstructured":"Drucker, N. A. et al. Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation 89, 252\u2013257 (1994).","journal-title":"Circulation"},{"key":"2178_CR337","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0828-282X(08)70638-X","volume":"24","author":"S Goland","year":"2008","unstructured":"Goland, S. et al. Intravenous immunoglobulin treatment for acute fulminant inflammatory cardiomyopathy: series of six patients and review of literature. Can. J. Cardiol. 24, 571\u2013574 (2008).","journal-title":"Can. J. Cardiol."},{"key":"2178_CR338","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1007\/s00380-013-0368-4","volume":"29","author":"C Kishimoto","year":"2014","unstructured":"Kishimoto, C. et al. Therapy with immunoglobulin in patients with acute myocarditis and cardiomyopathy: analysis of leukocyte balance. Heart Vessels 29, 336\u2013342 (2014).","journal-title":"Heart Vessels"},{"key":"2178_CR339","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1056\/NEJM199508033330501","volume":"333","author":"JW Mason","year":"1995","unstructured":"Mason, J. W. et al. A clinical trial of immunosuppressive therapy for myocarditis. The myocarditis treatment trial investigators. N. Engl. J. Med. 333, 269\u2013275 (1995).","journal-title":"N. Engl. J. Med."},{"key":"2178_CR340","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1161\/CIRCULATIONAHA.117.031139","volume":"137","author":"L Zhang","year":"2018","unstructured":"Zhang, L. et al. Functional metabolomics characterizes a key role for N-acetylneuraminic acid in coronary artery diseases. Circulation 137, 1374\u20131390 (2018).","journal-title":"Circulation"},{"key":"2178_CR341","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1007\/s00134-024-07485-6","volume":"50","author":"E Antonucci","year":"2024","unstructured":"Antonucci, E. et al. Incidence of acute kidney injury and attributive mortality in acute respiratory distress syndrome randomized trials. Intensive Care Med. 50, 1240\u20131250 (2024).","journal-title":"Intensive Care Med."},{"key":"2178_CR342","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1164\/rccm.201610-2156SO","volume":"196","author":"P Radermacher","year":"2017","unstructured":"Radermacher, P., Maggiore, S. M. & Mercat, A. Fifty years of research in ARDS. Gas exchange in acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 196, 964\u2013984 (2017).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2178_CR343","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1126\/science.abb8925","volume":"368","author":"JB Moore","year":"2020","unstructured":"Moore, J. B. & June, C. H. Cytokine release syndrome in severe COVID-19. Science 368, 473\u2013474 (2020).","journal-title":"Science"},{"key":"2178_CR344","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2015432","volume":"383","author":"M Ackermann","year":"2020","unstructured":"Ackermann, M. et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N. Engl. J. Med. 383, 120\u2013128 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2178_CR345","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41586-021-03570-8","volume":"595","author":"TM Delorey","year":"2021","unstructured":"Delorey, T. M. et al. COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets. Nature 595, 107\u2013113 (2021).","journal-title":"Nature"},{"key":"2178_CR346","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1164\/rccm.201101-0135OC","volume":"183","author":"C Brun-Buisson","year":"2011","unstructured":"Brun-Buisson, C., Richard, J. C., Mercat, A., Thi\u00e9baut, A. C. & Brochard, L. Early corticosteroids in severe influenza A\/H1N1 pneumonia and acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 183, 1200\u20131206 (2011).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2178_CR347","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1473-3099(13)70286-X","volume":"14","author":"KR Short","year":"2014","unstructured":"Short, K. R., Kroeze, E., Fouchier, R. A. M. & Kuiken, T. Pathogenesis of influenza-induced acute respiratory distress syndrome. Lancet Infect. Dis. 14, 57\u201369 (2014).","journal-title":"Lancet Infect. Dis."},{"key":"2178_CR348","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12931-020-01425-w","volume":"21","author":"LLY Chan","year":"2020","unstructured":"Chan, L. L. Y. et al. Host DNA released by NETosis in neutrophils exposed to seasonal H1N1 and highly pathogenic H5N1 influenza viruses. Respir. Res. 21, 160 (2020).","journal-title":"Respir. Res."},{"key":"2178_CR349","doi-asserted-by":"publisher","first-page":"e13279","DOI":"10.1111\/irv.13279","volume":"18","author":"J Kim","year":"2024","unstructured":"Kim, J., Hickerson, B. T. & Ilyushina, N. A. Coinfection of influenza A and B and human OC43 coronavirus in normal human bronchial epithelial cells. Influenza Other Respir. Viruses 18, e13279 (2024).","journal-title":"Influenza Other Respir. Viruses"},{"key":"2178_CR350","doi-asserted-by":"publisher","first-page":"117512","DOI":"10.1016\/j.jep.2023.117512","volume":"321","author":"W Huang","year":"2024","unstructured":"Huang, W. et al. Protection effects of mice liver and lung injury induced by coronavirus infection of Qingfei Paidu decoction involve inhibition of the NLRP3 signaling pathway. J. Ethnopharmacol. 321, 117512 (2024).","journal-title":"J. Ethnopharmacol."},{"key":"2178_CR351","doi-asserted-by":"publisher","first-page":"e46687","DOI":"10.2196\/46687","volume":"10","author":"KY Lau","year":"2024","unstructured":"Lau, K. Y. et al. Estimating the epidemic size of superspreading coronavirus outbreaks in real time: quantitative study. JMIR Public Health Surveill. 10, e46687 (2024).","journal-title":"JMIR Public Health Surveill."},{"key":"2178_CR352","doi-asserted-by":"publisher","first-page":"168797","DOI":"10.1016\/j.scitotenv.2023.168797","volume":"912","author":"S Fu","year":"2024","unstructured":"Fu, S. et al. Targeted amplicon sequencing facilitated a novel risk assessment framework for assessing the prevalence of broad spectrum bacterial and coronavirus diseases. Sci. Total Environ. 912, 168797 (2024).","journal-title":"Sci. Total Environ."},{"key":"2178_CR353","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41392-020-0191-1","volume":"5","author":"M Catanzaro","year":"2020","unstructured":"Catanzaro, M. et al. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct. Target. Ther. 5, 84 (2020).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2178_CR354","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cyto.2018.01.025","volume":"104","author":"WH Mahallawi","year":"2018","unstructured":"Mahallawi, W. H., Khabour, O. F., Zhang, Q., Makhdoum, H. M. & Suliman, B. A. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine 104, 8\u201313 (2018).","journal-title":"Cytokine"},{"key":"2178_CR355","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1365-2249.2004.02415.x","volume":"136","author":"CK Wong","year":"2004","unstructured":"Wong, C. K. et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin. Exp. Immunol. 136, 95\u2013103 (2004).","journal-title":"Clin. Exp. Immunol."},{"key":"2178_CR356","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41392-021-00726-w","volume":"6","author":"M Tian","year":"2021","unstructured":"Tian, M. et al. HIF-1alpha promotes SARS-CoV-2 infection and aggravates inflammatory responses to COVID-19. Signal Transduct. Target. Ther. 6, 308 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2178_CR357","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.tips.2020.06.007","volume":"41","author":"W Luo","year":"2020","unstructured":"Luo, W. et al. Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19. Trends Pharm. Sci. 41, 531\u2013543 (2020).","journal-title":"Trends Pharm. Sci."},{"key":"2178_CR358","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41392-022-01223-4","volume":"7","author":"YB Baek","year":"2022","unstructured":"Baek, Y. B. et al. Therapeutic strategy targeting host lipolysis limits infection by SARS-CoV-2 and influenza A virus. Signal Transduct. Target. Ther. 7, 367 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2178_CR359","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/aps.2013.121","volume":"34","author":"Q Liu","year":"2013","unstructured":"Liu, Q., Liu, D. Y. & Yang, Z. Q. Characteristics of human infection with avian influenza viruses and development of new antiviral agents. Acta Pharm. Sin. 34, 1257\u20131269 (2013).","journal-title":"Acta Pharm. Sin."},{"key":"2178_CR360","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1164\/rccm.201309-1616OC","volume":"189","author":"CM Oshansky","year":"2014","unstructured":"Oshansky, C. M. et al. Mucosal immune responses predict clinical outcomes during influenza infection independently of age and viral load. Am. J. Respir. Crit. Care Med. 189, 449\u2013462 (2014).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2178_CR361","doi-asserted-by":"publisher","first-page":"782","DOI":"10.3389\/fimmu.2017.00782","volume":"8","author":"BM Coates","year":"2017","unstructured":"Coates, B. M. et al. Inhibition of the NOD-like receptor protein 3 inflammasome is protective in juvenile influenza A virus infection. Front. Immunol. 8, 782 (2017).","journal-title":"Front. Immunol."},{"key":"2178_CR362","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00281-017-0636-y","volume":"39","author":"XJ Guo","year":"2017","unstructured":"Guo, X. J. & Thomas, P. G. New fronts emerge in the influenza cytokine storm. Semin. Immunopathol. 39, 541\u2013550 (2017).","journal-title":"Semin. Immunopathol."},{"key":"2178_CR363","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/cmi.2015.74","volume":"13","author":"Q Liu","year":"2016","unstructured":"Liu, Q., Zhou, Y. H. & Yang, Z. Q. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol. Immunol. 13, 3\u201310 (2016).","journal-title":"Cell Mol. Immunol."},{"key":"2178_CR364","first-page":"3","volume":"386","author":"JR Teijaro","year":"2015","unstructured":"Teijaro, J. R. The role of cytokine responses during influenza virus pathogenesis and potential therapeutic options. Curr. Top. Microbiol. Immunol. 386, 3\u201322 (2015).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"2178_CR365","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1146\/annurev.pathmechdis.3.121806.154316","volume":"3","author":"JK Taubenberger","year":"2008","unstructured":"Taubenberger, J. K. & Morens, D. M. The pathology of influenza virus infections. Annu Rev. Pathol. 3, 499\u2013522 (2008).","journal-title":"Annu Rev. Pathol."},{"key":"2178_CR366","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1164\/rccm.201406-1031OC","volume":"191","author":"VB Le","year":"2015","unstructured":"Le, V. B. et al. Platelet activation and aggregation promote lung inflammation and influenza virus pathogenesis. Am. J. Respir. Crit. Care Med. 191, 804\u2013819 (2015).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2178_CR367","doi-asserted-by":"publisher","first-page":"e2177","DOI":"10.1002\/rmv.2177","volume":"31","author":"S Pujhari","year":"2021","unstructured":"Pujhari, S., Paul, S., Ahluwalia, J. & Rasgon, J. L. Clotting disorder in severe acute respiratory syndrome coronavirus 2. Rev. Med. Virol. 31, e2177 (2021).","journal-title":"Rev. Med. Virol."},{"key":"2178_CR368","doi-asserted-by":"publisher","first-page":"107087","DOI":"10.1016\/j.intimp.2020.107087","volume":"89","author":"V Kumar","year":"2020","unstructured":"Kumar, V. Toll-like receptors in sepsis-associated cytokine storm and their endogenous negative regulators as future immunomodulatory targets. Int. Immunopharmacol. 89, 107087 (2020).","journal-title":"Int. Immunopharmacol."},{"key":"2178_CR369","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.virol.2010.12.003","volume":"411","author":"JS Rossman","year":"2011","unstructured":"Rossman, J. S. & Lamb, R. A. Influenza virus assembly and budding. Virology 411, 229\u2013236 (2011).","journal-title":"Virology"},{"key":"2178_CR370","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nri3665","volume":"14","author":"A Iwasaki","year":"2014","unstructured":"Iwasaki, A. & Pillai, P. S. Innate immunity to influenza virus infection. Nat. Rev. Immunol. 14, 315\u2013328 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"2178_CR371","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/imr.12101","volume":"255","author":"RK Durbin","year":"2013","unstructured":"Durbin, R. K., Kotenko, S. V. & Durbin, J. E. Interferon induction and function at the mucosal surface. Immunol. Rev. 255, 25\u201339 (2013).","journal-title":"Immunol. Rev."},{"key":"2178_CR372","doi-asserted-by":"publisher","first-page":"e1003256","DOI":"10.1371\/journal.ppat.1003256","volume":"9","author":"J Pothlichet","year":"2013","unstructured":"Pothlichet, J. et al. Type I IFN triggers RIG-I\/TLR3\/NLRP3-dependent inflammasome activation in influenza A virus infected cells. PLoS Pathog. 9, e1003256 (2013).","journal-title":"PLoS Pathog."},{"key":"2178_CR373","doi-asserted-by":"publisher","first-page":"17963","DOI":"10.1073\/pnas.1312571110","volume":"110","author":"T Ichinohe","year":"2013","unstructured":"Ichinohe, T., Yamazaki, T., Koshiba, T. & Yanagi, Y. Mitochondrial protein mitofusin 2 is required for NLRP3 inflammasome activation after RNA virus infection. Proc. Natl Acad. Sci. USA 110, 17963\u201317968 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2178_CR374","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1183\/09031936.00186214","volume":"45","author":"S Herold","year":"2015","unstructured":"Herold, S., Becker, C., Ridge, K. M. & Budinger, G. R. Influenza virus-induced lung injury: pathogenesis and implications for treatment. Eur. Respir. J. 45, 1463\u20131478 (2015).","journal-title":"Eur. Respir. J."},{"key":"2178_CR375","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4864","volume":"5","author":"S Davidson","year":"2014","unstructured":"Davidson, S., Crotta, S., McCabe, T. M. & Wack, A. Pathogenic potential of interferon alphabeta in acute influenza infection. Nat. Commun. 5, 3864 (2014).","journal-title":"Nat. Commun."},{"key":"2178_CR376","doi-asserted-by":"publisher","DOI":"10.1038\/srep27912","volume":"6","author":"MD Tate","year":"2016","unstructured":"Tate, M. D. et al. Reassessing the role of the NLRP3 inflammasome during pathogenic influenza A virus infection via temporal inhibition. Sci. Rep. 6, 27912 (2016).","journal-title":"Sci. Rep."},{"key":"2178_CR377","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-07384-5","volume":"7","author":"R Ren","year":"2017","unstructured":"Ren, R. et al. The H7N9 influenza A virus infection results in lethal inflammation in the mammalian host via the NLRP3-caspase-1 inflammasome. Sci. Rep. 7, 7625 (2017).","journal-title":"Sci. Rep."},{"key":"2178_CR378","doi-asserted-by":"publisher","DOI":"10.1186\/cc9324","volume":"14","author":"N Hagau","year":"2010","unstructured":"Hagau, N. et al. Clinical aspects and cytokine response in severe H1N1 influenza A virus infection. Crit. Care 14, R203 (2010).","journal-title":"Crit. Care"},{"key":"2178_CR379","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/cmi.2014.80","volume":"12","author":"J Wang","year":"2015","unstructured":"Wang, J. et al. Soluble interleukin-6 receptor is elevated during influenza A virus infection and mediates the IL-6 and IL-32 inflammatory cytokine burst. Cell Mol. Immunol. 12, 633\u2013644 (2015).","journal-title":"Cell Mol. Immunol."},{"key":"2178_CR380","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.3390\/v14061166","volume":"14","author":"E Cimini","year":"2022","unstructured":"Cimini, E. & Agrati, C. \u03b3\u03b4 T cells in emerging viral infection: an overview. Viruses 14, 1166 (2022).","journal-title":"Viruses"},{"key":"2178_CR381","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.chom.2009.09.011","volume":"6","author":"HW Stout-Delgado","year":"2009","unstructured":"Stout-Delgado, H. W., Du, W., Shirali, A. C., Booth, C. J. & Goldstein, D. R. Aging promotes neutrophil-induced mortality by augmenting IL-17 production during viral infection. Cell Host Microbe 6, 446\u2013456 (2009).","journal-title":"Cell Host Microbe"},{"key":"2178_CR382","doi-asserted-by":"publisher","DOI":"10.1186\/cc8208","volume":"13","author":"JF Bermejo-Martin","year":"2009","unstructured":"Bermejo-Martin, J. F. et al. Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Crit. Care 13, R201 (2009).","journal-title":"Crit. Care"},{"key":"2178_CR383","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1086\/650581","volume":"50","author":"KK To","year":"2010","unstructured":"To, K. K. et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin. Infect. Dis. 50, 850\u2013859 (2010).","journal-title":"Clin. Infect. Dis."},{"key":"2178_CR384","doi-asserted-by":"publisher","first-page":"5301","DOI":"10.4049\/jimmunol.0900995","volume":"183","author":"CR Crowe","year":"2009","unstructured":"Crowe, C. R. et al. Critical role of IL-17RA in immunopathology of influenza infection. J. Immunol. 183, 5301\u20135310 (2009).","journal-title":"J. Immunol."},{"key":"2178_CR385","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1001\/jama.2020.1585","volume":"323","author":"D Wang","year":"2020","unstructured":"Wang, D. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323, 1061\u20131069 (2020).","journal-title":"JAMA"},{"key":"2178_CR386","doi-asserted-by":"publisher","first-page":"eabf3041","DOI":"10.1126\/science.abf3041","volume":"376","author":"S Yazar","year":"2022","unstructured":"Yazar, S. et al. Single-cell eQTL mapping identifies cell type-specific genetic control of autoimmune disease. Science 376, eabf3041 (2022).","journal-title":"Science"},{"key":"2178_CR387","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41586-023-06422-9","volume":"621","author":"Y Aquino","year":"2023","unstructured":"Aquino, Y. et al. Dissecting human population variation in single-cell responses to SARS-CoV-2. Nature 621, 120\u2013128 (2023).","journal-title":"Nature"},{"key":"2178_CR388","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41586-024-07789-z","volume":"633","author":"T Lakshmikanth","year":"2024","unstructured":"Lakshmikanth, T. et al. Immune system adaptation during gender-affirming testosterone treatment. Nature 633, 155\u2013164 (2024).","journal-title":"Nature"},{"key":"2178_CR389","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","volume":"395","author":"CD Russell","year":"2020","unstructured":"Russell, C. D., Millar, J. E. & Baillie, J. K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 395, 473\u2013475 (2020).","journal-title":"Lancet"},{"key":"2178_CR390","doi-asserted-by":"publisher","first-page":"1233318","DOI":"10.3389\/fimmu.2023.1233318","volume":"14","author":"JJ Engel","year":"2023","unstructured":"Engel, J. J. et al. Dexamethasone attenuates interferon-related cytokine hyperresponsiveness in COVID-19 patients. Front. Immunol. 14, 1233318 (2023).","journal-title":"Front. Immunol."},{"key":"2178_CR391","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"RC Group","year":"2021","unstructured":"Group, R. C. et al. Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 384, 693\u2013704 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2178_CR392","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/jama.2020.17021","volume":"324","author":"BM Tomazini","year":"2020","unstructured":"Tomazini, B. M. et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA 324, 1307\u20131316 (2020).","journal-title":"JAMA"},{"key":"2178_CR393","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","volume":"22","author":"G Li","year":"2023","unstructured":"Li, G., Hilgenfeld, R., Whitley, R. & De Clercq, E. Therapeutic strategies for COVID-19: progress and lessons learned. Nat. Rev. Drug Discov. 22, 449\u2013475 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2178_CR394","doi-asserted-by":"publisher","first-page":"e139024","DOI":"10.1172\/jci.insight.139024","volume":"5","author":"M Luo","year":"2020","unstructured":"Luo, M. et al. IL-6 and CD8+ T cell counts combined are an early predictor of in-hospital mortality of patients with COVID-19. JCI Insight 5, e139024 (2020).","journal-title":"JCI Insight"},{"key":"2178_CR395","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","volume":"384","author":"R-C Investigators","year":"2021","unstructured":"Investigators, R.-C. et al. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. N. Engl. J. Med. 384, 1491\u20131502 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2178_CR396","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2213-2600(21)00081-3","volume":"9","author":"AS Soin","year":"2021","unstructured":"Soin, A. S. et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respir. Med. 9, 511\u2013521 (2021).","journal-title":"Lancet Respir. Med."},{"key":"2178_CR397","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2030340","volume":"384","author":"C Salama","year":"2021","unstructured":"Salama, C. et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N. Engl. J. Med. 384, 20\u201330 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2178_CR398","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","volume":"397","author":"RECOVERY Collaborative Group.","year":"2021","unstructured":"RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397, 1637\u20131645 (2021).","journal-title":"Lancet"},{"key":"2178_CR399","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","volume":"398","author":"DP McLornan","year":"2021","unstructured":"McLornan, D. P., Pope, J. E., Gotlib, J. & Harrison, C. N. Current and future status of JAK inhibitors. Lancet 398, 803\u2013816 (2021).","journal-title":"Lancet"},{"key":"2178_CR400","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/cid\/ciq106","volume":"52","author":"IF Hung","year":"2011","unstructured":"Hung, I. F. et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin. Infect. Dis. 52, 447\u2013456 (2011).","journal-title":"Clin. Infect. Dis."},{"key":"2178_CR401","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/S0140-6736(21)00897-7","volume":"397","author":"RECOVERY Collaborative Group.","year":"2021","unstructured":"RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet 397, 2049\u20132059 (2021).","journal-title":"Lancet"},{"key":"2178_CR402","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1378\/chest.101.6.1481","volume":"101","author":"RC Bone","year":"1992","unstructured":"Bone, R. C., Sibbald, W. J. & Sprung, C. L. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 101, 1481\u20131483 (1992).","journal-title":"Chest"},{"key":"2178_CR403","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer, M. et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315, 801\u2013810 (2016).","journal-title":"JAMA"},{"key":"2178_CR404","doi-asserted-by":"publisher","first-page":"106066","DOI":"10.1016\/j.intimp.2019.106066","volume":"78","author":"S Xie","year":"2020","unstructured":"Xie, S. et al. Astragaloside IV attenuates sepsis-induced intestinal barrier dysfunction via suppressing RhoA\/NLRP3 inflammasome signaling. Int. Immunopharmacol. 78, 106066 (2020).","journal-title":"Int. Immunopharmacol."},{"key":"2178_CR405","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00281-017-0639-8","volume":"39","author":"BG Chousterman","year":"2017","unstructured":"Chousterman, B. G., Swirski, F. K. & Weber, G. F. Cytokine storm and sepsis disease pathogenesis. Semin. Immunopathol. 39, 517\u2013528 (2017).","journal-title":"Semin. Immunopathol."},{"key":"2178_CR406","doi-asserted-by":"publisher","first-page":"5962","DOI":"10.4049\/jimmunol.169.10.5962","volume":"169","author":"IJ Laudes","year":"2002","unstructured":"Laudes, I. J. et al. Expression and function of C5a receptor in mouse microvascular endothelial cells. J. Immunol. 169, 5962\u20135970 (2002).","journal-title":"J. Immunol."},{"key":"2178_CR407","doi-asserted-by":"publisher","first-page":"5376","DOI":"10.3390\/ijms20215376","volume":"20","author":"M Huang","year":"2019","unstructured":"Huang, M., Cai, S. & Su, J. The pathogenesis of sepsis and potential therapeutic targets. Int. J. Mol. Sci. 20, 5376 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"2178_CR408","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.2147\/JIR.S453653","volume":"17","author":"L Cheng","year":"2024","unstructured":"Cheng, L. et al. Risk factors for systemic inflammatory response syndrome after percutaneous transhepatic cholangioscopic lithotripsy. J. Inflamm. Res. 17, 2575\u20132587 (2024).","journal-title":"J. Inflamm. Res."},{"key":"2178_CR409","doi-asserted-by":"publisher","first-page":"113754","DOI":"10.1016\/j.celrep.2024.113754","volume":"43","author":"M Ashayeripanah","year":"2024","unstructured":"Ashayeripanah, M. et al. Systemic inflammatory response syndrome triggered by blood-borne pathogens induces prolonged dendritic cell paralysis and immunosuppression. Cell Rep. 43, 113754 (2024).","journal-title":"Cell Rep."},{"key":"2178_CR410","doi-asserted-by":"publisher","first-page":"e0011422","DOI":"10.1128\/msphere.00114-22","volume":"7","author":"G Rajam","year":"2022","unstructured":"Rajam, G. et al. Development and validation of a sensitive and robust multiplex antigen capture assay to quantify streptococcus pneumoniae serotype-specific capsular polysaccharides in urine. mSphere 7, e0011422 (2022).","journal-title":"mSphere"},{"key":"2178_CR411","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1002\/imt2.82","volume":"2","author":"X Yang","year":"2023","unstructured":"Yang, X. et al. MBPD: a multiple bacterial pathogen detection pipeline for One Health practices. Imeta 2, e82 (2023).","journal-title":"Imeta"},{"key":"2178_CR412","doi-asserted-by":"publisher","first-page":"eaba9600","DOI":"10.1126\/scisignal.aba9600","volume":"13","author":"H Torrey","year":"2020","unstructured":"Torrey, H. et al. A novel TNFR2 agonist antibody expands highly potent regulatory T cells. Sci. Signal. 13, eaba9600 (2020).","journal-title":"Sci. Signal."},{"key":"2178_CR413","first-page":"103389","volume":"71","author":"M Kargar","year":"2023","unstructured":"Kargar, M., Torabizadeh, M., Purrahman, D., Zayeri, Z. D. & Saki, N. Regulatory factors involved in Th17\/Treg cell balance of immune thrombocytopenia. Curr. Res. Transl. Med. 71, 103389 (2023).","journal-title":"Curr. Res. Transl. Med."},{"key":"2178_CR414","doi-asserted-by":"publisher","first-page":"e784","DOI":"10.1002\/iid3.784","volume":"11","author":"R Ma","year":"2023","unstructured":"Ma, R., Su, H., Jiao, K. & Liu, J. Role of Th17 cells, Treg cells, and Th17\/Treg imbalance in immune homeostasis disorders in patients with chronic obstructive pulmonary disease. Immun. Inflamm. Dis. 11, e784 (2023).","journal-title":"Immun. Inflamm. Dis."},{"key":"2178_CR415","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1007\/s40265-020-01402-z","volume":"80","author":"P Vignon","year":"2020","unstructured":"Vignon, P., Laterre, P. F., Daix, T. & Fran\u00e7ois, B. New agents in development for sepsis: any reason for hope? Drugs 80, 1751\u20131761 (2020).","journal-title":"Drugs"},{"key":"2178_CR416","doi-asserted-by":"publisher","first-page":"e24669","DOI":"10.1002\/jcla.24669","volume":"37","author":"Z Jin","year":"2023","unstructured":"Jin, Z., Suolitiken, D., Wang, Y. & Wang, Z. The diagnostic importance of multiple cytokines in adult hemophagocytic lymphohistiocytosis. J. Clin. Lab. Anal. 37, e24669 (2023).","journal-title":"J. Clin. Lab. Anal."},{"key":"2178_CR417","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/07853890.2022.2149850","volume":"55","author":"S Yao","year":"2023","unstructured":"Yao, S. et al. Improved hemophagocytic lymphohistiocytosis index predicts prognosis of adult Epstein-Barr virus-associated HLH patients. Ann. Med. 55, 89\u2013100 (2023).","journal-title":"Ann. Med."},{"key":"2178_CR418","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01390-z","volume":"15","author":"J Zhang","year":"2020","unstructured":"Zhang, J. et al. Genotype characteristics and immunological indicator evaluation of 311 hemophagocytic lymphohistiocytosis cases in China. Orphanet J. Rare Dis. 15, 112 (2020).","journal-title":"Orphanet J. Rare Dis."},{"key":"2178_CR419","doi-asserted-by":"publisher","first-page":"955523","DOI":"10.3389\/fimmu.2022.955523","volume":"13","author":"L He","year":"2022","unstructured":"He, L. et al. Macrophage activation syndrome in adults: characteristics, outcomes, and therapeutic effectiveness of etoposide-based regimen. Front. Immunol. 13, 955523 (2022).","journal-title":"Front. Immunol."},{"key":"2178_CR420","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1309\/AJCP4ZDKJ4ICOUAT","volume":"139","author":"FG Rosado","year":"2013","unstructured":"Rosado, F. G. & Kim, A. S. Hemophagocytic lymphohistiocytosis: an update on diagnosis and pathogenesis. Am. J. Clin. Pathol. 139, 713\u2013727 (2013).","journal-title":"Am. J. Clin. Pathol."},{"key":"2178_CR421","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1182\/blood.2019000936","volume":"135","author":"SW Canna","year":"2020","unstructured":"Canna, S. W. & Marsh, R. A. Pediatric hemophagocytic lymphohistiocytosis. Blood 135, 1332\u20131343 (2020).","journal-title":"Blood"},{"key":"2178_CR422","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1146\/annurev-pathol-020117-043625","volume":"13","author":"H Al-Samkari","year":"2018","unstructured":"Al-Samkari, H. & Berliner, N. Hemophagocytic lymphohistiocytosis. Annu. Rev. Pathol. 13, 27\u201349 (2018).","journal-title":"Annu. Rev. Pathol."},{"key":"2178_CR423","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1182\/blood-2003-10-3413","volume":"104","author":"MB Jordan","year":"2004","unstructured":"Jordan, M. B., Hildeman, D., Kappler, J. & Marrack, P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 104, 735\u2013743 (2004).","journal-title":"Blood"},{"key":"2178_CR424","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1182\/blood-2012-07-441139","volume":"121","author":"T K\u00f6gl","year":"2013","unstructured":"K\u00f6gl, T. et al. Hemophagocytic lymphohistiocytosis in syntaxin-11-deficient mice: T-cell exhaustion limits fatal disease. Blood 121, 604\u2013613 (2013).","journal-title":"Blood"},{"key":"2178_CR425","doi-asserted-by":"publisher","first-page":"e666","DOI":"10.1002\/iid3.666","volume":"10","author":"D Suolitiken","year":"2022","unstructured":"Suolitiken, D., Wang, Y., Jin, Z. & Wang, Z. EBV protection- and susceptibility-related HLA alleles and EBV status in the Chinese population: a single-center study. Immun. Inflamm. Dis. 10, e666 (2022).","journal-title":"Immun. Inflamm. Dis."},{"key":"2178_CR426","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1182\/blood-2011-07-370148","volume":"118","author":"K Zhang","year":"2011","unstructured":"Zhang, K. et al. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. Blood 118, 5794\u20135798 (2011).","journal-title":"Blood"},{"key":"2178_CR427","doi-asserted-by":"publisher","first-page":"5425","DOI":"10.1172\/JCI130059","volume":"130","author":"K Ishii","year":"2020","unstructured":"Ishii, K. et al. Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients. J. Clin. Investig. 130, 5425\u20135443 (2020).","journal-title":"J. Clin. Investig."},{"key":"2178_CR428","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/pbc.20511","volume":"46","author":"I Ueda","year":"2006","unstructured":"Ueda, I. et al. Correlation between phenotypic heterogeneity and gene mutational characteristics in familial hemophagocytic lymphohistiocytosis (FHL). Pediatr. Blood Cancer 46, 482\u2013488 (2006).","journal-title":"Pediatr. Blood Cancer"},{"key":"2178_CR429","doi-asserted-by":"publisher","first-page":"6016","DOI":"10.1182\/blood-2011-12-398958","volume":"119","author":"J Pagel","year":"2012","unstructured":"Pagel, J. et al. Distinct mutations in STXBP2 are associated with variable clinical presentations in patients with familial hemophagocytic lymphohistiocytosis type 5 (FHL5). Blood 119, 6016\u20136024 (2012).","journal-title":"Blood"},{"key":"2178_CR430","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1182\/blood-2014-05-573105","volume":"124","author":"K Zhang","year":"2014","unstructured":"Zhang, K. et al. Synergistic defects of different molecules in the cytotoxic pathway lead to clinical familial hemophagocytic lymphohistiocytosis. Blood 124, 1331\u20131334 (2014).","journal-title":"Blood"},{"key":"2178_CR431","doi-asserted-by":"publisher","first-page":"507","DOI":"10.5858\/arpa.2020-0802-RA","volume":"146","author":"TS Ponnatt","year":"2022","unstructured":"Ponnatt, T. S., Lilley, C. M. & Mirza, K. M. Hemophagocytic lymphohistiocytosis. Arch. Pathol. Lab. Med. 146, 507\u2013519 (2022).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"2178_CR432","doi-asserted-by":"publisher","first-page":"788056","DOI":"10.3389\/fonc.2021.788056","volume":"11","author":"S Yao","year":"2021","unstructured":"Yao, S. et al. Clinical features and prognostic risk prediction of non-Hodgkin lymphoma-associated hemophagocytic syndrome. Front. Oncol. 11, 788056 (2021).","journal-title":"Front. Oncol."},{"key":"2178_CR433","doi-asserted-by":"publisher","first-page":"963689721105707","DOI":"10.1177\/09636897211057077","volume":"30","author":"Y Song","year":"2021","unstructured":"Song, Y., Yin, Q., Wang, J. & Wang, Z. Autologous hematopoietic stem cell transplantation for patients with lymphoma-associated hemophagocytic lymphohistiocytosis. Cell Transpl. 30, 9636897211057077 (2021).","journal-title":"Cell Transpl."},{"key":"2178_CR434","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1182\/blood.2023021074","volume":"143","author":"J Wang","year":"2024","unstructured":"Wang, J. et al. Chronic active Epstein-Barr virus disease originates from infected hematopoietic stem cells. Blood 143, 32\u201341 (2024).","journal-title":"Blood"},{"key":"2178_CR435","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3389\/fped.2018.00289","volume":"6","author":"J Ai","year":"2018","unstructured":"Ai, J. & Xie, Z. Epstein-Barr virus-positive T\/NK-cell lymphoproliferative diseases in Chinese mainland. Front. Pediatr. 6, 289 (2018).","journal-title":"Front. Pediatr."},{"key":"2178_CR436","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s11596-021-2375-5","volume":"41","author":"YQ Guan","year":"2021","unstructured":"Guan, Y. Q. et al. Inherited genetic susceptibility to nonimmunosuppressed Epstein-Barr virus-associated T\/NK-cell lymphoproliferative diseases in Chinese patients. Curr. Med. Sci. 41, 482\u2013490 (2021).","journal-title":"Curr. Med. Sci."},{"key":"2178_CR437","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s12185-023-03660-5","volume":"118","author":"JI Kawada","year":"2023","unstructured":"Kawada, J. I. et al. Updated guidelines for chronic active Epstein-Barr virus disease. Int. J. Hematol. 118, 568\u2013576 (2023).","journal-title":"Int. J. Hematol."},{"key":"2178_CR438","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/978-981-10-7230-7_21","volume":"1045","author":"H Kimura","year":"2018","unstructured":"Kimura, H. EBV in T-\/NK-cell tumorigenesis. Adv. Exp. Med. Biol. 1045, 459\u2013475 (2018).","journal-title":"Adv. Exp. Med. Biol."},{"key":"2178_CR439","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01976-1","volume":"16","author":"S Yao","year":"2021","unstructured":"Yao, S. et al. Epidemiological investigation of hemophagocytic lymphohistiocytosis in China. Orphanet J. Rare Dis. 16, 342 (2021).","journal-title":"Orphanet J. Rare Dis."},{"key":"2178_CR440","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3389\/fped.2016.00047","volume":"4","author":"E Ishii","year":"2016","unstructured":"Ishii, E. Hemophagocytic lymphohistiocytosis in children: pathogenesis and treatment. Front. Pediatr. 4, 47 (2016).","journal-title":"Front. Pediatr."},{"key":"2178_CR441","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1182\/blood.2023022739","volume":"143","author":"R Khanna","year":"2024","unstructured":"Khanna, R. & Gandhi, M. K. EBV-infected hematopoietic stem cells drive CAEBV. Blood 143, 2\u20134 (2024).","journal-title":"Blood"},{"key":"2178_CR442","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1182\/asheducation-2015.1.183","volume":"2015","author":"S Nikiforow","year":"2015","unstructured":"Nikiforow, S. & Berliner, N. The unique aspects of presentation and diagnosis of hemophagocytic lymphohistiocytosis in adults. Hematol. Am. Soc. Hematol. Educ. Program 2015, 183\u2013189 (2015).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"2178_CR443","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1080\/10428194.2016.1262034","volume":"58","author":"S Nanno","year":"2017","unstructured":"Nanno, S. et al. Diagnostic value of serum ferritin and the risk factors and cytokine profiles of hemophagocytic syndrome following allogeneic hematopoietic cell transplantation. Leuk. Lymphoma 58, 1664\u20131672 (2017).","journal-title":"Leuk. Lymphoma"},{"key":"2178_CR444","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1182\/blood.2021011898","volume":"138","author":"DA Lichtenstein","year":"2021","unstructured":"Lichtenstein, D. A. et al. Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. Blood 138, 2469\u20132484 (2021).","journal-title":"Blood"},{"key":"2178_CR445","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3389\/fimmu.2020.00524","volume":"11","author":"RD Sandler","year":"2020","unstructured":"Sandler, R. D. et al. Diagnosis and management of secondary HLH\/MAS following HSCT and CAR-T cell therapy in adults; a review of the literature and a survey of practice within EBMT centres on behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP). Front. Immunol. 11, 524 (2020).","journal-title":"Front. Immunol."},{"key":"2178_CR446","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1136\/ard-2023-224123","volume":"82","author":"B Shakoory","year":"2023","unstructured":"Shakoory, B. et al. The 2022 EULAR\/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis\/macrophage activation syndrome (HLH\/MAS). Ann. Rheum. Dis. 82, 1271\u20131285 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"2178_CR447","doi-asserted-by":"publisher","first-page":"1006817","DOI":"10.3389\/fped.2022.1006817","volume":"10","author":"L Xiao","year":"2022","unstructured":"Xiao, L. et al. Low total cholesterol predicts early death in children with hemophagocytic lymphohistiocytosis. Front. Pediatr. 10, 1006817 (2022).","journal-title":"Front. Pediatr."},{"key":"2178_CR448","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s12887-020-02178-7","volume":"20","author":"H Pan","year":"2020","unstructured":"Pan, H. et al. Treatment outcomes and prognostic factors for non- malignancy associated secondary hemophagocytic lymphohistiocytosis in children. BMC Pediatr. 20, 288 (2020).","journal-title":"BMC Pediatr."},{"key":"2178_CR449","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1182\/blood.2021012764","volume":"139","author":"A Zoref-Lorenz","year":"2022","unstructured":"Zoref-Lorenz, A. et al. An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis. Blood 139, 1098\u20131110 (2022).","journal-title":"Blood"},{"key":"2178_CR450","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00277-023-05606-7","volume":"103","author":"C Feng","year":"2024","unstructured":"Feng, C. et al. A convenient and practical index for predicting the induction response in adult patients with hemophagocytic lymphohistiocytosis: ferritin\/platelet ratio. Ann. Hematol. 103, 715\u2013723 (2024).","journal-title":"Ann. Hematol."},{"key":"2178_CR451","doi-asserted-by":"publisher","first-page":"1162320","DOI":"10.3389\/fimmu.2023.1162320","volume":"14","author":"W Cheng","year":"2023","unstructured":"Cheng, W. et al. Prognostic value of the albumin-bilirubin score in patients with non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis. Front. Immunol. 14, 1162320 (2023).","journal-title":"Front. Immunol."},{"key":"2178_CR452","doi-asserted-by":"publisher","first-page":"6704859","DOI":"10.1155\/2022\/6704859","volume":"2022","author":"R Zhang","year":"2022","unstructured":"Zhang, R. et al. A study on early death prognosis model in adult patients with secondary hemophagocytic lymphohistiocytosis. J. Health. Eng. 2022, 6704859 (2022).","journal-title":"J. Health. Eng."},{"key":"2178_CR453","doi-asserted-by":"publisher","first-page":"876415","DOI":"10.3389\/fimmu.2022.876415","volume":"13","author":"T Cui","year":"2022","unstructured":"Cui, T., Wang, J. & Wang, Z. The outcome of induction therapy for EBV-related hemophagocytic lymphohistiocytosis: a model for risk stratification. Front. Immunol. 13, 876415 (2022).","journal-title":"Front. Immunol."},{"key":"2178_CR454","doi-asserted-by":"publisher","first-page":"e22202","DOI":"10.1016\/j.heliyon.2023.e22202","volume":"9","author":"L Xiao","year":"2023","unstructured":"Xiao, L. et al. Predictive model for early death risk in pediatric hemophagocytic lymphohistiocytosis patients based on machine learning. Heliyon 9, e22202 (2023).","journal-title":"Heliyon"},{"key":"2178_CR455","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1182\/blood-2017-06-788349","volume":"130","author":"E Bergsten","year":"2017","unstructured":"Bergsten, E. et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood 130, 2728\u20132738 (2017).","journal-title":"Blood"},{"key":"2178_CR456","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00281-024-01013-w","volume":"46","author":"AD Hughes","year":"2024","unstructured":"Hughes, A. D., Teachey, D. T. & Diorio, C. Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy. Semin. Immunopathol. 46, 5 (2024).","journal-title":"Semin. Immunopathol."},{"key":"2178_CR457","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1007\/s00277-022-04946-0","volume":"101","author":"L Chen","year":"2022","unstructured":"Chen, L., Wang, J. & Wang, Z. L-DEP regimen is effective as an initial therapy for adult EBV-HLH. Ann. Hematol. 101, 2461\u20132470 (2022).","journal-title":"Ann. Hematol."},{"key":"2178_CR458","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1182\/blood-2015-05-644914","volume":"126","author":"Y Wang","year":"2015","unstructured":"Wang, Y. et al. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis. Blood 126, 2186\u20132192 (2015).","journal-title":"Blood"},{"key":"2178_CR459","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-016-0317-7","volume":"9","author":"J Wang","year":"2016","unstructured":"Wang, J. et al. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J. Hematol. Oncol. 9, 84 (2016).","journal-title":"J. Hematol. Oncol."},{"key":"2178_CR460","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40265-018-1046-8","volume":"79","author":"ZT Al-Salama","year":"2019","unstructured":"Al-Salama, Z. T. Emapalumab: first global approval. Drugs 79, 99\u2013103 (2019).","journal-title":"Drugs"},{"key":"2178_CR461","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","volume":"382","author":"F Locatelli","year":"2020","unstructured":"Locatelli, F. et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N. Engl. J. Med. 382, 1811\u20131822 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2178_CR462","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1182\/blood-2012-07-445858","volume":"121","author":"C Rivat","year":"2013","unstructured":"Rivat, C. et al. SAP gene transfer restores cellular and humoral immune function in a murine model of X-linked lymphoproliferative disease. Blood 121, 1073\u20131076 (2013).","journal-title":"Blood"},{"key":"2178_CR463","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/mt.2014.242","volume":"23","author":"M Carmo","year":"2015","unstructured":"Carmo, M. et al. Perforin gene transfer into hematopoietic stem cells improves immune dysregulation in murine models of perforin deficiency. Mol. Ther. 23, 737\u2013745 (2015).","journal-title":"Mol. Ther."},{"key":"2178_CR464","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1182\/bloodadvances.2017012088","volume":"1","author":"T Soheili","year":"2017","unstructured":"Soheili, T. et al. Gene transfer into hematopoietic stem cells reduces HLH manifestations in a murine model of Munc13-4 deficiency. Blood Adv. 1, 2781\u20132789 (2017).","journal-title":"Blood Adv."},{"key":"2178_CR465","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3390\/ijms20061283","volume":"20","author":"MR Benmebarek","year":"2019","unstructured":"Benmebarek, M. R. et al. Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int. J. Mol. Sci. 20, 1283 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"2178_CR466","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/ajh.25418","volume":"94","author":"S Feins","year":"2019","unstructured":"Feins, S., Kong, W., Williams, E. F., Milone, M. C. & Fraietta, J. A. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am. J. Hematol. 94, S3\u2013s9 (2019).","journal-title":"Am. J. Hematol."},{"key":"2178_CR467","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00134-017-4943-5","volume":"44","author":"P G\u00f6del","year":"2018","unstructured":"G\u00f6del, P., Shimabukuro-Vornhagen, A. & von Bergwelt-Baildon, M. Understanding cytokine release syndrome. Intensive Care Med. 44, 371\u2013373 (2018).","journal-title":"Intensive Care Med."},{"key":"2178_CR468","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay, K. A. et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130, 2295\u20132306 (2017).","journal-title":"Blood"},{"key":"2178_CR469","first-page":"333","volume":"19","author":"H Guo","year":"2021","unstructured":"Guo, H., Qian, L. & Cui, J. Focused evaluation of the roles of macrophages in chimeric antigen receptor (CAR) T cell therapy associated cytokine release syndrome. Cancer Biol. Med. 19, 333\u2013342 (2021).","journal-title":"Cancer Biol. Med."},{"key":"2178_CR470","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis, T. et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat. Med. 24, 731\u2013738 (2018).","journal-title":"Nat. Med."},{"key":"2178_CR471","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","volume":"20","author":"SL Maude","year":"2014","unstructured":"Maude, S. L., Barrett, D., Teachey, D. T. & Grupp, S. A. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 20, 119\u2013122 (2014).","journal-title":"Cancer J."},{"key":"2178_CR472","doi-asserted-by":"publisher","first-page":"224ra225","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila, M. L. et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra225 (2014).","journal-title":"Sci. Transl. Med."},{"key":"2178_CR473","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1182\/blood-2017-08-802413","volume":"130","author":"AE Obstfeld","year":"2017","unstructured":"Obstfeld, A. E. et al. Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights. Blood 130, 2569\u20132572 (2017).","journal-title":"Blood"},{"key":"2178_CR474","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.jcyt.2017.04.001","volume":"19","author":"N Singh","year":"2017","unstructured":"Singh, N. et al. Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function. Cytotherapy 19, 867\u2013880 (2017).","journal-title":"Cytotherapy"},{"key":"2178_CR475","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","volume":"27","author":"CA Dinarello","year":"2009","unstructured":"Dinarello, C. A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 27, 519\u2013550 (2009).","journal-title":"Annu. Rev. Immunol."},{"key":"2178_CR476","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/nrd.2016.231","volume":"16","author":"JA Hamilton","year":"2016","unstructured":"Hamilton, J. A., Cook, A. D. & Tak, P. P. Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases. Nat. Rev. Drug Discov. 16, 53\u201370 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2178_CR477","doi-asserted-by":"publisher","first-page":"5430","DOI":"10.1074\/jbc.AC119.007558","volume":"294","author":"M Sachdeva","year":"2019","unstructured":"Sachdeva, M., Duchateau, P., Depil, S., Poirot, L. & Valton, J. Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators. J. Biol. Chem. 294, 5430\u20135437 (2019).","journal-title":"J. Biol. Chem."},{"key":"2178_CR478","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","volume":"133","author":"RM Sterner","year":"2019","unstructured":"Sterner, R. M. et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood 133, 697\u2013709 (2019).","journal-title":"Blood"},{"key":"2178_CR479","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1002\/eji.201444960","volume":"45","author":"DY Vogel","year":"2015","unstructured":"Vogel, D. Y. et al. GM-CSF promotes migration of human monocytes across the blood brain barrier. Eur. J. Immunol. 45, 1808\u20131819 (2015).","journal-title":"Eur. J. Immunol."},{"key":"2178_CR480","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.neuroscience.2005.06.090","volume":"135","author":"JD Johnson","year":"2005","unstructured":"Johnson, J. D. et al. Catecholamines mediate stress-induced increases in peripheral and central inflammatory cytokines. Neuroscience 135, 1295\u20131307 (2005).","journal-title":"Neuroscience"},{"key":"2178_CR481","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-018-0774-y","volume":"564","author":"V Staedtke","year":"2018","unstructured":"Staedtke, V. et al. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature 564, 273\u2013277 (2018).","journal-title":"Nature"},{"key":"2178_CR482","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno, J. N. & Kochenderfer, J. N. Current understanding and management of CAR T cell-associated toxicities. Nat. Rev. Clin. Oncol. 21, 501\u2013521 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2178_CR483","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transpl. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"2178_CR484","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/bjh.18873","volume":"202","author":"L Zhou","year":"2023","unstructured":"Zhou, L. et al. Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: a multi-centre study. Br. J. Haematol. 202, 517\u2013524 (2023).","journal-title":"Br. J. Haematol."},{"key":"2178_CR485","doi-asserted-by":"publisher","first-page":"1273507","DOI":"10.3389\/fimmu.2023.1273507","volume":"14","author":"Z Wei","year":"2023","unstructured":"Wei, Z. et al. Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells. Front. Immunol. 14, 1273507 (2023).","journal-title":"Front. Immunol."},{"key":"2178_CR486","doi-asserted-by":"publisher","first-page":"e006365","DOI":"10.1136\/jitc-2022-006365","volume":"11","author":"AB Moreno-Casta\u00f1o","year":"2023","unstructured":"Moreno-Casta\u00f1o, A. B. et al. Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: laboratory tools for an early and differential diagnosis. J. Immunother. Cancer 11, e006365 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"2178_CR487","doi-asserted-by":"publisher","first-page":"11063","DOI":"10.1111\/jcmm.17029","volume":"25","author":"F Hong","year":"2021","unstructured":"Hong, F. et al. Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia. J. Cell Mol. Med. 25, 11063\u201311074 (2021).","journal-title":"J. Cell Mol. Med."},{"key":"2178_CR488","doi-asserted-by":"publisher","first-page":"877477","DOI":"10.3389\/fimmu.2022.877477","volume":"13","author":"F Korell","year":"2022","unstructured":"Korell, F. et al. EASIX and severe endothelial complications after CD19-directed CAR-T cell therapy\u2014a cohort study. Front. Immunol. 13, 877477 (2022).","journal-title":"Front. Immunol."},{"key":"2178_CR489","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","volume":"5","author":"U Greenbaum","year":"2021","unstructured":"Greenbaum, U. et al. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv. 5, 2799\u20132806 (2021).","journal-title":"Blood Adv."},{"key":"2178_CR490","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","volume":"5","author":"M Pennisi","year":"2021","unstructured":"Pennisi, M. et al. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Adv. 5, 3397\u20133406 (2021).","journal-title":"Blood Adv."},{"key":"2178_CR491","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","volume":"40","author":"X Xiao","year":"2021","unstructured":"Xiao, X. et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J. Exp. Clin. Cancer Res. 40, 367 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2178_CR492","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli, M. et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 24, 739\u2013748 (2018).","journal-title":"Nat. Med."},{"key":"2178_CR493","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","volume":"25","author":"N Frey","year":"2019","unstructured":"Frey, N. & Porter, D. Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol. Blood Marrow Transpl. 25, e123\u2013e127 (2019).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"2178_CR494","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1002\/cncr.35316","volume":"130","author":"X Wang","year":"2024","unstructured":"Wang, X. et al. Impact of tocilizumab on anti-CD19 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia. Cancer 130, 2660\u20132669 (2024).","journal-title":"Cancer"},{"key":"2178_CR495","doi-asserted-by":"publisher","first-page":"2083479","DOI":"10.1080\/2162402X.2022.2083479","volume":"11","author":"G Leclercq","year":"2022","unstructured":"Leclercq, G. et al. Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors. Oncoimmunology 11, 2083479 (2022).","journal-title":"Oncoimmunology"},{"key":"2178_CR496","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1200\/JCO.20.02477","volume":"39","author":"S Kadauke","year":"2021","unstructured":"Kadauke, S. et al. Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-Cell acute lymphoblastic leukemia: a prospective clinical trial. J. Clin. Oncol. 39, 920\u2013930 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2178_CR497","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3324\/haematol.2019.229781","volume":"105","author":"I Yakoub-Agha","year":"2020","unstructured":"Yakoub-Agha, I. et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica 105, 297\u2013316 (2020).","journal-title":"Haematologica"},{"key":"2178_CR498","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1182\/bloodadvances.2020002328","volume":"4","author":"P Strati","year":"2020","unstructured":"Strati, P. et al. Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Adv. 4, 3123\u20133127 (2020).","journal-title":"Blood Adv."},{"key":"2178_CR499","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1182\/bloodadvances.2022006983","volume":"6","author":"C Diorio","year":"2022","unstructured":"Diorio, C. et al. Anakinra utilization in refractory pediatric CAR T-cell associated toxicities. Blood Adv. 6, 3398\u20133403 (2022).","journal-title":"Blood Adv."},{"key":"2178_CR500","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris, A. C. et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol. Blood Marrow Transpl. 22, 4\u201310 (2016).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"2178_CR501","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3389\/fimmu.2017.00079","volume":"8","author":"S Ghimire","year":"2017","unstructured":"Ghimire, S. et al. Pathophysiology of GvHD and other HSCT-related major complications. Front. Immunol. 8, 79 (2017).","journal-title":"Front. Immunol."},{"key":"2178_CR502","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nri3212","volume":"12","author":"BR Blazar","year":"2012","unstructured":"Blazar, B. R., Murphy, W. J. & Abedi, M. Advances in graft-versus-host disease biology and therapy. Nat. Rev. Immunol. 12, 443\u2013458 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"2178_CR503","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41375-020-0804-2","volume":"34","author":"F Malard","year":"2020","unstructured":"Malard, F., Huang, X. J. & Sim, J. P. Y. Treatment and unmet needs in steroid-refractory acute graft-versus-host disease. Leukemia 34, 1229\u20131240 (2020).","journal-title":"Leukemia"},{"key":"2178_CR504","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMra1609337","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser, R. & Blazar, B. R. Acute graft-versus-host disease\u2014biologic process, prevention, and therapy. N. Engl. J. Med. 377, 2167\u20132179 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2178_CR505","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1182\/blood.2019000823","volume":"134","author":"M Koyama","year":"2019","unstructured":"Koyama, M. & Hill, G. R. The primacy of gastrointestinal tract antigen-presenting cells in lethal graft-versus-host disease. Blood 134, 2139\u20132148 (2019).","journal-title":"Blood"},{"key":"2178_CR506","doi-asserted-by":"publisher","first-page":"eaat8410","DOI":"10.1126\/scitranslmed.aat8410","volume":"10","author":"S Tugues","year":"2018","unstructured":"Tugues, S. et al. Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF-licensed myeloid cells. Sci. Transl. Med. 10, eaat8410 (2018).","journal-title":"Sci. Transl. Med."},{"key":"2178_CR507","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s11427-022-2170-2","volume":"66","author":"Q Wen","year":"2023","unstructured":"Wen, Q. et al. Glucocorticoid and glycolysis inhibitors cooperatively abrogate acute graft-versus-host disease. Sci. China Life Sci. 66, 528\u2013544 (2023).","journal-title":"Sci. China Life Sci."},{"key":"2178_CR508","doi-asserted-by":"publisher","first-page":"e99672","DOI":"10.1172\/jci.insight.99672","volume":"3","author":"X Wu","year":"2018","unstructured":"Wu, X. et al. Prediction of acute GVHD and relapse by metabolic biomarkers after allogeneic hematopoietic stem cell transplantation. JCI Insight 3, e99672 (2018).","journal-title":"JCI Insight"},{"key":"2178_CR509","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/ajt.15654","volume":"20","author":"L Han","year":"2020","unstructured":"Han, L. et al. A gut microbiota score predicting acute graft-versus-host disease following myeloablative allogeneic hematopoietic stem cell transplantation. Am. J. Transpl. 20, 1014\u20131027 (2020).","journal-title":"Am. J. Transpl."},{"key":"2178_CR510","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1182\/blood-2014-01-550566","volume":"124","author":"ML Sorror","year":"2014","unstructured":"Sorror, M. L. et al. Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. Blood 124, 287\u2013295 (2014).","journal-title":"Blood"},{"key":"2178_CR511","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s40265-023-01889-2","volume":"83","author":"DA Patel","year":"2023","unstructured":"Patel, D. A., Crain, M., Pusic, I. & Schroeder, M. A. Acute graft-versus-host disease: an update on new treatment options. Drugs 83, 893\u2013907 (2023).","journal-title":"Drugs"},{"key":"2178_CR512","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1182\/blood-2015-03-636753","volume":"126","author":"GB McDonald","year":"2015","unstructured":"McDonald, G. B. et al. Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment. Blood 126, 113\u2013120 (2015).","journal-title":"Blood"},{"key":"2178_CR513","doi-asserted-by":"publisher","first-page":"e89798","DOI":"10.1172\/jci.insight.89798","volume":"2","author":"MJ Hartwell","year":"2017","unstructured":"Hartwell, M. J. et al. An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. JCI Insight 2, e89798 (2017).","journal-title":"JCI Insight"},{"key":"2178_CR514","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1038\/s41375-020-0726-z","volume":"34","author":"MD Aziz","year":"2020","unstructured":"Aziz, M. D. et al. Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant. Leukemia 34, 1898\u20131906 (2020).","journal-title":"Leukemia"},{"key":"2178_CR515","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1182\/blood-2011-02-334821","volume":"118","author":"T Luft","year":"2011","unstructured":"Luft, T. et al. Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood 118, 1685\u20131692 (2011).","journal-title":"Blood"},{"key":"2178_CR516","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.bbmt.2014.04.030","volume":"20","author":"N Ueda","year":"2014","unstructured":"Ueda, N. et al. Predictive value of circulating angiopoietin-2 for endothelial damage-related complications in allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transpl. 20, 1335\u20131340 (2014).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"2178_CR517","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s43856-023-00323-8","volume":"3","author":"T Jo","year":"2023","unstructured":"Jo, T. et al. Author Correction: a convolutional neural network-based model that predicts acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Commun. Med. 3, 89 (2023).","journal-title":"Commun. Med."},{"key":"2178_CR518","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1182\/bloodadvances.2017011502","volume":"2","author":"C Mart\u00ednez-Laperche","year":"2018","unstructured":"Mart\u00ednez-Laperche, C. et al. A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms. Blood Adv. 2, 1719\u20131737 (2018).","journal-title":"Blood Adv."},{"key":"2178_CR519","doi-asserted-by":"publisher","first-page":"eadf0567","DOI":"10.1126\/sciadv.adf0567","volume":"9","author":"NJ Hess","year":"2023","unstructured":"Hess, N. J. et al. Inflammatory CD4\/CD8 double-positive human T cells arise from reactive CD8 T cells and are sufficient to mediate GVHD pathology. Sci. Adv. 9, eadf0567 (2023).","journal-title":"Sci. Adv."},{"key":"2178_CR520","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","volume":"11","author":"O Penack","year":"2024","unstructured":"Penack, O. et al. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 11, e147\u2013e159 (2024).","journal-title":"Lancet Haematol."},{"key":"2178_CR521","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13045-018-0564-x","volume":"11","author":"L Xu","year":"2018","unstructured":"Xu, L. et al. The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology. J. Hematol. Oncol. 11, 33 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"2178_CR522","doi-asserted-by":"publisher","first-page":"5584","DOI":"10.1182\/blood-2011-11-389809","volume":"119","author":"XJ Huang","year":"2012","unstructured":"Huang, X. J. et al. The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission. Blood 119, 5584\u20135590 (2012).","journal-title":"Blood"},{"key":"2178_CR523","first-page":"1778","volume":"117","author":"XJ Huang","year":"2004","unstructured":"Huang, X. J. et al. A novel approach to human leukocyte antigen-mismatched transplantation in patients with malignant hematological disease. Chin. Med. J. 117, 1778\u20131785 (2004).","journal-title":"Chin. Med. J."},{"key":"2178_CR524","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1182\/blood-2014-04-571570","volume":"124","author":"Y Luo","year":"2014","unstructured":"Luo, Y. et al. T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT. Blood 124, 2735\u20132743 (2014).","journal-title":"Blood"},{"key":"2178_CR525","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/s41409-018-0364-5","volume":"54","author":"I Danylesko","year":"2019","unstructured":"Danylesko, I. et al. Anti-\u03b14\u03b27 integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease. Bone Marrow Transpl. 54, 987\u2013993 (2019).","journal-title":"Bone Marrow Transpl."},{"key":"2178_CR526","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1182\/blood.2021011216","volume":"138","author":"LT Khuat","year":"2021","unstructured":"Khuat, L. T. et al. Increased efficacy of dual proinflammatory cytokine blockade on acute GVHD while maintaining GVT effects. Blood 138, 2583\u20132588 (2021).","journal-title":"Blood"},{"key":"2178_CR527","doi-asserted-by":"publisher","first-page":"106707","DOI":"10.1016\/j.phrs.2023.106707","volume":"189","author":"R Wang","year":"2023","unstructured":"Wang, R. et al. USP11 plays a critical role in the onset and progression of acute graft-versus-host disease: Novel target for precision therapeutics. Pharm. Res. 189, 106707 (2023).","journal-title":"Pharm. Res."},{"key":"2178_CR528","doi-asserted-by":"publisher","first-page":"e003847","DOI":"10.1136\/jitc-2021-003847","volume":"10","author":"M Wehrli","year":"2022","unstructured":"Wehrli, M. et al. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). J. Immunother. Cancer 10, e003847 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"2178_CR529","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.3899\/jrheum.111549","volume":"39","author":"D Nordstr\u00f6m","year":"2012","unstructured":"Nordstr\u00f6m, D. et al. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still\u2019s disease. An open, randomized, multicenter study. J. Rheumatol. 39, 2008\u20132011 (2012).","journal-title":"J. Rheumatol."},{"key":"2178_CR530","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/ard.2010.134254","volume":"70","author":"P Quartier","year":"2011","unstructured":"Quartier, P. et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann. Rheum. Dis. 70, 747\u2013754 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"2178_CR531","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00395-019-0719-0","volume":"114","author":"L Kraft","year":"2019","unstructured":"Kraft, L., Erdenesukh, T., Sauter, M., Tsch\u00f6pe, C. & Klingel, K. Blocking the IL-1\u03b2 signalling pathway prevents chronic viral myocarditis and cardiac remodeling. Basic Res. Cardiol. 114, 11 (2019).","journal-title":"Basic Res. Cardiol."},{"key":"2178_CR532","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/1744666X.2019.1629904","volume":"15","author":"C Kotch","year":"2019","unstructured":"Kotch, C., Barrett, D. & Teachey, D. T. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev. Clin. Immunol. 15, 813\u2013822 (2019).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"2178_CR533","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone, J. H. et al. Trial of tocilizumab in giant-cell arteritis. N. Engl. J. Med. 377, 317\u2013328 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2178_CR534","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1158\/1078-0432.CCR-15-0134","volume":"21","author":"C Casper","year":"2015","unstructured":"Casper, C. et al. Analysis of inflammatory and anemia-related biomarkers in a randomized, double-blind, placebo-controlled study of siltuximab (Anti-IL6 Monoclonal Antibody) in patients with multicentric castleman disease. Clin. Cancer Res. 21, 4294\u20134304 (2015).","journal-title":"Clin. Cancer Res."},{"key":"2178_CR535","first-page":"50","volume":"66","author":"J Gauthier","year":"2018","unstructured":"Gauthier, J. & Turtle, C. J. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr. Res. Transl. Med. 66, 50\u201352 (2018).","journal-title":"Curr. Res. Transl. Med."},{"key":"2178_CR536","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1182\/blood.2019000761","volume":"134","author":"S Albeituni","year":"2019","unstructured":"Albeituni, S. et al. Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis. Blood 134, 147\u2013159 (2019).","journal-title":"Blood"},{"key":"2178_CR537","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","volume":"384","author":"AC Kalil","year":"2021","unstructured":"Kalil, A. C. et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N. Engl. J. Med. 384, 795\u2013807 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2178_CR538","doi-asserted-by":"publisher","first-page":"e2107719","DOI":"10.1002\/adma.202107719","volume":"34","author":"S Wang","year":"2022","unstructured":"Wang, S. et al. Cellular nanosponges for biological neutralization. Adv. Mater. 34, e2107719 (2022).","journal-title":"Adv. Mater."},{"key":"2178_CR539","first-page":"531","volume":"21","author":"H Wang","year":"2023","unstructured":"Wang, H. et al. Cytokine nanosponges suppressing overactive macrophages and dampening systematic cytokine storm for the treatment of hemophagocytic lymphohistiocytosis. Bioact. Mater. 21, 531\u2013546 (2023).","journal-title":"Bioact. Mater."},{"key":"2178_CR540","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1038\/s41565-018-0254-4","volume":"13","author":"Q Zhang","year":"2018","unstructured":"Zhang, Q. et al. Neutrophil membrane-coated nanoparticles inhibit synovial inflammation and alleviate joint damage in inflammatory arthritis. Nat. Nanotechnol. 13, 1182\u20131190 (2018).","journal-title":"Nat. Nanotechnol."},{"key":"2178_CR541","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici, M. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315\u2013317 (2006).","journal-title":"Cytotherapy"},{"key":"2178_CR542","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/nri2395","volume":"8","author":"A Uccelli","year":"2008","unstructured":"Uccelli, A., Moretta, L. & Pistoia, V. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol. 8, 726\u2013736 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"2178_CR543","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1423-0127-18-49","volume":"18","author":"PM Chen","year":"2011","unstructured":"Chen, P. M., Yen, M. L., Liu, K. J., Sytwu, H. K. & Yen, B. L. Immunomodulatory properties of human adult and fetal multipotent mesenchymal stem cells. J. Biomed. Sci. 18, 49 (2011).","journal-title":"J. Biomed. Sci."},{"key":"2178_CR544","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1002\/sctm.21-0021","volume":"10","author":"LT Wang","year":"2021","unstructured":"Wang, L. T., Liu, K. J., Sytwu, H. K., Yen, M. L. & Yen, B. L. Advances in mesenchymal stem cell therapy for immune and inflammatory diseases: Use of cell-free products and human pluripotent stem cell-derived mesenchymal stem cells. Stem Cells Transl. Med. 10, 1288\u20131303 (2021).","journal-title":"Stem Cells Transl. Med."},{"key":"2178_CR545","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1365-3083.2010.02491.x","volume":"73","author":"M Sioud","year":"2011","unstructured":"Sioud, M. New insights into mesenchymal stromal cell-mediated T-cell suppression through galectins. Scand. J. Immunol. 73, 79\u201384 (2011).","journal-title":"Scand. J. Immunol."},{"key":"2178_CR546","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12929-016-0289-5","volume":"23","author":"LT Wang","year":"2016","unstructured":"Wang, L. T. et al. Human mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation-mediated diseases: review of current clinical trials. J. Biomed. Sci. 23, 76 (2016).","journal-title":"J. Biomed. Sci."},{"key":"2178_CR547","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/S0140-6736(04)16104-7","volume":"363","author":"K Le Blanc","year":"2004","unstructured":"Le Blanc, K. et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363, 1439\u20131441 (2004).","journal-title":"Lancet"},{"key":"2178_CR548","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05358-6","volume":"22","author":"W Lu","year":"2024","unstructured":"Lu, W. et al. Efficacy and safety of mesenchymal stem cells therapy in COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials. J. Transl. Med. 22, 550 (2024).","journal-title":"J. Transl. Med."},{"key":"2178_CR549","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41392-021-00488-5","volume":"6","author":"L Shi","year":"2021","unstructured":"Shi, L. et al. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct. Target. Ther. 6, 58 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2178_CR550","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-022-03930-4","volume":"26","author":"A Monsel","year":"2022","unstructured":"Monsel, A. et al. Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial. Crit. Care 26, 48 (2022).","journal-title":"Crit. Care"},{"key":"2178_CR551","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1744-9987.2006.00342.x","volume":"10","author":"K Tsuchida","year":"2006","unstructured":"Tsuchida, K., Yoshimura, R., Nakatani, T. & Takemoto, Y. Blood purification for critical illness: cytokines adsorption therapy. Ther. Apher. Dial. 10, 25\u201331 (2006).","journal-title":"Ther. Apher. Dial."},{"key":"2178_CR552","doi-asserted-by":"publisher","DOI":"10.1186\/s40635-021-00414-7","volume":"9","author":"Y Sekiya","year":"2021","unstructured":"Sekiya, Y. et al. Evaluation of a simultaneous adsorption device for cytokines and platelet-neutrophil complexes in vitro and in a rabbit acute lung injury model. Intensive Care Med. Exp. 9, 49 (2021).","journal-title":"Intensive Care Med. Exp."},{"key":"2178_CR553","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13045-024-01621-x","volume":"17","author":"Y Wu","year":"2024","unstructured":"Wu, Y. et al. Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms. J. Hematol. Oncol. 17, 106 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"2178_CR554","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/ar3843","volume":"14","author":"SF Bode","year":"2012","unstructured":"Bode, S. F. et al. Recent advances in the diagnosis and treatment of hemophagocytic lymphohistiocytosis. Arthritis Res. Ther. 14, 213 (2012).","journal-title":"Arthritis Res. Ther."},{"key":"2178_CR555","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S0140-6736(21)00439-6","volume":"398","author":"NJ Meyer","year":"2021","unstructured":"Meyer, N. J., Gattinoni, L. & Calfee, C. S. Acute respiratory distress syndrome. Lancet 398, 622\u2013637 (2021).","journal-title":"Lancet"},{"key":"2178_CR556","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu, S. S. et al. Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15, 47\u201362 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2178_CR557","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","volume":"78","author":"A Goldman","year":"2021","unstructured":"Goldman, A. et al. Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy. J. Am. Coll. Cardiol. 78, 1800\u20131813 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2178_CR558","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10067-018-4387-5","volume":"38","author":"R Baker","year":"2019","unstructured":"Baker, R., Liew, J. W., Simonson, P. D., Soma, L. A. & Starkebaum, G. Macrophage activation syndrome in a patient with axial spondyloarthritis on adalimumab. Clin. Rheumatol. 38, 603\u2013608 (2019).","journal-title":"Clin. Rheumatol."},{"key":"2178_CR559","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1136\/ard-2023-223850","volume":"83","author":"M Bonelli","year":"2024","unstructured":"Bonelli, M. et al. Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story. Ann. Rheum. Dis. 83, 139\u2013160 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"2178_CR560","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/1744666X.2022.2014323","volume":"18","author":"MA Adas","year":"2022","unstructured":"Adas, M. A. et al. The infection risks of JAK inhibition. Expert Rev. Clin. Immunol. 18, 253\u2013261 (2022).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"2178_CR561","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1182\/blood.2020007930","volume":"138","author":"V Chaturvedi","year":"2021","unstructured":"Chaturvedi, V., Lakes, N., Tran, M., Castillo, N. & Jordan, M. B. JAK inhibition for murine HLH requires complete blockade of IFN-\u03b3 signaling and is limited by toxicity of JAK2 inhibition. Blood 138, 1034\u20131039 (2021).","journal-title":"Blood"},{"key":"2178_CR562","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa2201422","volume":"387","author":"BP Griffith","year":"2022","unstructured":"Griffith, B. P. et al. Genetically modified porcine-to-human cardiac xenotransplantation. N. Engl. J. Med. 387, 35\u201344 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2178_CR563","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","volume":"117","author":"CA Dinarello","year":"2011","unstructured":"Dinarello, C. A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117, 3720\u20133732 (2011).","journal-title":"Blood"},{"key":"2178_CR564","doi-asserted-by":"publisher","first-page":"eaat1482","DOI":"10.1126\/sciimmunol.aat1482","volume":"3","author":"AK Abbas","year":"2018","unstructured":"Abbas, A. K., Trotta, E., Simeonov, D. R., Marson, A. & Bluestone, J. A. Revisiting IL-2: biology and therapeutic prospects. Sci. Immunol. 3, eaat1482 (2018).","journal-title":"Sci. Immunol."},{"key":"2178_CR565","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nrrheum.2014.127","volume":"10","author":"LH Calabrese","year":"2014","unstructured":"Calabrese, L. H. & Rose-John, S. IL-6 biology: implications for clinical targeting in rheumatic disease. Nat. Rev. Rheumatol. 10, 720\u2013727 (2014).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2178_CR566","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.4373","volume":"23","author":"S Rauber","year":"2017","unstructured":"Rauber, S. et al. Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells. Nat. Med. 23, 938\u2013944 (2017).","journal-title":"Nat. Med."},{"key":"2178_CR567","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41586-024-07098-5","volume":"627","author":"AG York","year":"2024","unstructured":"York, A. G. et al. IL-10 constrains sphingolipid metabolism to limit inflammation. Nature 627, 628\u2013635 (2024).","journal-title":"Nature"},{"key":"2178_CR568","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nm.3895","volume":"21","author":"MW Teng","year":"2015","unstructured":"Teng, M. W. et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat. Med. 21, 719\u2013729 (2015).","journal-title":"Nat. Med."},{"key":"2178_CR569","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1182\/blood.2022017326","volume":"140","author":"J Melo-Cardenas","year":"2022","unstructured":"Melo-Cardenas, J. et al. IL-13\/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms. Blood 140, 2805\u20132817 (2022).","journal-title":"Blood"},{"key":"2178_CR570","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-023-01620-3","volume":"8","author":"L Huangfu","year":"2023","unstructured":"Huangfu, L., Li, R., Huang, Y. & Wang, S. The IL-17 family in diseases: from bench to bedside. Signal Transduct. Target. Ther. 8, 402 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2178_CR571","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41584-023-01053-w","volume":"20","author":"E Landy","year":"2024","unstructured":"Landy, E., Carol, H., Ring, A. & Canna, S. Biological and clinical roles of IL-18 in inflammatory diseases. Nat. Rev. Rheumatol. 20, 33\u201347 (2024).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2178_CR572","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.immuni.2022.01.018","volume":"55","author":"R Zander","year":"2022","unstructured":"Zander, R. et al. Tfh-cell-derived interleukin 21 sustains effector CD8(+) T cell responses during chronic viral infection. Immunity 55, 475\u2013493.e475 (2022).","journal-title":"Immunity"},{"key":"2178_CR573","doi-asserted-by":"publisher","first-page":"e20192195","DOI":"10.1084\/jem.20192195","volume":"217","author":"M Keir","year":"2020","unstructured":"Keir, M., Yi, Y., Lu, T. & Ghilardi, N. The role of IL-22 in intestinal health and disease. J. Exp. Med. 217, e20192195 (2020).","journal-title":"J. Exp. Med."},{"key":"2178_CR574","doi-asserted-by":"publisher","first-page":"eabi6887","DOI":"10.1126\/sciimmunol.abi6887","volume":"8","author":"MS Fassett","year":"2023","unstructured":"Fassett, M. S. et al. IL-31-dependent neurogenic inflammation restrains cutaneous type 2 immune response in allergic dermatitis. Sci. Immunol. 8, eabi6887 (2023).","journal-title":"Sci. Immunol."},{"key":"2178_CR575","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nri.2016.95","volume":"16","author":"FY Liew","year":"2016","unstructured":"Liew, F. Y., Girard, J. P. & Turnquist, H. R. Interleukin-33 in health and disease. Nat. Rev. Immunol. 16, 676\u2013689 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"2178_CR576","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/ni.2406","volume":"13","author":"J Banchereau","year":"2012","unstructured":"Banchereau, J., Pascual, V. & O\u2019Garra, A. From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat. Immunol. 13, 925\u2013931 (2012).","journal-title":"Nat. Immunol."},{"key":"2178_CR577","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nri3581","volume":"14","author":"LB Ivashkiv","year":"2014","unstructured":"Ivashkiv, L. B. & Donlin, L. T. Regulation of type I interferon responses. Nat. Rev. Immunol. 14, 36\u201349 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"2178_CR578","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.it.2016.01.006","volume":"37","author":"A Deczkowska","year":"2016","unstructured":"Deczkowska, A., Baruch, K. & Schwartz, M. Type I\/II interferon balance in the regulation of brain physiology and pathology. Trends Immunol. 37, 181\u2013192 (2016).","journal-title":"Trends Immunol."},{"key":"2178_CR579","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41392-024-01764-w","volume":"9","author":"Z Deng","year":"2024","unstructured":"Deng, Z. et al. TGF-\u03b2 signaling in health, disease, and therapeutics. Signal Transduct. Target. Ther. 9, 61 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2178_CR580","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrrheum.2015.169","volume":"12","author":"GD Kalliolias","year":"2016","unstructured":"Kalliolias, G. D. & Ivashkiv, L. B. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat. Rev. Rheumatol. 12, 49\u201362 (2016).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2178_CR581","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/cmi.2017.135","volume":"15","author":"T Yoshimura","year":"2018","unstructured":"Yoshimura, T. The chemokine MCP-1 (CCL2) in the host interaction with cancer: a foe or ally? Cell. Mol. Immunol. 15, 335\u2013345 (2018).","journal-title":"Cell. Mol. Immunol."},{"key":"2178_CR582","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.semcancer.2022.02.007","volume":"86","author":"SN Jia","year":"2022","unstructured":"Jia, S. N., Han, Y. B., Yang, R. & Yang, Z. C. Chemokines in colon cancer progression. Semin. Cancer Biol. 86, 400\u2013407 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"2178_CR583","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/hep.31412","volume":"73","author":"N Zhao","year":"2021","unstructured":"Zhao, N. et al. Intratumoral \u03b3\u03b4 T-cell infiltrates, chemokine (C-C Motif) ligand 4\/chemokine (C-C Motif) ligand 5 protein expression and survival in patients with hepatocellular carcinoma. Hepatology 73, 1045\u20131060 (2021).","journal-title":"Hepatology"},{"key":"2178_CR584","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.7150\/thno.15625","volume":"7","author":"H Ha","year":"2017","unstructured":"Ha, H., Debnath, B. & Neamati, N. Role of the CXCL8-CXCR1\/2 axis in cancer and inflammatory diseases. Theranostics 7, 1543\u20131588 (2017).","journal-title":"Theranostics"},{"key":"2178_CR585","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","volume":"63","author":"R Tokunaga","year":"2018","unstructured":"Tokunaga, R. et al. CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation\u2014a target for novel cancer therapy. Cancer Treat. Rev. 63, 40\u201347 (2018).","journal-title":"Cancer Treat. Rev."},{"key":"2178_CR586","first-page":"2022","volume":"188799","author":"B Wang","year":"1877","unstructured":"Wang, B., Wang, M., Ao, D. & Wei, X. CXCL13-CXCR5 axis: regulation in inflammatory diseases and cancer. Biochim. Biophys. Acta Rev. Cancer 188799, 2022 (1877).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"2178_CR587","first-page":"1245","volume":"21","author":"R Goyal","year":"2022","unstructured":"Goyal, R. et al. Comparative highlights on MERS-CoV, SARS-CoV-1, SARS-CoV-2, and NEO-CoV. EXCLI J. 21, 1245\u20131272 (2022).","journal-title":"EXCLI J."},{"key":"2178_CR588","doi-asserted-by":"publisher","first-page":"102","DOI":"10.31083\/j.fbl2703102","volume":"27","author":"R Xu","year":"2022","unstructured":"Xu, R. et al. Role of cytokine storm in coronavirus infections: culprit or accomplice? Front. Biosci. 27, 102 (2022).","journal-title":"Front. Biosci."},{"key":"2178_CR589","doi-asserted-by":"publisher","first-page":"286.e287","DOI":"10.1016\/j.cmi.2020.09.051","volume":"27","author":"L Petrone","year":"2021","unstructured":"Petrone, L. et al. A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients. Clin. Microbiol. Infect. 27, 286.e287\u2013e213 (2021).","journal-title":"Clin. Microbiol. Infect."},{"key":"2178_CR590","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/febs.15782","volume":"289","author":"P Pandey","year":"2022","unstructured":"Pandey, P. & Karupiah, G. Targeting tumour necrosis factor to ameliorate viral pneumonia. FEBS J. 289, 883\u2013900 (2022).","journal-title":"FEBS J."},{"key":"2178_CR591","doi-asserted-by":"publisher","first-page":"e20192275","DOI":"10.1084\/jem.20192275","volume":"217","author":"CN Castro","year":"2020","unstructured":"Castro, C. N. et al. NCKAP1L defects lead to a novel syndrome combining immunodeficiency, lymphoproliferation, and hyperinflammation. J. Exp. Med. 217, e20192275 (2020).","journal-title":"J. Exp. Med."},{"key":"2178_CR592","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12704-6","volume":"10","author":"SJ Tavernier","year":"2019","unstructured":"Tavernier, S. J. et al. A human immune dysregulation syndrome characterized by severe hyperinflammation with a homozygous nonsense Roquin-1 mutation. Nat. Commun. 10, 4779 (2019).","journal-title":"Nat. Commun."},{"key":"2178_CR593","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1182\/blood.2020008738","volume":"137","author":"A Kalinichenko","year":"2021","unstructured":"Kalinichenko, A. et al. RhoG deficiency abrogates cytotoxicity of human lymphocytes and causes hemophagocytic lymphohistiocytosis. Blood 137, 2033\u20132045 (2021).","journal-title":"Blood"},{"key":"2178_CR594","doi-asserted-by":"publisher","first-page":"937108","DOI":"10.3389\/fimmu.2022.937108","volume":"13","author":"E Drago","year":"2022","unstructured":"Drago, E. et al. Case report: susceptibility to viral infections and secondary hemophagocytic lymphohistiocytosis responsive to intravenous immunoglobulin as primary manifestations of adenosine deaminase 2 deficiency. Front. Immunol. 13, 937108 (2022).","journal-title":"Front. Immunol."},{"key":"2178_CR595","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12969-019-0328-3","volume":"17","author":"A Arduini","year":"2019","unstructured":"Arduini, A. et al. An unusual presentation of purine nucleoside phosphorylase deficiency mimicking systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome. Pediatr. Rheumatol. Online J. 17, 25 (2019).","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"2178_CR596","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1080\/08880010500278871","volume":"22","author":"S Wu","year":"2005","unstructured":"Wu, S., Gonzalez-Gomez, I., Coates, T. & Yano, S. Cobalamin C disease presenting with hemophagocytic lymphohistiocytosis. Pediatr. Hematol. Oncol. 22, 717\u2013721 (2005).","journal-title":"Pediatr. Hematol. Oncol."},{"key":"2178_CR597","doi-asserted-by":"publisher","first-page":"867753","DOI":"10.3389\/fimmu.2022.867753","volume":"13","author":"P Vignesh","year":"2022","unstructured":"Vignesh, P. et al. Features of hemophagocytic lymphohistiocytosis in infants with severe combined immunodeficiency: our experience from Chandigarh, North India. Front. Immunol. 13, 867753 (2022).","journal-title":"Front. Immunol."},{"key":"2178_CR598","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.3389\/fimmu.2019.01953","volume":"10","author":"SP Han","year":"2019","unstructured":"Han, S. P., Lin, Y. F., Weng, H. Y., Tsai, S. F. & Fu, L. S. A novel BTK gene mutation in a child with atypical X-linked agammaglobulinemia and recurrent hemophagocytosis: a case report. Front. Immunol. 10, 1953 (2019).","journal-title":"Front. Immunol."},{"key":"2178_CR599","doi-asserted-by":"publisher","first-page":"49","DOI":"10.18176\/jiaci.0322","volume":"29","author":"M Nittner-Marszalska","year":"2019","unstructured":"Nittner-Marszalska, M. et al. Hemophagocytic lymphohistiocytosis (HLH) triggered by wasp venom immunotherapy is rare but noteworthy. J. Investig. Allergol. Clin. Immunol. 29, 49\u201351 (2019).","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"2178_CR600","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/petr.12081","volume":"17","author":"N Amayiri","year":"2013","unstructured":"Amayiri, N., Al-Zaben, A., Ghatasheh, L., Frangoul, H. & Hussein, A. A. Hematopoietic stem cell transplantation for children with primary immunodeficiency diseases: single center experience in Jordan. Pediatr. Transpl. 17, 394\u2013402 (2013).","journal-title":"Pediatr. Transpl."},{"key":"2178_CR601","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/14397595.2018.1442639","volume":"29","author":"T Tanaka","year":"2019","unstructured":"Tanaka, T. et al. National survey of Japanese patients with mevalonate kinase deficiency reveals distinctive genetic and clinical characteristics. Mod. Rheumatol. 29, 181\u2013187 (2019).","journal-title":"Mod. Rheumatol."},{"key":"2178_CR602","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3109\/08880018.2011.601402","volume":"29","author":"M Gokce","year":"2012","unstructured":"Gokce, M. et al. Secondary hemophagocytosis in 3 patients with organic acidemia involving propionate metabolism. Pediatr. Hematol. Oncol. 29, 92\u201398 (2012).","journal-title":"Pediatr. Hematol. Oncol."},{"key":"2178_CR603","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12969-020-00474-1","volume":"18","author":"AS Chau","year":"2020","unstructured":"Chau, A. S. et al. Heme oxygenase-1 deficiency presenting with interstitial lung disease and hemophagocytic flares. Pediatr. Rheumatol. Online J. 18, 80 (2020).","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"2178_CR604","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-024-01579-w","volume":"17","author":"P Sesques","year":"2024","unstructured":"Sesques, P. et al. Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma. J. Hematol. Oncol. 17, 61 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"2178_CR605","doi-asserted-by":"publisher","first-page":"e007790","DOI":"10.1136\/jitc-2023-007790","volume":"11","author":"M Zhang","year":"2023","unstructured":"Zhang, M. et al. Assessment and predictive ability of the absolute neutrophil count in peripheral blood for in vivo CAR T cells expansion and CRS. J. Immunother. Cancer 11, e007790 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"2178_CR606","doi-asserted-by":"publisher","first-page":"1169071","DOI":"10.3389\/fimmu.2023.1169071","volume":"14","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed\/refractory multiple myeloma patients treated with CAR-T cells. Front. Immunol. 14, 1169071 (2023).","journal-title":"Front. Immunol."},{"key":"2178_CR607","doi-asserted-by":"publisher","first-page":"100058","DOI":"10.1016\/j.cytox.2021.100058","volume":"3","author":"AF Berg","year":"2021","unstructured":"Berg, A. F. et al. Exclusive inhibition of IL-6 trans-signaling by soluble gp130(FlyR)Fc. Cytokine. X 3, 100058 (2021).","journal-title":"Cytokine. X"},{"key":"2178_CR608","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s43588-022-00213-4","volume":"2","author":"X Liu","year":"2022","unstructured":"Liu, X. et al. Dynamic forecasting of severe acute graft-versus-host disease after transplantation. Nat. Comput. Sci. 2, 153\u2013159 (2022).","journal-title":"Nat. Comput. Sci."},{"key":"2178_CR609","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3324\/haematol.2019.220970","volume":"105","author":"ML MacMillan","year":"2020","unstructured":"MacMillan, M. L. et al. Validation of Minnesota acute graft-versus-host disease Risk Score. Haematologica 105, 519\u2013524 (2020).","journal-title":"Haematologica"},{"key":"2178_CR610","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1093\/cid\/cix699","volume":"65","author":"JL Golob","year":"2017","unstructured":"Golob, J. L. et al. Stool microbiota at neutrophil recovery is predictive for severe acute graft vs host disease after hematopoietic cell transplantation. Clin. Infect. Dis. 65, 1984\u20131991 (2017).","journal-title":"Clin. Infect. Dis."},{"key":"2178_CR611","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2352-3026(14)00035-0","volume":"2","author":"JE Levine","year":"2015","unstructured":"Levine, J. E. et al. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. Lancet Haematol. 2, e21\u2013e29 (2015).","journal-title":"Lancet Haematol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02178-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02178-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02178-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T19:01:51Z","timestamp":1744743711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02178-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":611,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2178"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02178-y","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"9 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.W.W. is the editorial board member of Signal Transduction and Targeted Therapy, but he has not been involved in the process of the manuscript handling. The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"112"}}